Document:

<Page>

                                                                   Exhibit 10.11
                             CONFIDENTIAL TREATMENT

                  RESEARCH, LICENSE AND COLLABORATION AGREEMENT

                                     BETWEEN

                             CELLTECH R & D LIMITED

                                       AND

                         NEOGENESIS DRUG DISCOVERY, INC.

                               DATED JULY 11, 2001

<Page>

                                TABLE OF CONTENTS

<Table>
<Caption>
                                                                                      Page
                                                                                      ----
<S>                      <C>                                                           <C>
ARTICLE I.   DEFINITIONS ............................................................   1
          Section 1.1.   AAA ........................................................   2
          Section 1.2.   AFFILIATE ..................................................   2
          Section 1.3.   AGREEMENT ..................................................   2
          Section 1.4.   ALIS .......................................................   2
          Section 1.5.   APPLICABLE LAWS ............................................   2
          Section 1.6.   APPROVAL LETTER ............................................   2
          Section 1.7.   APPROVED TARGET(S) .........................................   2
          Section 1.8.   APPROVED TARGET EXCLUSIVITY PERIOD .........................   2
          Section 1.9.   CELLTECH INDEMNIFIED PARTY .................................   3
          Section 1.10.  CELLTECH TECHNOLOGY ........................................   3
          Section 1.11.  CELLTECH DERIVATIVES .......................................   3
          Section 1.12.  CIP ........................................................   4
          Section 1.13.  COMMERCIALIZATION ..........................................   4
          Section 1.14.  COMMERCIALLY REASONABLE EFFORTS ............................   4
          Section 1.15.  CONFIDENTIAL INFORMATION ...................................   4
          Section 1.16.  CONTROL OR CONTROLLED ......................................   4
          Section 1.17.  DESIGNATED COMPOUND ........................................   4
          Section 1.18.  DISCLOSING PARTY ...........................................   5
          Section 1.19.  EFFECTIVE DATE .............................................   5
          Section 1.20.  FDA ........................................................   5
          Section 1.21.  FD&C Act ...................................................   5
          Section 1.22.  FIRST COMMERCIAL SALE ......................................   5
          Section 1.23.  FOB ........................................................   5
          Section 1.24.  FORCE MAJEURE ..............................................   5
          Section 1.25.  FTE ........................................................   6
          Section 1.26.  GOOD CLINICAL PRACTICE .....................................   6
          Section 1.27.  GOOD LABORATORY PRACTICE ...................................   6
          Section 1.28.  GOOD MANUFACTURING PRACTICE ................................   6
          Section 1.29.  INDEMNIFIED PARTY(IES) .....................................   6
          Section 1.30.  INDEMNIFYING PARTY .........................................   7
          Section 1.31.  KNOW HOW ...................................................   7
          Section 1.32.  LICENSED PRODUCT(S) ........................................   7
          Section 1.33.  LOCK UP PERIOD .............................................   7
          Section 1.34.  MAJOR COUNTRY ..............................................   7
          Section 1.35.  MANUFACTURING ..............................................   7
          Section 1.36.  MASK .......................................................   8
          Section 1.37.  NDA ........................................................   8

                                       -i-

<Page>

          Section 1.38.  NEOGENESIS INDEMNIFIED PARTY(IES) ..........................   8
          Section 1.39.  NEOGENESIS TARGET ..........................................   8
          Section 1.40.  NEOGENESIS TECHNOLOGY ......................................   8
          Section 1.41.  NEOGENESIS DERIVATIVES .....................................   8
          Section 1.42.  NEOMORPH CHEMISTRY .........................................   9
          Section 1.43.  NEOMORPH FOCUSED LIBRARIES .................................   9
          Section 1.44.  NEOMORPH SCREENING LIBRARY .................................   9
          Section 1.45.  NET SALES ..................................................   9
          Section 1.46.  PATENTS ....................................................   10
          Section 1.47.  PERSON .....................................................   10
          Section 1.48.  PHASE I CLINICAL TRIALS ....................................   10
          Section 1.49.  PHASE III CLINICAL TRIALS ..................................   10
          Section 1.50.  PRELIMINARY COMPOUND .......................................   11
          Section 1.51.  PRELIMINARY COMPOUND EXCLUSIVITY PERIOD ....................   11
          Section 1.52.  PRIMARY ACTIVE COMPOUND ....................................   11
          Section 1.53.  PRIMARY ACTIVE COMPOUND EXCLUSIVITY PERIOD .................   11
          Section 1.54.  PROGRAM TECHNOLOGY .........................................   11
          Section 1.55.  PROPRIETARY TARGET .........................................   12
          Section 1.56.  PUBLIC TARGET ..............................................   12
          Section 1.57.  QSCD .......................................................   12
          Section 1.58.  QSCD PRELIMINARY COMPOUNDS .................................   12
          Section 1.59.  QSCD PRIMARY ACTIVE COMPOUNDS ..............................   12
          Section 1.60.  QUARTER ....................................................   12
          Section 1.61.  R&D Program ................................................   12
          Section 1.62.  RECEIVING PARTY ............................................   13
          Section 1.63.  REGULATORY APPROVALS .......................................   13
          Section 1.64.  REGULATORY AUTHORITY .......................................   13
          Section 1.65.  RESEARCH COLLABORATION .....................................   13
          Section 1.66.  RESEARCH COLLABORATION PLAN ................................   13
          Section 1.67.  RESEARCH TERM ..............................................   13
          Section 1.68.  STEERING COMMITTEE .........................................   13
          Section 1.69.  STOCK PURCHASE AGREEMENT ...................................   14
          Section 1.70.  TARGET .....................................................   14
          Section 1.71.  TARGET GUIDELINES ..........................................   14
          Section 1.72.  TERM .......................................................   14
          Section 1.73.  TERRITORY ..................................................   14
          Section 1.74.  THIRD PARTY (THIRD PARTIES) ................................   14
          Section 1.75.  THIRD PARTY CLAIM ..........................................   14

ARTICLE II.   GRANT, RIGHTS AND RESTRICTIONS ........................................   14
          Section 2.1.  GRANT OF RESEARCH LICENSE. ..................................   14
          Section 2.2.  NEOGENESIS GRANT OF LICENSE. ................................   15
          Section 2.3.  RETAINED RIGHTS. ............................................   16

                                      -ii-

<Page>

ARTICLE III.   RESEARCH COLLABORATION PLAN ..........................................   16
          Section 3.1.  DILIGENCE. ..................................................   16
          Section 3.2.  RESEARCH COLLABORATION. .....................................   16
          Section 3.3.  NUMBER OF TARGETS. ..........................................   16

ARTICLE IV.   STEERING COMMITTEE ....................................................   17
          Section 4.1.  STEERING COMMITTEE. .........................................   17
                    (a)  STEERING COMMITTEE ACTIVITIES. .............................   17
                    (b)  STEERING COMMITTEE MEETINGS. ...............................   17
                    (c)  STEERING COMMITTEE GOVERNANCE. .............................   18

ARTICLE V.   RESEARCH FUNDING .......................................................   18
          Section 5.1.  RESEARCH COLLABORATION FUNDING. .............................   18
                    (a)  STOCK PURCHASE. ............................................   18
                    (b)  FTE FUNDING. ...............................................   19
                    (c)  QUARTERLY PAYMENTS. ........................................   19

ARTICLE VI.   MILESTONES AND ROYALTY PAYMENTS .......................................   19
          Section 6.1.  MILESTONES. .................................................   19
                    (a)  PHASE I. ...................................................   19
                    (b)  PHASE III. .................................................   20
                    (c)  APPROVAL LETTER. ...........................................   20
                    (d)  MILESTONE FREQUENCY. .......................................   20
          Section 6.2.  ROYALTIES. ..................................................   20
                    (a)  NON-QSCD DISCOVERED COMPOUNDS. .............................   21
                    (b)  QSCD DISCOVERED COMPOUNDS. .................................   21
                    (c)  ROYALTY PAYMENTS AND TERM. .................................   21
                    (d)  ROYALTY ADJUSTMENTS. .......................................   21
          Section 6.3.  REMITTANCE. .................................................   21
                    (a)  FUNDS/EXCHANGE RATE. .......................................   21
                    (b)  INTEREST. ..................................................   22
          Section 6.4.  RECORDS. ....................................................   22
          Section 6.5.  INSPECTION. .................................................   22
                    (a)  AUDIT. .....................................................   22
                    (b)  DISPUTES. ..................................................   23
          Section 6.6.  TAXES. ......................................................   23

ARTICLE VII.   REGULATORY AND MARKETING OBLIGATIONS .................................   24
          Section 7.1.  PRODUCT DEVELOPMENT. ........................................   24
          Section 7.2.  MANUFACTURE OF PRODUCT. .....................................   24
          Section 7.3.  REGULATORY MATTERS. .........................................   24
          Section 7.4.  MARKETING AND SALE. .........................................   24
                    (a)  RESPONSIBILITY. ............................................   24

                                      -iii-

<Page>

                    (b)  MARKING. ...................................................   24
                    (c)  THIRD PARTY LICENSES. ......................................   25
          Section 7.5.  PERIODIC REVIEW. ............................................   25

ARTICLE VIII.   RIGHTS IN TECHNOLOGY, PATENTS AND KNOW HOW ..........................   25
          Section 8.1.  OWNERSHIP OF PROGRAM TECHNOLOGY. ............................   25
                    (a)  CELLTECH OWNED PROGRAM TECHNOLOGY. .........................   25
                    (b)  NEOGENESIS OWNED PROGRAM TECHNOLOGY. .......................   26
                    (c)  JOINTLY OWNED PROGRAM TECHNOLOGY. ..........................   26
          Section 8.2.  DISCLOSURE BY EMPLOYEES, AGENTS OR INDEPENDENT CONTRACTORS. .   27
          Section 8.3.  PATENT PROSECUTION AND RELATED ACTIVITIES. ..................   27
                    (a)  NEOGENESIS OWNED PROGRAM TECHNOLOGY. .......................   27
                    (b)  CELLTECH OWNED PROGRAM TECHNOLOGY. .........................   28
                    (c)  JOINTLY OWNED PROGRAM TECHNOLOGY. ..........................   28
                    (d)  COOPERATION. ...............................................   29
          Section 8.4.  THIRD PARTY INFRINGEMENT. ...................................   29
                    (a)  ENFORCEMENT. ...............................................   29
                    (b)  FAILURE TO ENFORCE. ........................................   29
                    (c)  DIVISION OF RECOVERIES. ....................................   30
                    (d)  COOPERATION. ...............................................   30
          Section 8.5.  INFRINGEMENT CLAIMS BY THIRD PARTIES. .......................   30
                    (a)  THIRD PARTY CLAIMS. ........................................   30
                    (b)  RESPONSE TO THIRD PARTY CLAIMS. ............................   31

ARTICLE IX.   CONFIDENTIALITY .......................................................   31
          Section 9.1.  CONFIDENTIALITY. ............................................   31
          Section 9.2.  OBLIGATIONS OF CONFIDENTIALITY. .............................   32
          Section 9.3.  LEGAL DISCLOSURE. ...........................................   32
          Section 9.4.  OWNERSHIP OF INFORMATION. ...................................   33
          Section 9.5.  EXPIRATION OR TERMINATION. ..................................   33
          Section 9.6.  PUBLICITY. ..................................................   33
          Section 9.7.  PUBLICATION. ................................................   34

ARTICLE X.   REPRESENTATIONS AND WARRANTIES .........................................   34
          Section 10.1.  NEOGENESIS REPRESENTATIONS AND WARRANTIES. .................   34
                    (a)  ORGANIZATION. ..............................................   34
                    (b)  AUTHORITY. .................................................   35
                    (c)  GOVERNMENTAL CONSENTS. .....................................   35
                    (d)  NO CONFLICT WITH OTHER AGREEMENTS. .........................   35
                    (e)  PATENT INFRINGEMENT. .......................................   36
                    (f)  DEBARRED. ..................................................   36
                    (g)  DISCLAIMER. ................................................   36

                                      -iv-

<Page>

          Section 10.2.  CELLTECH REPRESENTATIONS AND WARRANTIES. ...................   36
                    (a)  ORGANIZATION. ..............................................   36
                    (b)  AUTHORITY. .................................................   37
                    (c)  GOVERNMENTAL CONSENTS. .....................................   37
                    (d)  NO CONFLICT WITH OTHER AGREEMENTS. .........................   37
                    (e)  DISCLAIMER. ................................................   37

ARTICLE XI.   INDEMNIFICATION .......................................................   38
          Section 11.1.  LIMITATION OF LIABILITY. ...................................   38
          Section 11.2.  INFRINGEMENT INDEMNIFICATION. ..............................   38
                    (a)  NEOGENESIS. ................................................   38
                    (b)  CELLTECH. ..................................................   39
          Section 11.3.  OTHER CLAIMS. ..............................................   39
                    (a)  NEOGENESIS. ................................................   39
                    (b)  CELLTECH. ..................................................   40
          Section 11.4.  PROCEDURE. .................................................   40

ARTICLE XII.   TERM AND TERMINATION .................................................   40
          Section 12.1.  TERM. ......................................................   40
          Section 12.2.  TERMINATION. ...............................................   41
                    (a)  MATERIAL BREACH. ...........................................   41
                    (b)  BANKRUPTCY OR RECEIVERSHIP OF A PARTY. .....................   41
                    (c)  TERMINATION BY CELLTECH. ...................................   41
          Section 12.3.  EFFECT OF TERMINATION. .....................................   41
                    (a)  TERMINATION ACTIVITIES. ....................................   42
                    (b)  RETURN OF CONFIDENTIAL INFORMATION. ........................   42
                    (c)  RIGHTS UPON TERMINATION. ...................................   42
          (d)  No ReleaSE OF MATURED OBLIGATION. ....................................   43
                    SECTION 12.4  SURVIVAL. .........................................   43

ARTICLE XIII.   GENERAL PROVISIONS ..................................................   43
          Section 13.1.  ISSUE RESOLUTION. ..........................................   43
                    (a)  NOTIFICATION OF DISPUTE. ...................................   43
                    (b)  LIMITATIONS. ...............................................   44
                    (c)  ARBITRATION RULES. .........................................   44
                    (d)  APPLICABLE LAW. ............................................   45
                    (e)  RESTRICTIONS ON DAMAGES. ...................................   45
          Section 13.2.  GOVERNING LAW. .............................................   45
          Section 13.3.  AMENDMENT AND WAIVER. ......................................   46
          Section 13.4.  INDEPENDENT CONTRACTORS. ...................................   46
          Section 13.5.  ASSIGNMENT. ................................................   46
          Section 13.6.  SUCCESSORS AND ASSIGNS. ....................................   47
          Section 13.7.  NOTICES. ...................................................   47
          Section 13.8.  SEVERABILITY. ..............................................   47

                                       -v-

<Page>

          Section 13.9.  CAPTIONS. ..................................................   47
          Section 13.10.  WORD MEANINGS. ............................................   47
          Section 13.11.  ENTIRE AGREEMENT. .........................................   48
          Section 13.12.  RULES OF CONSTRUCTION. ....................................   48
          Section 13.13.  COUNTERPARTS. .............................................   48
          Section 13.14.  FORCE MAJEURE. ............................................   48
          Section 13.15.  FURTHER ASSURANCES. .......................................   48

EXHIBIT A ...........................................................................  A-1

EXHIBIT B ...........................................................................  B-1
</Table>

                                      -vi-

<Page>

                  RESEARCH, LICENSE AND COLLABORATION AGREEMENT

         This Research, License and Collaboration Agreement (the "Agreement") is
entered into as of July 11, 2001 ("Effective Date") by and between Celltech R &
D Limited whose registered office is situate at 208 Bath Road, Slough, Berkshire
SL1 3WE, England ("Celltech") and NeoGenesis Drug Discovery, Inc., having an
address of 840 Memorial Drive, Cambridge, MA 02139, USA ("NeoGenesis"). Each of
Celltech and NeoGenesis may individually be referred to as a "Party" and
collectively as "Parties".

         WHEREAS, Celltech is a biopharmaceutical company with an ongoing
interest in research, development and commercialization of pharmaceutical
products for treatment of certain human diseases and wishes to identify
compounds that exhibit a high affinity and functional activity to protein
targets for the development, manufacture and commercialization of pharmaceutical
products;

         WHEREAS, NeoGenesis is a chemical genomics based drug discovery company
and has certain technology and know-how, including screening processes of
libraries of mass-encoded small molecule compounds built around an expanding set
of diverse cores, relating to the identification, discovery, validation and
optimization of chemical compounds that exhibit a high affinity to protein
targets useful for development of pharmaceutical products;

         WHEREAS, Celltech has certain technology and know-how relating to the
identification of protein targets implicated in disease;

         WHEREAS, Celltech and NeoGenesis desire to jointly collaborate in
research to identify compounds from NeoGenesis' libraries that exhibit high
affinity and functional activity to specific protein targets provided by
Celltech;

         NOW THEREFORE, in consideration of the mutual covenants and promises
contained in this Agreement, Celltech and NeoGenesis agree as follows:

                                   ARTICLE I.
                                   DEFINITIONS

         Capitalized terms used in this Agreement and not otherwise defined
herein shall have the meaning set forth below.

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       1
<Page>

         SECTION 1.1. AAA shall have the meaning set forth in Section 13.1 (c)
hereof.

         SECTION 1.2. AFFILIATE shall mean with respect to either Party, any
Person that, directly or indirectly, is controlled by, controls or is under
common control with such Party. For purposes of this definition, control means,
with respect to any Person, the direct or indirect ownership of more than fifty
percent (50%) of the voting or income interest in such Person or the possession
otherwise, directly or indirectly, of the power to direct the management or
policies of such Person.

         SECTION 1.3. AGREEMENT shall mean this Research, License and
Collaboration Agreement and any Exhibits or Schedules appended hereto, as the
same may be amended from time to time by the Parties in accordance with Section
3.2 or Section 13.3, as applicable.

         SECTION 1.4. ALIS shall mean the Automated Ligand Identification
System, an automated, ultra-high throughput ligand selection system proprietary
to NeoGenesis that is used to identify multiple classes of chemical compounds
against target proteins.

         SECTION 1.5. APPLICABLE LAWS shall mean all laws, statutes, regulations
and ordinances of any Regulatory Authority, including without limitation the
FD&C Act.

         SECTION 1.6. APPROVAL LETTER shall have the meaning set forth in
Section 6.1(c) hereof.

         SECTION 1.7. APPROVED TARGET(S) shall mean any Target that NeoGenesis
has approved for entry into the Research Collaboration based on the Target
Guidelines.

         SECTION 1.8. APPROVED TARGET EXCLUSIVITY PERIOD shall mean the period
of time during which NeoGenesis will not approve or screen an Approved Target
for a Third Party. For a Public Target and homologs thereof that are [*]
homologus at the peptide level such exclusivity period shall begin upon
NeoGenesis' approval of such Target as set forth in Exhibit A, paragraph 1(a) or
paragraph 1(b) of the Research Collaboration Plan and end [*] thereafter. For a
Proprietary Target, such exclusivity period shall begin upon NeoGenesis'
approval of such Approved Target as set forth in Exhibit A, paragraph 1(a) or
paragraph 1(b) of the Research Collaboration Plan and end as follows: (i) where
a patent(s) has issued to Celltech or an Affiliate, in any Major Country in the
Territory claiming such target, the exclusivity period

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       2
<Page>

shall end when the last of the patent(s) expires, lapses, or is held invalid or
unenforceable by a final decision, which is unappealed or unappealable, of a
court of competent jurisdiction or of an administrative agency having authority
over patents; and (ii) where a patent application has been filed and such patent
application has not been the subject of a rejection notice from which an appeal
cannot be taken or in respect of which the applicable period of appeal has not
expired, the exclusivity period shall end on the later of: (A) the date that is
[*] after the priority date of such patent application (measured from the
original filing date) or (B) the date that is [*] after NeoGenesis' receipt of
such Approved Target from Celltech. Where a patent issues from a patent
application as described in (ii) above, such patent shall be covered under (i)
as set forth above.

         SECTION 1.9. CELLTECH INDEMNIFIED PARTY shall have the meaning set
forth in Section 11.1 (a) hereof.

         SECTION 1.10. CELLTECH TECHNOLOGY shall mean any and all Patents and
Know-How that are owned or Controlled by Celltech necessary for the performance
of this Agreement, as determined by Celltech. The term Celltech Technology,
however, does not include the NeoGenesis Technology or any Know-How, after such
time as it becomes generally available to the public.

         SECTION 1.11. CELLTECH DERIVATIVES shall mean those derivatives of
Designated Compounds that are developed through optimizations performed by
Celltech and that have a Kd [*] and are functionally active against the
relevant Approved Target, functional activity being deemed if IC(50) is [*].
Derivatives shall include, but not be limited to analogs, isomers, chemical
homologs and salts thereof.

         SECTION 1.12. CIP shall mean "Carriage and Insurance Paid", as that
expression is defined in INCOTERMS 2000, ICC Publishing S.A.

         SECTION 1.13. COMMERCIALIZATION shall mean any and all activities of
using, importing, exporting, marketing, promoting, distributing, offering for
sale and selling a Licensed Product. When used as a verb, "COMMERCIALIZE" means
to engage in Commercialization.

         SECTION 1.14. COMMERCIALLY REASONABLE EFFORTS shall mean, with respect
to (i) any objective by any Party, reasonable, diligent, good faith efforts to
accomplish such objective as such Party would normally use to accomplish a
similar objective under similar circumstances; and (ii) with respect to any
objective relating to the development or Commercialization of any Licensed
Product by any Party efforts and resources normally used by

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       3
<Page>

such Party with respect to a product owned by such Party or to which such Party
has similar rights which is of similar market potential at a similar stage in
the development or life of such product, taking into account issues of safety,
efficacy, product profile, the competitiveness of the marketplace, the
proprietary position of the product, the regulatory structure involved,
profitability of the product and other relevant commercial factors.

         SECTION 1.15. CONFIDENTIAL INFORMATION shall have the meaning set forth
in Section 9. l.

         SECTION 1.16. CONTROL OR CONTROLLED shall mean with respect to any (a)
item of information or (b) intellectual property right, including, without
limitation, Celltech Technology and NeoGenesis Technology, the possession
(whether by ownership or license, other than pursuant to this Agreement) by a
Party or an Affiliate thereof of the ability to grant to the other Party access
or a license under such item or right without violating the terms of any
agreement or other arrangements, between such Party or its Affiliate and any
Third Party, existing before or after the Effective Date.

         SECTION 1.17. DESIGNATED COMPOUND shall mean any (a) Preliminary
Compound(s), Primary Active Compound, QSCD Preliminary Compound(s), QSCD
Primary Active Compound(s) designated by Celltech pursuant to paragraph 4(a)
of the Research Collaboration Plan and (b) NeoGenesis Derivatives of such
compounds designated from Primary Active Compounds and QSCD Primary Active
Compounds but not designated from Preliminary Compounds or QSCD Preliminary
Compounds provided, that such NeoGenesis Derivatives have a Kd [*] and are
functionally active against the relevant Approved Target, functional activity
being deemed if IC(50) is [*].

         SECTION 1.18. DISCLOSING PARTY shall have the meaning set forth in
Section 9.1.

         SECTION 1.19. EFFECTIVE DATE shall mean the date first written above.

         SECTION 1.20. FDA shall mean the United States Food and Drug
Administration or any successor entity thereto.

         SECTION 1.21. FD&C ACT shall mean the United States Federal Food, Drug
and Cosmetic Act of 1938, as amended.

         SECTION 1.22. FIRST COMMERCIAL SALE shall mean the first transfer for
value in an arms-length transaction to an independent Third Party

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       4
<Page>

distributor, agent or end user after obtaining all necessary Regulatory
Approvals as may be necessary for such transfer of Licensed Product(s).

         SECTION 1.23. FOB means "Free On Board", as that expression is defined
in INCOTERMS 2000, ICC Publishing S.A.

         SECTION 1.24. FORCE MAJEURE shall mean any event beyond the control of
the Parties, including, without limitation, failures of computers,
computer-related equipment, hardware or software, fire, flood, riots, strikes,
epidemics, war (declared or undeclared and including the continuance, expansion
or new outbreak of any war or conflict now in existence), embargoes and
governmental actions or decrees.

         SECTION 1.25. FTE shall mean the per annum rate of a full time,
(including reasonable and customary vacations, sick days and holidays), work of
a NeoGenesis employee who is adequately trained to perform screening and
optimization and who performs screening and optimization activities pursuant to
this Agreement.

         SECTION 1.26. GOOD CLINICAL PRACTICE shall mean the then current
standards for clinical trials for pharmaceuticals, as set forth in the FD&C Act
and applicable regulations promulgated thereunder, as amended from time to time,
and such standards of good clinical practice as are required by the European
Union and other Regulatory Authorities in countries in which the Licensed
Product is intended to be sold, to the extent such standards are not in
contravention with United States Good Clinical Practices.

         SECTION 1.27. GOOD LABORATORY PRACTICE shall mean the then current
standards for laboratory activities for pharmaceuticals, as set forth in the
FD&C Act and applicable regulations promulgated thereunder, as amended from time
to time, and such standards of good laboratory practice as are required by the
European Union and other Regulatory Authorities in countries in which the
Product is intended to be sold, to the extent such standards are not in
contravention with United States Good Laboratory Practices.

         SECTION 1.28. GOOD MANUFACTURING PRACTICE shall mean the current
standards for the manufacture of pharmaceuticals, as set forth in the FD&C Act
and applicable regulations promulgated thereunder, as amended from time to time,
and such standards of good manufacturing practice as are required by the
European Union and other Regulatory Authorities in countries in which the
Product is intended to be sold, to the extent such

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       5
<Page>

standards are not in contravention with United States Good Manufacturing
Practices.

         SECTION 1.29. INDEMNIFIED PARTY(IES) shall mean a Celltech Indemnified
Party or NeoGenesis Indemnified Party, as the case may be.

         SECTION 1.30. INDEMNIFYING PARTY shall have the meaning set forth in
Section 11.3.

         SECTION 1.31. KNOW-HOW shall mean, to the extent not publicly known,
any information and materials relating to, or discoveries made (whether in
electronic, magnetic, graphic or written form), including, without limitation,
regulatory approvals, processes, techniques, formulas, data, database
information, methods, equipment designs, know-how, show-how and trade secrets,
discoveries, practices, knowledge, ideas, skill, experience, inventions,
technology, manufacturing procedures, test procedures, purification and
isolation techniques, instructions, technical and scientific data, pre-clinical
and clinical data, test data and other intellectual property, whether or not
patentable, tangible or intangible. Know-How does not include Patents.

         SECTION 1.32. LICENSED PRODUCT(S) shall mean any product (a) whose
pharmaceutical composition contains any formulation or dosage of a Designated
Compound or any Celltech Derivatives or improvements thereof as a
pharmaceutically active ingredient and (b) the development, manufacture, use, or
sale of which, absent the rights assigned and licenses granted to Celltech under
this Agreement, would infringe the NeoGenesis Technology or which makes use of
any Patents comprised in Program Technology with respect to which NeoGenesis is
an inventor.

         SECTION 1.33. LOCK UP PERIOD shall mean the period of time ending
eighteen (18) months from the Effective Date.

         SECTION 1.34. MAJOR COUNTRY shall mean any or all of the United States,
the United Kingdom, France, Germany, and Japan, as the case may be.

         SECTION 1.35. MANUFACTURING shall mean any and all activities involved
in the production of a Licensed Product to be developed and/or Commercialized
under this Agreement. When used as a verb, Manufacture means to engage in
Manufacturing.

         SECTION 1.36. MASK shall mean the process whereby NeoGenesis shall take
all necessary steps to prevent a Preliminary Compound or Primary

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       6
<Page>

Active Compound from being identified or revealed as a ligand against any Third
Party targets during the Preliminary Compound Exclusivity Period or Primary
Active Compound Exclusivity Period, as the case may be.

         SECTION 1.37. NDA shall mean a new drug application as defined in the
FD&C Act and applicable regulations thereunder.

         SECTION 1.38. NEOGENESIS INDEMNIFIED PARTY(IES) shall have the meaning
set forth in Section 11.1 (b)

         SECTION 1.39. NEOGENESIS TARGET shall mean a target that is the subject
of an ongoing research project for NeoGenesis at the time NeoGenesis is
requested by Celltech to determine whether it can accept a Target for entry into
the Research Collaboration by reference to the Target Guidelines.

         SECTION 1.40. NEOGENESIS TECHNOLOGY shall mean any and all Patents and
Know-How that are owned or Controlled by NeoGenesis necessary for the
performance of this Agreement. The term NeoGenesis Technology, however, does not
include any Celltech Technology or any Know-How, after such time as such
Know-How becomes generally available to the public.

         SECTION 1.41. NEOGENESIS DERIVATIVES shall mean those derivatives of
Designated Compounds that are developed through optimizations performed by
NeoGenesis and that have a Kd [*] and are functionally active against the
relevant Approved Target, functional activity being deemed if IC50 is [*].
Derivatives shall include, but not be limited to analogs, isomers, chemical
homologs and salts thereof.

         SECTION 1.42. NEOMORPH CHEMISTRY shall mean the process, proprietary to
NeoGenesis, of forming libraries and sub-libraries of discrete compounds by
coupling a broad set of diverse cores with diverse sets of building blocks
employing proprietary mass-coding algorithms.

         SECTION 1.43. NEOMORPH FOCUSED LIBRARIES shall mean those compounds
synthesized by NeoGenesis during the optimization of either the Preliminary
Compounds identified from the NeoMorph Screening Library or further optimization
of compounds identified in any rounds of optimization.

         SECTION 1.44. NEOMORPH SCREENING LIBRARY shall mean the constantly
expanding collection of libraries consisting of mass-encoded small molecule
organic compounds owned by NeoGenesis and developed with

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       7
<Page>

NeoMorph Chemistry, currently comprising about 10,000,000 unique compounds.

         SECTION 1.45. NET SALES means the aggregate amounts invoiced for the
first sale or transfer for value of Licensed Products by Celltech, its
Affiliates or any of its sublicensees to an independent non-sublicensee Third
Party distributor, agent or end user in the Territory (other than sales of
Licensed Products at cost by Celltech, its Affiliates or sublicensees to a
non-sublicensee Third Party for use in a clinical study prior to Regulatory
Approval of such Licensed Product in a Major Country) less the following
deductions: (a) credits, refunds, allowances and price adjustments separately
and actually credited to such customers for defective, spoiled, damaged,
outdated, and returned Licensed Products, (b) offered and taken trade and cash
discounts and rebates in amounts customary to the trade and as required to do
business in the country in which they are made, (c) sales, excise, value added,
turnover, use, and other like taxes, and customs duties, paid, absorbed or
allowed excluding net income tax, and (d) special outbound packing,
transportation, insurance and handling charges separately billed to Celltech,
its Affiliates or sublicensees or prepaid. Net Sales shall not include revenue
received by Celltech, its Affiliates or sublicensees from transactions with an
Affiliate or sublicensee, where the Licensed Product in question will be resold
to an independent non-sublicensee Third Party distributor, agent or end user by
the Affiliate or sublicensee PROVIDED such revenue received by the Affiliate or
sublicensee from such resale is included in Net Sales. Net Sales received by
Celltech (or any of its Affiliates) from transactions with an Affiliate, where
the Licensed Product in question is used by the Affiliate solely for such
Affiliate's internal purposes shall not be included in Net Sales. In the event
that a Licensed Product is sold as part of a kit or combination product, Net
Sales from the kit or combination product for the purposes of determining
royalty payments, shall be determined by multiplying the Net Sales (as defined
above) of the combination product by the fraction, A/(A+B) where A is the
average sale price of the Licensed Product when sold separately in finished form
and B is the average sale price of the other product(s) sold separately in
finished form, so that A+B is the average sale price of the product(s) together.
In the event that such average sale price cannot be determined for both the
Licensed Product and such other product(s) in combination, Net Sales shall be
determined by good faith negotiation between the parties, and that failing, by
arbitration in accordance with Section 13.

         SECTION 1.46. PATENTS shall mean (i) any foreign or domestic patent
applications and patents, and all patents and patent applications based on, or
claiming or corresponding to the priority date(s), of any of the foregoing; (ii)

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       8
<Page>

any reissues, extensions (or other governmental actions that provide exclusive
rights to the patent holder in the patented subject matter beyond the original
patent expiration date), substitutions, confirmations, registrations,
revalidations, re-examinations, additions, continuations, continued
prosecutions, continuations-in-part, or divisions of or to any of the foregoing;
and (iii) any supplementary protection certificates.

         SECTION 1.47. PERSON shall mean any individual, corporation,
association, partnership (general or limited), joint venture, trust, estate,
limited liability company, limited liability partnership, unincorporated
organization, government (or any agency or political subdivision thereof) or
other legal entity or organization.

         SECTION 1.48. PHASE I CLINICAL TRIALS shall have the meaning set forth
in Section 6.1(a).

         SECTION 1.49. PHASE III CLINICAL TRIALS shall have the meaning set
forth in Section 6.1(b).

         SECTION 1.50. PRELIMINARY COMPOUND shall mean any NeoGenesis compound
identified from the NeoMorph Screening Library which binds an Approved Target
with a minimum affinity set by the Steering Committee on an Approved Target by
Approved Target basis.

         SECTION 1.51. PRELIMINARY COMPOUND EXCLUSIVITY PERIOD shall mean the
period of time from the identification of a Preliminary Compound until Celltech
abandons the Preliminary Compound. Abandonment shall occur on a specific
Preliminary Compound upon the first to occur of the following: (i) express
abandonment in writing by Celltech, (ii) lack of functional biological activity
in a cell-based assay as set forth in paragraph 3(b) of the research
Collaboration Plan or (iii) failure of Celltech to determine activity, as set
forth in paragraph 3(b) of the Research Collaboration Plan, within [*] of
receipt by Celltech of such Preliminary Compound.

         SECTION 1.52. PRIMARY ACTIVE COMPOUND shall mean any Preliminary
Compound which demonstrates an activity in a cell-based functional assay as set
forth in paragraph 3(b) of the research Collaboration Plan.

         SECTION 1.53. PRIMARY ACTIVE COMPOUND EXCLUSIVITY PERIOD shall mean the
period of time from the identification of a Primary Active Compound until
Celltech abandons the Primary Active Compound. Abandonment shall occur on a
specific Primary Active Compound upon the

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       9
<Page>

first to occur of the following: (i) express abandonment in writing by Celltech,
or (ii) failure of Celltech to designate such Primary Active Compound as a
Designated Compound within the applicable time period specified in paragraph
4(a) of the Research Collaboration Plan.

         SECTION 1.54. PROGRAM TECHNOLOGY shall mean individually and
collectively all Patents, Know-How, discoveries, inventions, techniques,
methodologies, modifications, improvements, works of authorship, designs and
data (whether or not protectable under patent, copyright, trade secrecy or
similar laws) that are conceived, created, discovered, developed, or reduced to
practice or tangible medium of expression during the Research Term in the course
of the Research Collaboration Plan, including without limitation, all
Preliminary Compound(s), NeoMorph Focused Libraries, Primary Active Compound(s),
QSCD Preliminary Compound(s), QSCD Primary Active Compound(s) and Designated
Compound(s), (a) solely by one or more employees or consultants of NeoGenesis;
(b) jointly by one or more employees or consultants of NeoGenesis and one or
more employees or consultants of Celltech, or (c) solely by one or more
employees or consultants of Celltech.

         SECTION 1.55. PROPRIETARY TARGET shall mean a Target for which (a) a
patent has issued to and is Controlled by Celltech or an Affiliate, in any Major
Country in the Territory claiming such target and such patent has not expired,
lapsed, or been held invalid or unenforceable by a final decision, which is
unappealed or unappealable, of a court of competent jurisdiction or of an
administrative agency having authority over patents; or (b) a patent application
has been filed and is Controlled by Celltech or an affiliate and such patent
application has not been the subject of a rejection notice from which an appeal
cannot be taken or in respect of which the applicable period for appeal has not
expired.

         SECTION 1.56. PUBLIC TARGET shall mean any target that is not a
Proprietary Target.

         SECTION 1.57. QSCD shall mean Quantisized Surface Complementary
Diversity, a technology proprietary to NeoGenesis, in terms of which discrete
chemical complements to the surfaces of Approved Targets may be defined.

         SECTION 1.58. QSCD PRELIMINARY COMPOUNDS shall have the meaning set
forth in Exhibit A, paragraph 3(e).

         SECTION 1.59. QSCD PRIMARY ACTIVE COMPOUNDS shall have the meaning set
forth in Exhibit A, paragraph 3(e).

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       10
<Page>

         SECTION 1.60. QUARTER shall mean a three (3) month period ending March
31, June 30, September 30 and December 31.

         SECTION 1.61. R&D PROGRAM means on a Designated Compound-by-Designated
Compound and country-by-country basis the activities necessary or desirable to
be undertaken in connection with the research and development of such Designated
Compound prior to obtaining Regulatory Approval for a Licensed Product in such
country (regardless of the country in which such activities are conducted).

         SECTION 1.62. RECEIVING PARTY shall have the meaning set forth in
Section 9.1.

         SECTION 1.63. REGULATORY APPROVALS shall mean, for any country in the
Territory, those authorizations by the appropriate Regulatory Authority(ies)
required for the manufacture, importation, marketing, promotion, pricing and
sale of the Licensed Product(s) in such country.

         SECTION 1.64. REGULATORY AUTHORITY shall mean any national,
supra-national, regional, state or local regulatory agency, department, bureau,
commission, council or other governmental entity in the Territory, including,
without limitation, the FDA.

         SECTION 1.65. RESEARCH COLLABORATION means the joint effort between
Celltech and NeoGenesis to identify compounds from NeoGenesis' libraries that
exhibit high affinity and functional activity to specific Targets.

         SECTION 1.66. RESEARCH COLLABORATION PLAN shall mean the screening
program for each Approved Target described on Exhibit A as the same may be
amended during the Research Term by the Steering Committee (as defined below).
The goals of the Plan will be directed toward the discovery and development of
Preliminary Compounds, QSCD Preliminary Compounds, Primary Active Compounds,
QSCD Primary Active Compounds and Designated Compounds for the Approved Targets.

         SECTION 1.67. RESEARCH TERM shall have the meaning set forth in Section
3.2 hereof.

         SECTION 1.68. STEERING COMMITTEE shall have the meaning set forth in
Section 4.1.

         SECTION 1.69. STOCK PURCHASE AGREEMENT shall mean the Subscription
Agreement between Celltech and NeoGenesis signed

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       11
<Page>

contemporaneously with this Agreement pursuant to which Celltech is purchasing
NeoGenesis Series E Preferred Stock.

         SECTION 1.70. TARGET shall mean a specific polypeptide sequence or
protein selected by Celltech to enter the Research Collaboration.

         SECTION 1.71. TARGET GUIDELINES shall mean the following parameters
pursuant to which NeoGenesis shall be able to reject a Target from entering the
Research Collaboration: the Target is [*] at the peptide level with (1) a target
that is subject to an exclusivity period in an ongoing agreement between
NeoGenesis and a Third Party at the time Celltech requests inclusion of the
Target in the Research Collaboration or (2) the Target is a NeoGenesis Target.

         SECTION 1.72. TERM shall have the meaning set forth in Section 12.1
hereof.

         SECTION 1.73. TERRITORY shall mean all the countries of the world.

         SECTION 1.74. THIRD PARTY (THIRD PARTIES) shall mean any person other
than NeoGenesis and its Affiliates and Celltech and its Affiliates.

         SECTION 1.75. THIRD PARTY CLAIM shall have the meaning set forth in
Section 8.5.

                                   ARTICLE II.
                         GRANT, RIGHTS AND RESTRICTIONS

         SECTION 2.1. GRANT OF RESEARCH LICENSE. Subject to the terms and
conditions of this Agreement, Celltech hereby grants to NeoGenesis and
NeoGenesis hereby accepts, a nonexclusive, nonsublicenseable; nontransferable,
non-assignable, royalty-free license to Celltech Technology solely for purposes
of performing NeoGenesis' obligations to Celltech under the Research
Collaboration Plan during the Research Term. NeoGenesis shall not use Celltech
Technology for any other purpose. NeoGenesis shall not (i) grant, or attempt to
grant, a sub-license to Celltech Technology to any Person, (ii) perform any
tests on any Approved Target(s) other than as part of the Research Collaboration
Plan, or (iii) modify the Approved Targets supplied by Celltech, including,
without limitation, the making of any derivatives, analogs or components
thereof. In the event that NeoGenesis does not consume all of the Approved
Target(s) supplied by Celltech in performance of the Research Collaboration
Plan, NeoGenesis shall, upon Celltech's request, promptly return to Celltech any
remaining quantities of such Approved Target(s).

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       12
<Page>

         SECTION 2.2. NEOGENESIS GRANT OF LICENSE. Subject to the terms and
conditions of this Agreement, including the payment of all applicable fees,
NeoGenesis hereby grants to Celltech, and its Affiliates:

         (a) an exclusive, worldwide, right and license, within the Territory to
NeoGenesis Technology and NeoGenesis' interest in any Program Technology, as
embodied in or related to any Preliminary Compound(s), Primary Active
Compound(s), QSCD Preliminary Compound(s), QSCD Primary Active Compound(s) and
Designated Compounds solely for the purpose of conducting Celltech's activities
under the Research Collaboration, to research, develop, make, have made, use and
import Preliminary Compound(s), Primary Active Compound(s), QSCD Preliminary
Compound(s), QSCD Primary Active Compound(s) and Designated Compounds to develop
Licensed Product(s); and

         (b) an exclusive, worldwide, right and license, within the Territory,
to the NeoGenesis Technology and NeoGenesis' interest in any Program Technology,
as embodied in or related to any Designated Compounds, necessary to make, have
made, develop, have developed, use, distribute for sale, promote, market, offer
for sale, sell, have sold, import and export Licensed Product(s).

         (c) Celltech and its Affiliates may grant sublicenses of its rights
under this Section 2.2; provided that Celltech obtains each sublicensee's
written agreement to be subject to similar obligations as is Celltech and its
Affiliates under Sections 2.3, 6.4-6.6, 7.4(b) and all of Article IX of this
Agreement (or substantially identical provisions).

         SECTION 2.3. RETAINED RIGHTS. This Agreement does not convey to
NeoGenesis any ownership rights in any Celltech Technology by implication,
estoppel or otherwise except for the rights expressly granted in Section 2.1 and
Section 8.1. This Agreement does not convey to Celltech any ownership rights in
any NeoGenesis Technology by implication, estoppel or otherwise except for the
rights expressly granted in Section 2.2 and Section 8.1.

                                  ARTICLE III.
                           RESEARCH COLLABORATION PLAN

         SECTION 3.1. DILIGENCE. The Parties hereto agree to use Commercially
Reasonable Efforts to conduct the Research Collaboration under this Agreement
during the Research Term.

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       13
<Page>

         SECTION 3.2. RESEARCH COLLABORATION. The Research Collaboration shall
be carried out in accordance with the Research Collaboration Plan, as detailed
in Exhibit A, as may be amended from time to time by the Steering Committee
during the Research Term. The Research Term shall begin on the Effective Date
and end December 31, 2005, unless earlier terminated pursuant to Article XII
("Research Term"). The Research Term may be amended by the Parties consistent
with the terms of the Agreement.

         SECTION 3.3. NUMBER OF TARGETS. NeoGenesis shall fulfill its
obligations under the Research Collaboration Plan for a minimum of [*] Approved
Targets during the Research Term. The following schedule may be utilized by the
Steering Committee as a general guideline for the number of Approved Targets to
be completed per year under the Research Collaboration Plan. Any Approved
Targets not completed in a given year shall carryover to any of the following
years until [*] Approved Targets have completed pursuant to the Research
Collaboration Plan.

                                 TARGET SCHEDULE
<Table>
<Caption>
  YEAR                                                APPROVED TARGETS
  ----                                                -----------------
  <S>                                                 <C>
  2001                                                [*]
  2002                                                [*]
  2003                                                [*]
  2004                                                [*]
  2005                                                [*]
                                                      ---
  TOTAL                                               [*]
                                                      ===
</Table>

                                   ARTICLE IV.
                               STEERING COMMITTEE

         SECTION 4.1. STEERING COMMITTEE. The Steering Committee shall consist
of six members, three members to be appointed by each of NeoGenesis and Celltech
("Steering Committee"). Each Party may, with written notice to the other,
substitute any of its members serving on the Steering Committee. The initial
Celltech members shall be Melanie Lee, Mark J. Litton and John Montana and the
initial NeoGenesis members shall be Satish Jindal, Huw Nash and Arshad Siddiqui.

         (a) STEERING COMMITTEE ACTIVITIES. The Steering Committee shall be
responsible for the management and conduct of the Research Collaboration Plan
during the Research Term and shall in particular: (i) consider, review and amend
the Research Collaboration Plan from time to time in such manner as may be
appropriate; (ii) monitor progress of the Research Collaboration Plan; (iii)
report regularly to the management of both

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       14
<Page>

Parties upon the progress of the Research Collaboration Plan; and (iv) be the
initial medium for transfer of information between the Parties. All oversight
activities and governance rights of the Steering Committee shall terminate, on a
compound by compound basis, on a compound has been designated as a Designated
Compound. Upon conclusion of the Research Term, the Steering Committee shall
only perform the functions set forth in Article VIII hereof, or as otherwise
agreed by the Parties in writing.

         (b) STEERING COMMITTEE MEETINGS. The Steering Committee shall hold
meetings as mutually agreed by the Parties (but in no event less than Quarterly
during the Research Term) to review the Research Collaboration Plan. The first
meeting of the Steering Committee shall be held within forty-five (45) days of
the Effective Date and shall be held in Cambridge, MA. Thereafter, meetings may
be held by telephone or video conference if requested by either Party in writing
to the other, PROVIDED that the Steering Committee shall meet in person at least
once per annum during the Research Term. Minutes of all meetings setting forth
decisions of the Steering Committee relative to the Research Collaboration Plan
shall be prepared by the host Party and circulated to both Parties within
fifteen (15) days after each meeting. The minutes shall not become official
until approved by both Parties (the Parties shall use Commercially Reasonable
Efforts to give approval within thirty (30) days of receipt of such minutes).

         (c) STEERING COMMITTEE GOVERNANCE. The quorum for Steering Committee
meetings shall be four (4) members, provided that at least two (2) members from
each of NeoGenesis and Celltech are present. Each member of the Steering
Committee will have one vote and all decisions of the Steering Committee will be
by unanimous agreement. In the event that unanimity is not reached Celltech
shall have the final say on all issues relating to (i) the Research
Collaboration Plan as set forth in Exhibit A, (provided, that in the event and
to the extent that any disagreement concerns whether or not the budgeted FTE
funding for a particular period has been exhausted in accordance with the
provisions of this Agreement (including Exhibit B), such matter shall be
resolved in accordance with the procedure specified immediately below) and (ii)
the timing for filing and the contents of any patent applications that contain
or are based on any Celltech data or information. Any other disagreements at the
Steering Committee shall be resolved via good-faith discussions; PROVIDED, that
in the event of a disagreement that cannot be resolved within thirty (30) days
after the date on which the disagreement arose, the matter shall be referred to
designees selected by the Chief Executive Officer of each of Celltech and
NeoGenesis for resolution; PROVIDED, that such designees shall not be members of
the Steering Committee. Thereafter, if any such disagreement is not resolved

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       15
<Page>

within sixty (60) days, the matter shall be resolved using the procedure
specified in Section 13. l, where applicable.

                                   ARTICLE V.
                                RESEARCH FUNDING

         SECTION 5.1.  RESEARCH COLLABORATION FUNDING.

         (a) STOCK PURCHASE. As partial consideration for the Research
Collaboration activities under this Agreement, Celltech shall, contemporaneously
with this Agreement, execute a Stock Purchase Agreement with NeoGenesis for the
purchase of Ten Million US Dollars ($10,000,000.00) of NeoGenesis Series E
Convertible Preferred Stock at a price of Five and 97/100's US Dollars per
share.

         (b) FTE FUNDING. As additional consideration for the activities
undertaken pursuant to this Agreement and subject to NeoGenesis' performance of
its obligations hereunder and under the Research Collaboration Plan, Celltech
shall fund FTEs at the rate of [*] per FTE per annum during the Research Term
according to the FTE schedule set forth below.

                                  FTE SCHEDULE
<Table>
<Caption>
                                                                                    QUARTERLY
         PERIOD                MINIMUM FTES                TOTAL PAYMENT            PAYMENTS
         ------                ------------                -------------            --------
  <S>                               <C>                  <C>                        <C>
  Last 1/2 of 2001                  [*]                              [*]                 [*]
  2002                              [*]                              [*]                 [*]
  2003                              [*]                              [*]                 [*]
  2004                              [*]                              [*]                 [*]
  2005                              [*]                              [*]                 [*]
  TOTAL                             [*]                  $10,750,000.00
                                                         --------------
</Table>

         (c) QUARTERLY PAYMENTS. Invoicing and payment for FTEs shall be as set
forth on Exhibit B hereto.

                                   ARTICLE VI.
                         MILESTONES AND ROYALTY PAYMENTS

         SECTION 6.1. MILESTONES. In further consideration of the rights granted
by NeoGenesis to Celltech hereunder, Celltech shall pay NeoGenesis each of the
following milestone payments in respect of Licensed Product as specified in this
Section 6.1.

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       16
<Page>

         (a) PHASE I. Within thirty (30) days following the date on which
Celltech first administers any Licensed Product to a human subject in a Phase I
Clinical Trial, Celltech shall pay NeoGenesis [*]. "Phase I Clinical Trial"
shall mean any clinical study in any Major Country which provides for the
initial trials of a Licensed Product for the primary purpose of making a
preliminary determination of safety of the Licensed Product for its intended use
in healthy individuals or patients to support its continued testing in similar
clinical trials prescribed by the relevant Regulatory Authority.

         (b) PHASE III. Within thirty (30) days following the date on which
Celltech first administers any Licensed Product to a human subject in a Phase
III Clinical Trial on a Licensed Product, Celltech shall pay NeoGenesis [*].
"Phase III Clinical Trial" shall mean any clinical study in any Major Country of
a Licensed Product, the primary purpose of which is evaluating statistical
significance of the safety and efficacy of the Licensed Product in patients with
the disease target being studied as required by the relevant Regulatory
Authority to evaluate the overall benefit-risk relationship of the drug and to
provide an adequate basis for physician labeling.

         (c) APPROVAL LETTER. Within thirty (30) days following the date on
which Celltech receives an Approval Letter covering a Licensed Product, Celltech
shall pay NeoGenesis [*]. "Approval Letter" shall mean a written communication
to Celltech from the FDA approving an NDA on a Licensed Product.

         (d) MILESTONE FREQUENCY. Milestones identified in Section 6.1(a)-(c)
shall be due once for each Licensed Product meeting such milestone, but shall
not include improvements or derivatives thereof or new indications for the same
Licensed Product. On the date any one milestone with respect to any Licensed
Product is achieved, all lower numbered unachieved milestones shall be deemed to
have been achieved with respect to that Licensed Product; PROVIDED that with
respect to the milestone specified in Section 6.1(a), no payment of such
milestone amount shall be due upon the achievement of the milestone specified in
Section 6.1 (b) if Phase I Clinical Trials are not required but such milestone
shall be paid upon the achievement of the milestone specified in Section 6.1(c).

         SECTION 6.2. ROYALTIES. In further consideration of the rights granted
by NeoGenesis to Celltech hereunder, Celltech shall pay NeoGenesis the following
royalties on a per annum basis commencing with the First Commercial Sale of
Licensed Product(s) by Celltech, its Affiliates or sublicensees in the
Territory:

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       17
<Page>

         (a) NON-QSCD DISCOVERED COMPOUNDS. On all Licensed Products which were
not discovered using QSCD, Celltech shall pay royalties of [*] of Net Sales of
Licensed Product [*] per annum and [*] of Net Sales of Licensed Product [*] per
annum;

         (b) QSCD DISCOVERED COMPOUNDS. On all Licensed Products which were
discovered using QSCD, as verified in writing by the Steering Committee prior to
the performance of such QSCD, Celltech shall pay royalties of [*] of Net Sales
of License Product [*] per annum and [*] of Net Sales of Licensed Product [*]
per annum.

         (c) ROYALTY PAYMENTS AND TERM. Celltech shall pay to NeoGenesis the
above royalties no later than sixty (60) days following each Quarter commencing
with the First Commercial Sale of Licensed Product by Celltech, its Affiliates
or sublicensees in the Territory. Celltech shall make the royalty payments with
respect to each Licensed Product sold by Celltech, its Affiliates and
sublicensees on a country by country basis until the later of (1) expiration or
revocation or rejection or complete abandonment of the last to expire or to be
revoked or to be abandoned of any issued NeoGenesis patent right covering such
Licensed Product in the country in which the Licensed Product is manufactured or
sold or the issuance of a final decision, which is unappealed or unappealable,
of a court of competent jurisdiction or of an administrative agency having
authority over patents, that all patents covering such Licensed Product are
invalid, unpatentable or unenforceable, or (2) if no NeoGenesis patent right
exists in the relevant country covering the manufacture, use or sale of the
Licensed Product, until ten (10) years from the First Commercial Sale of such
Licensed Product in the relevant country. Upon expiration of such period,
Celltech's license under Section 2.2 shall be deemed to be fully paid and
Celltech shall be able to continue Commercialization of the relevant Licensed
Product in the relevant country(ies) without any further liability to
NeoGenesis.

         (d) ROYALTY ADJUSTMENTS. The royalty rates set forth in this Section
6.2 are subject to reduction pursuant to Section 8.5(b)(iv), hereof.

         SECTION 6.3.  REMITTANCE.

         (a) FUNDS/EXCHANGE RATE. All royalties and milestone payments required
under Section 6 shall be payable in full in the United States in United States
Dollars, regardless of the countries in which sales were made. For the purpose
of computing Net Sales for which a currency other than United States Dollars is
received, such currency shall be converted into United States Dollars at the
exchange rate for buying United States Dollars

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       18
<Page>

in effect on the close of business on the last business day of the Quarter by
Chase Bank, New York, New York.

         (b) INTEREST. In the event that any undisputed payment due NeoGenesis
under this Agreement is not made when due, NeoGenesis may collect interest
calculated at an annual rate equal to one percent (1%) above the prime interest
rate as published on the close of business by Chase Bank, New York, New York on
the due date. Such payment when made shall be accompanied by all interest so
accrued.

         SECTION 6.4. RECORDS. Beginning after the First Commercial Sale of
Licensed Product, on a Licensed Product by Licensed Product basis, Celltech, its
Affiliates and sublicenses shall keep and maintain for a period of at least two
(2) years from the date of each payment of royalties, records (prepared in
accordance with United States Generally Accepted Accounting Principles,
consistently applied) sufficient to determine the amounts of Net Sales and
payments due under Section 6.2. Within sixty (60) days following each Quarter in
which payments are due under Section 6.2, Celltech shall provide NeoGenesis with
a report including at least: (a) the quantities of Licensed Products that
Celltech, its Affiliate(s) and sublicensee(s) sold during the preceding quarter
in each country in which Licensed Products were sold; (b) the monetary amount,
in the national currency of such country, of such sales; (c) actual Net Sales,
by country; (d) the currency conversion rate used and U.S. dollar-equivalent of
such sales as calculated pursuant to 6.3(a); and (e) the total royalties so
computed and due NeoGenesis. Such reports shall be submitted to NeoGenesis
whether or not any sales of Licensed Product have been made during such period.
Upon delivery of the report due for the period ending December 31 of each year,
Celltech shall also report to NeoGenesis the aggregate royalties paid to
NeoGenesis for the entire preceding year.

         SECTION 6.5.  INSPECTION.

         (a) AUDIT. Celltech and its Affiliates shall, and Celltech shall
provide in any agreements with its sublicensees that such sublicensees shall,
each make its records available for audit by an independent certified public
accountant selected by NeoGenesis and reasonably acceptable to Celltech, during
regular business hours at such place or places where such records are
customarily kept, upon reasonable notice from NeoGenesis, solely to verify the
accuracy of the reports and payments set forth in Section 6.4 hereof. Celltech
and its Affiliates shall only disclose such records relating to the accuracy of
the royalty payments to NeoGenesis. Such audit right shall not be exercised more
than once in any calendar year nor more than once with respect to sales of
Licensed Products in any given payment period.

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       19
<Page>

NeoGenesis agrees to hold all information learned from such audits as
Confidential Information, except to the extent necessary for NeoGenesis to
reveal such information in order to enforce its rights under this Agreement. Any
person or entity conducting such audit or inspection must agree in writing with
NeoGenesis to treat all records reviewed in the course of the audit or
inspection as the Confidential Information of Celltech under terms and
conditions no less restrictive than the terms contained in Article IX. The
results of each audit shall be binding on both Parties. The independent
accountant shall simultaneously supply both Celltech and NeoGenesis with a copy
of any report prepared as a result of such audit. NeoGenesis shall pay for such
inspections, except that in the event there is any upward adjustment in
aggregate royalties payable for any year shown by such inspection of more than
five percent (5%) of the amount paid, Celltech shall pay for such inspection.

         (b) DISPUTES. All reports and payments not disputed as to correctness
by either Party within two (2) years after receipt thereof shall thereafter
conclusively be deemed correct.

         SECTION 6.6. TAXES. Except for income taxes that may be assessed
against NeoGenesis, all taxes and charges that may be imposed by any government
taxing authority on the amounts paid by Celltech to NeoGenesis under this
Agreement shall be paid by Celltech for NeoGenesis' account. In the event
Celltech is required to pay the taxes or charges for the account of NeoGenesis,
and therefore withholds such taxes or charges from the amounts paid to
NeoGenesis under this Agreement, Celltech shall deliver to NeoGenesis true
copies of the receipts and/or returns covering all such payments and the
appropriate documentation which is necessary to obtain a tax credit, to the
extent such tax credit can be obtained, as determined by NeoGenesis. Each Party
shall provide assistance to the other Party in seeking any benefits available to
such Party with respect to government tax withholdings by any relevant law or
double tax treaty.

                                  ARTICLE VII.
                      REGULATORY AND MARKETING OBLIGATIONS

         SECTION 7.1. PRODUCT DEVELOPMENT. Celltech, at its sole expense, shall
be responsible for and shall use Commercially Reasonable Efforts with respect to
conducting the R&D Program related to Designated Compounds and Licensed Products
and for obtaining Regulatory Approvals for Licensed Products.

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       20
<Page>

         SECTION 7.2. MANUFACTURE OF PRODUCT. Celltech, at its sole expense,
shall be responsible for and shall use Commercially Reasonable Efforts with
respect to the Manufacture of the Licensed Products in accordance with the
Regulatory Approvals, Applicable Laws, Good Laboratory Practices and Good
Manufacturing Practices.

         SECTION 7.3. REGULATORY MATTERS. Celltech, at its sole expense, shall
be responsible for and shall use Commercially Reasonable Efforts with respect to
the preparation and filing with the appropriate Regulatory Authorities, of all
documents that are necessary to conduct clinical studies of Licensed Products
and Regulatory Approval applications that are necessary to market and sell
Licensed Products. Celltech shall notify NeoGenesis, in writing, that such
regulatory filing has been made.

         SECTION 7.4.  MARKETING AND SALE.

         (a) RESPONSIBILITY. Celltech, at its sole expense, shall be responsible
for and shall use Commercially Reasonable Efforts with respect to the
Commercialization of Licensed Products in the Territory. Celltech shall be
solely responsible for establishing the price of each Licensed Product sold by
or on behalf of it pursuant to this Agreement.

         (b) MARKING. Celltech, its Affiliates and sublicensees shall mark or
have marked all containers or packages of Licensed Product(s) that are the
subject of the License granted under Section 2.2 in accordance with the patent
marking laws of the jurisdiction in which such Licensed Product(s) are sold.

         (c) THIRD PARTY LICENSES. Celltech shall be solely responsible, at its
sole discretion, for (a) obtaining any and all licenses from third parties
necessary or desirable to perform the R&D Program and/or to Commercialize any
Licensed Product and (b) except as otherwise provided in Section 6.2(d), any and
all consideration payable with respect to such licenses.

         SECTION 7.5. PERIODIC REVIEW. Celltech and NeoGenesis shall meet, at
such times and places as are mutually agreed upon, for Celltech to provide
NeoGenesis with an update on the status of the progress of Celltech's
Commercialization of each Licensed Product; provided, however, that such
meetings shall occur no more than once per calendar year unless the parties
agree, in writing, to meet more often. Celltech and NeoGenesis shall each be
responsible for its own expenses incurred in connection with attending such
meetings.

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       21
<Page>

                                  ARTICLE VIII.
                   RIGHTS IN TECHNOLOGY, PATENTS AND KNOW-HOW

         SECTION 8.1. OWNERSHIP OF PROGRAM TECHNOLOGY. Subject to the terms of
this Agreement, the Parties ownership rights in Program Technology, regardless
of inventorship, are as follows:

         (a) CELLTECH OWNED PROGRAM TECHNOLOGY. As between Celltech and
NeoGenesis, Celltech shall have and retain all right, title and interest in and
to any and all Program Technology solely related to Targets or the uses thereof,
Celltech cell-based or biochemical assays, Designated Compound(s) and Licensed
Product(s) and any method of manufacturing or using any Designated Compound(s)
or Licensed Product(s), and to the extent that any of the forgoing shall have
been invented by NeoGenesis employees or consultants (whether solely or jointly
with Celltech employees or consultants), NeoGenesis hereby assigns all right,
title and interest therein throughout the Territory and shall use Commercially
Reasonable Efforts to assign all right, title and interest therein; PROVIDED,
HOWEVER, that notwithstanding any provision of this Agreement (including the
Research Collaboration Plan) to the contrary, NeoGenesis shall not be required
to assign to Celltech all right title and interest in more than: (i) [*]
Designated Compounds when the optimization as set forth in paragraph 3(d) of the
Research Collaboration Plan is performed by Celltech and such Designated
Compounds are taken directly from the NeoMorph Screening Library or (ii) [*]
Designated Compounds when the optimization as set forth in paragraph 3(d) of the
Research Collaboration Plan is performed by NeoGenesis and such Designated
Compounds are taken from NeoMorph Focused Libraries. In the event that Celltech
undesignates any Designated Compound in and to whose right, title and interest
has been assigned by NeoGenesis under this Section 8.1 (a) using the procedure
specified in Paragraph 4(a) of the Research Collaboration Plan, Celltech shall,
upon written request by NeoGenesis, (i) return the Designated Compound to
NeoGenesis and (ii) assign all right title and interest in such Designated
Compound back to NeoGenesis, including any patents or patent applications (if
any) Controlled by Celltech or any Affiliate, provided such patents or patent
applications cover solely such undesignated Designated Compound. To the extent
that such patents or patent applications cover more than such Designated
Compound, Celltech shall grant an exclusive license to NeoGenesis for such
patents or patent applications to the extent they cover such Designated
Compound. In the event of an assignment of all right title and interest in such
undesignated Designated Compound, NeoGenesis shall reimburse Celltech for all
reasonable costs associated with filing, prosecuting or maintaining such patents
or patent applications. It is understood that Celltech shall be under

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       22
<Page>

no obligation to assign or license to NeoGenesis any Celltech Derivatives. Any
restrictions with respect to an undesignated Designated Compound shall expire
and NeoGenesis shall be permitted to use such undesignated Designated Compound
for any purpose not otherwise prohibited by this Agreement.

         (b) NEOGENESIS OWNED PROGRAM TECHNOLOGY. As between NeoGenesis and
Celltech, NeoGenesis shall have and retain all right, title and interest in and
to any Preliminary Compound(s), Primary Active Compound(s), NeoMorph Focused
Libraries, QSCD Preliminary Compound(s), QSCD Primary Active Compound(s) and
NeoMorph Screening Library(s) unless and until they become Designated Compounds
and all Program Technology solely related to ALIS screening technology or QSCD.

         (c) JOINTLY OWNED PROGRAM TECHNOLOGY. As between Celltech and
NeoGenesis, each Party shall own an undivided one-half interest in and title to
all Program Technology not specifically accounted for in Section 8.1 (a) and
(b).

         SECTION 8.2. DISCLOSURE BY EMPLOYEES, AGENTS OR INDEPENDENT
CONTRACTORS. Celltech and NeoGenesis agree that, as to any employees, agents or
independent contractors of Celltech and NeoGenesis presently in their employ, or
who are hired or retained by either Party, to perform, manage performance of, or
participate in the research done pursuant to this Agreement, Celltech and
NeoGenesis shall ensure that such employees, agents and independent contractors
will promptly disclose and assign to the Party engaging them any and all rights
to inventions, developments or improvements (whether patentable or not),
conceived and/or reduced to practice during the course of their duties.

         SECTION 8.3. PATENT PROSECUTION AND RELATED ACTIVITIES. Upon
notification by either Party of the existence of any Program Technology, the
Parties shall confer through the Steering Committee as to appropriate protection
for such Program Technology. In addition, subject to Section 4.1(c), the
Steering Committee shall determine the timing of all patent filings on all
Program Technology.

         (a) NEOGENESIS OWNED PROGRAM TECHNOLOGY. NeoGenesis shall have the sole
right, but not the obligation, to prepare, file, prosecute, and maintain, at
NeoGenesis' sole expense, any Patent(s) on the Program Technology set forth in
Section 8.1(b) throughout the Territory. In the event that NeoGenesis elects not
to file for patent protection or elects not to prosecute or maintain a Patent(s)
on the Program Technology set forth in

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       23
<Page>

Section 8.1(b), it shall notify Celltech in writing of such decision and provide
Celltech a one (1) month period from receipt of such written notification in
which to respond to such notice before abandoning and/or discontinuing its
obligations to file, prosecute or maintain such Patent(s). Celltech shall have
the right, but not the obligation to assume the responsibility therefor, at its
own cost and expense. If Celltech responds within such one (1) month response
period that it wishes to file, prosecute or maintain such Patent(s), then
NeoGenesis shall promptly transfer and assign all right, title and interest in
and to such Patent(s) to Celltech and shall continue to file, prosecute and
maintain such Patent(s) until such transfer and assignment become effective.
Celltech shall reimburse NeoGenesis for all reasonable costs associated with
filing, prosecuting or maintaining such Patent(s). Upon such transfer and
assignment becoming effective, NeoGenesis shall reasonably assist Celltech in
the filing, prosecuting and maintaining such Patent(s).

         (b) CELLTECH OWNED PROGRAM TECHNOLOGY. Celltech shall have the sole
right, but not the obligation, to prepare, file, prosecute, and maintain, at
Celltech's sole expense, any Patent(s) on the Program Technology set forth in
Section 8.1 (a) throughout the Territory. In the event that Celltech elects not
to prepare or file for patent protection or elects not to prosecute or maintain
a Patent(s) on Celltech Program Technology set forth in Section 8.1(a), it shall
notify NeoGenesis but shall have no obligation to continue with the filing,
preparing, prosecuting or maintaining any Patent(s).

         (c) JOINTLY OWNED PROGRAM TECHNOLOGY. NeoGenesis shall have the sole
right, but not the obligation, to prepare, file, prosecute, and maintain, at
NeoGenesis' expense, any Patent(s) on Program Technology set forth in Section
8.1(c) throughout the Territory. NeoGenesis shall keep Celltech currently
advised as to the status of all Patent(s) with respect to the Program Technology
set forth in Section 8.1(c) and shall supply Celltech promptly with copies of
all patents, patent applications, substantive patent office actions, substantive
responses received or filed in connection with such applications. Celltech may
itself or through its attorney offer comments and suggestions with respect to
the matters that are the subject of this Section 8.3(c) and NeoGenesis agrees to
consider such comments and suggestions; PROVIDED that nothing herein shall
obligate NeoGenesis to adopt or follow such comments or suggestions. In the
event that NeoGenesis elects not to file for patent protection or elects not to
prosecute or maintain a Patent(s) on the Program Technology set forth in Section
8.1(c), it shall notify Celltech in writing of such decision and provide
Celltech a one (1) month period from receipt of such written notification in
which to respond to such notice before abandoning and/or discontinuing its
obligations to file, prosecute or maintain

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       24
<Page>

such Patent(s). Celltech shall have the right, but not the obligation to assume
the responsibility therefore, at its own cost and expense. If Celltech responds
within such one (1) month response period that it wishes to file, prosecute or
maintain such Patent(s), then NeoGenesis shall promptly transfer and assign all
right, title and interest in and to such Patent(s) to Celltech and shall
continue to file, prosecute and maintain such Patent(s) until such transfer and
assignment become effective. Celltech shall reimburse NeoGenesis for all
reasonable costs associated with filing, prosecuting or maintaining such
Patent(s) from date it notifies NeoGenesis it wishes to assume responsibility
for the patent(s) until the transfer and assignment becomes effective shall be
paid by Celltech. Upon such transfer and assignment becoming effective,
NeoGenesis shall reasonably assist Celltech in the filing, prosecuting and
maintaining of such Patent(s).

         (d) COOPERATION. Each Party shall keep the Steering Committee informed
as to the status of patent matters set forth in this Section 8.3 during the
Research Term. To the extent necessary, and at the requesting Party's expense,
each Party shall use Commercially Reasonable Efforts to cooperate and assist the
other Party with the preparation, filing and prosecution of Patent(s).

         SECTION 8.4.  THIRD PARTY INFRINGEMENT.

         (a) ENFORCEMENT. In the event that either Party becomes aware that any
NeoGenesis Technology, or Program Technology are infringed or misappropriated by
a Third Party or are subject to a declaratory judgment action, the Party
becoming aware of such event shall promptly notify the other Party. The Party
with the right to prepare, file, prosecute, and maintain a Patent(s) with
respect to such NeoGenesis Technology, or Program technology, as the case may
be, and which is then maintaining said Patent(s), in its sole discretion, shall
have the right and shall be solely responsible for pursuing any action for
infringement or misappropriation against Third Parties or defending any
declaratory judgment action relating thereto. To the extent that the Program
Technology being pursued is Program Technology as set forth in Section 8.1(c),
the Party not having the right to prepare, file, prosecute, and maintain a
Patent(s) with respect to such NeoGenesis Technology, or Program technology, as
the case may be, and which is not then actually maintaining said Patent(s) shall
have the option to participate in such action at its sole expense.

         (b) FAILURE TO ENFORCE. If the Party with the right to pursue any
action for infringement or misappropriation against Third Parties or defending
any declaratory judgment action as set forth in Section 8.4(a)

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       25
<Page>

above fails to pursue or defend such action relating to Program Technology set
forth in Section 8.1 (c) within sixty (60) days written notice by the other
Party of its desire to proceed, then the other Party shall have the option to
pursue or defend such actions; PROVIDED, that such Party pays all costs and
expenses related to the same, and keeps the other Party reasonably informed of
its progress and provides copies of any documents related to such proceedings
and reasonable notice of all proceedings relating to same. A Party electing to
exercise its option to proceed under this Section 8.4(b) shall notify the other
Party of its decision to exercise its option as soon as possible.

         (c) DIVISION OF RECOVERIES. Any recovery of damages received in
connection with a suit (including by way of settlement) under Section 8.4(a)
involving Program Technology set forth in Section 8.1 (a) or (b) shall be
retained by the Party that owns said Program Technology; PROVIDED that any
recovery of ordinary damages (including by way of settlement) based upon
infringement of Program Technology set forth in Section 8.1 (a) shall be deemed
to be Net Sales and Celltech shall pay NeoGenesis an amount calculated in
accordance with Section 6.2 to reimburse NeoGenesis for royalties due in respect
of lost sales of Licensed Products represented by such ordinary damages. Any
recovery of damages received in connection with a suit (including by way of
settlement) under Section 8.4(a) involving the Program Technology set forth in
Section 8.1 (c) brought by NeoGenesis or Celltech shall be retained by the Party
that conducted such suit. Any recovery of damages received in connection with a
suit (including by way of settlement) jointly brought by NeoGenesis and Celltech
(other than the assistance that each party is required to provide to the
litigating party pursuant to Section 8.4(d) and for which it has been
reimbursed) shall be used first to reimburse the Parties, on a pro-rata basis,
for all expenses actually incurred in such suit, and any remainder shall divided
equally between Celltech and NeoGenesis after payment by Celltech of any
obligations it may have to any sublicensee in relation to any recovery.

         (d) COOPERATION. In any claim, suit or proceeding under Section 8.4
which either Party may become involved, the other Party shall, at the request
and expense of the Party initiating or defending the claim, suit or proceeding,
cooperate and assist such Party in all reasonable respects, including having its
employees testify when requested and making available relevant records, papers,
information, specimens and the like.

         SECTION 8.5.  INFRINGEMENT CLAIMS BY THIRD PARTIES.

         (a) THIRD PARTY CLAIMS. If the making, having made, using, distributing
for sale, promoting, marketing, offering for sale, selling, having

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       26
<Page>

sold, importing or exporting of any Licensed Products results in an assertion or
a claim against a Party of infringement or misappropriation of any Third Party's
intellectual property right ("Third Party Claim"), the Party first having notice
of a Third Party Claim shall promptly notify the other Party in writing
specifying in reasonable detail the alleged grounds or basis for the Third Party
Claim.

         (b) RESPONSE TO THIRD PARTY CLAIMS. In the event of a Third Party
Claim, the Parties agree to respond to and/or defend against the Third Party
Claim as follows:

                  (i) Each Party shall use Commercially Reasonable Efforts in
responding to and defending against such Third Party Claim, and will render such
reasonable assistance as the other Party may request, at the requesting Party's
expense, in defending such Third Party Claim.

                  (ii) Neither Party shall settle any Third Party Claim in a
manner that is prejudicial to either Party without the other Party's prior
written consent.

                  (iii) Each Party shall be responsible for its own fees and
costs of attorneys and consultants, together with court costs, incurred in
defending against the Third Party Claim.

                  (iv) If Celltech, by court order, settlement or other
agreement entered into in good faith, is required to pay royalties and/or
damages to any Third Parties in connection with the disposition of a Third Party
Claim to avoid infringement by any Licensed Product of such Third Party
patent(s), then Celltech shall be entitled, beginning from the date Celltech
commences payment to any such Third Parties, to reduce the royalties payable to
NeoGenesis by [*] of the amount of any such royalties and/or damages payable to
such Third Parties; provided that: (1) such infringement is on a Licensed
Product provided that such infringement is primarily related to the
pharmaceutically active ingredient of the Licensed Product and (2) such
deductions reduce by no more than [*] the royalties otherwise due NeoGenesis
under Section 6.2 with respect to such Licensed Product.

                                   ARTICLE IX.
                                 CONFIDENTIALITY

         SECTION 9.1. CONFIDENTIALITY. As used in this Agreement, the term
"Confidential Information" shall mean any and all non-public, proprietary or
otherwise confidential information pertaining to or developed under this

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       27
<Page>

Agreement furnished to either Party ("Receiving Party") by or on behalf of the
other Party ("Disclosing Party"). Such Confidential Information includes, but is
not limited to, trade secrets, know-how, inventions, formulations, compositions,
technical data or specifications, testing methods, business or financial
information, research and development activities, product and marketing plans
and customer and supplier information together with all portions of analysis,
studies and other documents prepared by or for the benefit of a Party.

         SECTION 9.2. OBLIGATIONS OF CONFIDENTIALITY. The Receiving Party shall:
(a) maintain all Confidential Information in strict confidence, except that the
Receiving Party may disclose or permit the disclosure of any Confidential
Information to its directors, officers, employees, consultants and advisors who
are obligated to maintain the confidential nature of such Confidential
Information and who need to know such Confidential Information to perform this
Agreement; (b) use all Confidential Information solely for purposes of
performing its obligations or exercising its rights under this Agreement; and
(c) reproduce the Confidential Information only to the extent necessary to
perform this Agreement, with all such reproductions being considered
Confidential Information.

         SECTION 9.3. LEGAL DISCLOSURE. The obligations of the Receiving Party
under Section 9.2 hereof shall not apply to the extent that the Receiving Party
can demonstrate by competent written documentation that certain Confidential
Information; (a) was in the public domain prior to the time of its disclosure
under this Agreement; (b) entered the public domain after the time of its
disclosure under this Agreement through means other than an unauthorized
disclosure resulting from an act or omission by the Receiving Party; (c) was
independently developed or discovered by the Receiving Party prior to the time
of its disclosure under this Agreement, as evidenced by the Receiving Party's
records; (d) is or was disclosed to the Receiving Party at any time, whether
prior to or after the time of its disclosure under this Agreement, by third
Party having no fiduciary relationship with the Disclosing Party and having no
obligation of confidentiality with respect to such Confidential Information.
Nothing herein shall prevent the Receiving Party from disclosing all or part of
the Confidential Information as necessary pursuant to the lawful requirement of
a governmental agency or when disclosure is required by operation of law;
PROVIDED that prior to any such disclosure, the Receiving Party shall use
reasonable efforts to: (i) promptly notify the Disclosing Party in writing of
such requirement to disclose; and (ii) cooperate fully with the Disclosing Party
in protecting against any such disclosure or obtaining a protective order. A
Party's Confidential Information shall not be deemed to be within

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       28
<Page>

any of the foregoing exceptions merely because it is embraced by general
disclosures within such exceptions, nor shall a Party's Confidential Information
be deemed to be within any of the foregoing exceptions merely because individual
items are in such exceptions.

         SECTION 9.4. OWNERSHIP OF INFORMATION. Except as provided in this
Agreement with respect to ownership of Program Technology, the Receiving Party
agrees that the Disclosing Party (or any Third Party entrusting its own
Confidential Information to the Disclosing Party) is and shall remain the
exclusive owner of the Confidential Information disclosed by the Disclosing
Party and all patent, copyright, trademark, trade secret, and other intellectual
property rights in, or arising from, such Confidential Information. No option,
license, or conveyance of such rights to the Receiving Party is granted or
implied under this Agreement unless expressly set forth herein. If any such
rights are to be granted to the Receiving Party outside of this Agreement, such
grant shall be expressly set forth in a separate written instrument.

         SECTION 9.5. EXPIRATION OR TERMINATION. Upon the expiration or
termination, by either Party, of this Agreement, the Receiving Party shall
return to the Disclosing Party all originals, copies, and summaries of
documents, materials, and other tangible manifestations of Confidential
Information owned by the Disclosing Party and in the possession or control of
the Receiving Party, except to the extent the Receiving Party has the right to
continue to use such information pursuant to Section 12.3. The obligation of
confidentiality set forth in this Article IX shall remain in effect for a period
of ten (10) years after such termination or expiration hereof. Each Party may
keep one (1) copy of such Confidential Information in its legal files to monitor
any continuing obligations under this Agreement.

         SECTION 9.6. PUBLICITY. Except as is necessary to comply with
applicable laws and regulations or to enforce their respective rights under this
Agreement, or to a Party's legal or financial advisors, and except as otherwise
agreed to by the Parties in writing, the Parties shall: keep the material terms
of this Agreement confidential, agree upon the text and the exact timing of an
initial public announcement relating to the transactions contemplated by this
Agreement as soon as practicable after the Effective Date (such agreement not to
be unreasonably withheld or delayed) and agree on the text and the timing of any
subsequent public announcements regarding this Agreement or the transactions
contemplated herein.

         SECTION 9.7. PUBLICATION. Celltech and NeoGenesis shall not publish, in
any form, the other Party's Confidential Information. However,

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       29
<Page>

each Party acknowledges the importance of publication and that a Party may
desire to publicize results from the Research Collaboration at seminars,
meetings, conferences, and in peer reviewed journals. A Party shall have the
right to publish the results from the Research Collaboration, PROVIDED ALWAYS,
that prior to submission for publication or presentation of any results based on
the Research Collaboration, the publishing Party shall provide the other Party
thirty (30) days to review and comment upon the manuscript or other material for
such publication. If requested in writing during the aforementioned review
period of thirty (30) days, by the reviewing Party, the publishing Party shall,
at the sole discretion of the reviewing Party either, (i) delay publication for
an additional ninety (90) days to allow for filing of a patent application; or
(ii) preclude publication in the event the reviewing Party believes the
publication contains Confidential Information of such other party. In such event
of an objection to publication based upon Section 9.7(ii), the publishing Party
shall modify or delete the Confidential Information before the reviewing Party
is obligated to grant approval to publish the modified publication. If the
reviewing Party does not request in writing that the publishing Party delay the
publication under Section 9.7(i) or (ii) during the aforementioned review period
of thirty (30) days, then the publishing Party may publish the results of the
Research Collaboration accordingly.

                                   ARTICLE X.
                         REPRESENTATIONS AND WARRANTIES

         SECTION 10.1. NEOGENESIS REPRESENTATIONS AND WARRANTIES. NeoGenesis
represents and warrants to Celltech as follows:

         (a) ORGANIZATION. NeoGenesis is a corporation duly organized, validly
existing and in good standing under the laws Delaware, and has all requisite
corporate power and authority to carry on its business as now conducted and as
proposed to be conducted. NeoGenesis is duly qualified to transact business and
is in good standing in each jurisdiction in which the failure so to qualify
would have a material adverse effect on its business or properties.

         (b) AUTHORITY. All corporate action on the part of NeoGenesis, its
officers, directors and stockholders necessary for the authorization, execution
and delivery of this Agreement has been taken or will be taken prior to or as of
the Effective Date. NeoGenesis has the requisite corporate power to enter into
this Agreement and carry out and perform its obligations under the terms of this
Agreement. This Agreement has been duly authorized, executed

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       30
<Page>

and delivered by NeoGenesis and, upon due execution and delivery by Celltech,
this Agreement will be a legal, valid and binding agreement of NeoGenesis
enforceable against NeoGenesis in accordance with its terms, except as limited
by bankruptcy, insolvency, reorganization, moratorium or similar laws of general
application affecting creditors' rights generally or as limited by laws relating
to the availability of specific performance, injunctive relief or other
equitable remedies.

         (c) GOVERNMENTAL CONSENTS. To the best of NeoGenesis' knowledge, no
consent, approval, order or authorization of, or registration, qualification,
designation, declaration or filing with, any federal, state, local or provincial
governmental authority on the part of NeoGenesis is required in connection with
the consummation of the transactions contemplated by this Agreement.

         (d) NO CONFLICT WITH OTHER AGREEMENTS. The execution, delivery and
performance of this Agreement will not result in any violation of, be in
conflict with, or constitute a default under, with or without the passage of
time or the giving of notice: (a) any provision of NeoGenesis' Certificate of
Incorporation or Bylaws as either are currently in effect; (b) any provision of
any judgment, decree or order to which NeoGenesis is a party or by which it is
bound; (c) any material contract, obligation or commitment to which NeoGenesis
is a party or by which it is bound; or (d) to NeoGenesis' knowledge, any
statute, rule or governmental regulation applicable to NeoGenesis.

         (e) PATENT INFRINGEMENT. As of the Effective Date, (i) there are no
pending or, to the best of NeoGenesis' knowledge, threatened actions, suits or
claims against it with respect to any NeoGenesis Technology, and (ii) NeoGenesis
is not aware of any patents owned or controlled by a Third Party that would be
infringed by the activities of NeoGenesis contemplated under the Research
Collaboration Plan.

         (f) DEBARRED. NeoGenesis certifies that it is not debarred under 21 USC
335(a) or (b) of the Federal Food, Drug, and Cosmetic Act and that it has not
used and will not use in any capacity the services of any Person debarred under
such laws with respect to services to be performed under the Agreement.

         (g) DISCLAIMER. EXCEPT FOR THE WARRANTIES EXPRESSLY MADE BY NEOGENESIS
IN SECTION 10.1(a)-(f), NEOGENESIS MAKES NO OTHER REPRESENTATION OR WARRANTY,
EITHER EXPRESS OR IMPLIED (WHETHER WRITTEN OR ORAL), INCLUDING, WITHOUT
LIMITATION ANY WARRANTY AGAINST INFRINGEMENT OF ANY

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       31
<Page>

THIRD PARTY PATENT OR OTHER INTELLECTUAL PROPERTY RIGHTS, ANY WARRANTY OF
MERCHANTABILITY OR ANY WARRANTY OF FITNESS FOR A PARTICULAR PURPOSE WITH RESPECT
TO THE NEOMORPH SCREENING LIBRARY, THE NEOMORPH FOCUSED LIBRARIES, QSCD, THE
PRELIMINARY COMPOUNDS, THE PRIMARY ACTIVE COMPOUNDS, THE DESIGNATED COMPOUNDS,
THE LICENSED PRODUCTS, THE NEOGENESIS TECHNOLOGY, THE SCOPE, VALIDITY OR
ENFORCEABILITY OF ANY NEOGENESIS PATENT RIGHTS OR NEOGENESIS' OBLIGATIONS UNDER
THIS AGREEMENT. THE REPRESENTATIONS AND WARRANTIES OF NEOGENESIS EXTEND ONLY TO
CELLTECH AND ITS AFFILIATES. NEOGENESIS SHALL NOT BE LIABLE FOR ANY CLAIM OR
DEMAND AGAINST CELLTECH BY A THIRD PARTY, EXCEPT TO THE EXTENT PROVIDED IN
SECTIONS 11.1-11.2.

         SECTION 10.2.  CELLTECH REPRESENTATIONS AND WARRANTIES.

         (a) ORGANIZATION. Celltech is a corporation duly organized, validly
existing and in good standing under the laws of England, and has all requisite
corporate power and authority to carry on their business as now conducted and as
proposed to be conducted. Celltech is duly qualified to transact business and is
in good standing in each jurisdiction in which the failure so to qualify would
have a material adverse effect on its business or properties.

         (b) AUTHORITY. All corporate action on the part of Celltech, its
officers, directors and stockholders necessary for the authorization, execution
and delivery of this Agreement has been taken or will be taken prior to or as of
the Effective Date. Celltech has the requisite corporate power to enter into
this Agreement and carry out and perform its obligations under the terms of this
Agreement. This Agreement has been duly authorized, executed and delivered by
Celltech and, upon due execution and delivery by NeoGenesis, this Agreement will
be a legal, valid and binding agreement of the Celltech enforceable against
Celltech in accordance with its terms, except as limited by bankruptcy,
insolvency, reorganization, moratorium or similar laws of general application
affecting creditors' rights generally or as limited by laws relating to the
availability of specific performance, injunctive relief or other equitable
remedies.

         (c) GOVERNMENTAL CONSENTS. To the best of Celltech's knowledge, no
consent, approval, order or authorization of, or registration, qualification,
designation, declaration or filing with, any federal, state, local or provincial

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       32
<Page>

governmental authority on the part of Celltech is required in connection with
the consummation of the transactions contemplated by this Agreement.

         (d) NO CONFLICT WITH OTHER AGREEMENTS. The execution, delivery and
performance of this Agreement will not result in any violation of, be in
conflict with, or constitute a default under, with or without the passage of
time or the giving of notice: (a) any provision of Celltech's Certificate of
Incorporation or Bylaws as either are currently in effect; (b) any provision of
any judgment, decree or order to which Celltech is a party or by which it is
bound; (c) any material contract, obligation or commitment to which Celltech is
a party or by which it is bound; or (d) to Celltech's knowledge, any statute,
rule or governmental regulation applicable to Celltech.

         (e) DISCLAIMER. EXCEPT FOR THE WARRANTIES EXPRESSLY MADE BY CELLTECH IN
SECTION 10.2(a)-(d), CELLTECH MAKES NO OTHER REPRESENTATION OR WARRANTY, EITHER
EXPRESS OR IMPLIED (WHETHER WRITTEN OR ORAL), INCLUDING, WITHOUT LIMITATION ANY
WARRANTY AGAINST INFRINGEMENT OF ANY THIRD PARTY PATENT OR OTHER INTELLECTUAL
PROPERTY RIGHTS, ANY WARRANTY OF MERCHANTABILITY OR ANY WARRANTY OF FITNESS FOR
A PARTICULAR PURPOSE WITH RESPECT TO THE APPROVED TARGETS, THE CELLTECH
TECHNOLOGY, THE SCOPE, VALIDITY OR ENFORCEABILITY OF ANY CELLTECH PATENT OR
CELLTECH'S OBLIGATIONS UNDER THIS AGREEMENT. THE REPRESENTATIONS AND WARRANTIES
OF CELLTECH EXTEND ONLY TO NEOGENESIS AND ITS AFFILIATES. CELLTECH SHALL NOT BE
LIABLE FOR ANY CLAIM OR DEMAND AGAINST NEOGENESIS BY A THIRD PARTY, EXCEPT TO
THE EXTENT PROVIDED IN SECTIONS 11.1 AND 11.2.

                                   ARTICLE XI.
                                 INDEMNIFICATION

         SECTION 11.1. LIMITATION OF LIABILITY. EXCEPT FOR INFRINGEMENT OF THE
OTHER PARTY'S INTELLECTUAL PROPERTY RIGHTS OR BREACH OF CONFIDENTIALITY
OBLIGATIONS UNDER ARTICLE 9 AND EXCEPT AS OTHERWISE PROVIDED IN SECTIONS
11.1-11.2 WITH RESPECT TO THIRD PARTY CLAIMS, IN NO EVENT SHALL EITHER PARTY BE
LIABLE TO THE OTHER FOR LOST PROFITS OR SAVINGS OR FOR ANY INDIRECT, INCIDENTAL,
CONSEQUENTIAL, SPECIAL, PUNITIVE OR EXEMPLARY DAMAGES IN CONNECTION WITH THIS
AGREEMENT OR THE TRANSACTIONS

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       33
<Page>

CONTEMPLATED BY THIS AGREEMENT, HOWEVER CAUSED, UNDER ANY THEORY OF LIABILITY.

         SECTION 11.2.  INFRINGEMENT INDEMNIFICATION.

         (a) NEOGENESIS. Subject to the provisions of Section 11.3 and
notwithstanding Section 10.1(g), NeoGenesis shall defend, indemnify and hold
harmless Celltech, its subsidiaries, parent corporations, Affiliates, officers,
directors, independent contractors, partners, members, employees, agents,
successors and assigns (collectively, "Celltech Indemnified Parties") from and
against any claim, suit, demand, loss, damage, expense (including reasonable
attorney's fees of indemnitee(s) and those that may be asserted by a Third
Party) or liability imposed upon them by any Third Party and arising from a
Third Party claim that (i) use of NeoGenesis Technology or (ii) practice of any
NeoGenesis Patents by Celltech in accordance with the terms of this Agreement
violates or infringes the intellectual property rights of any Third Party.
NeoGenesis shall have no liability or obligation to Celltech under this Section
11.1 (a) in the event and to the extent that the alleged infringement is caused
by (1) modifications, alterations, combinations or enhancements of the
Designated Compounds not created by NeoGenesis, or (2) willful misconduct or
negligent acts or omissions of Celltech or its Affiliates, or its or their
respective employees, officers, directors or agents.

         (b) CELLTECH. Subject to the provisions of Section 11.3 and
notwithstanding Section 10.2(e), Celltech shall defend, indemnify and hold
harmless NeoGenesis, its subsidiaries, parent corporations, Affiliates,
officers, directors, independent contractors, partners, shareholders, employees,
agents, successors and assigns (collectively, "NeoGenesis Indemnified Parties")
from and against any losses imposed upon them by any Third Party and arising
from a Third Party claim that (i) the use of the Celltech Technology, or (ii)
the practice of any Celltech Patents by NeoGenesis in accordance with the terms
of this Agreement violates or infringes the intellectual property rights of any
Third Party. Celltech shall have no obligation or liability to NeoGenesis under
this Section 11.1(b) in the event and to the extent that the alleged
infringement (1) is covered by Section 11.1 (a) or (2) results from willful
misconduct or negligent acts or omissions of NeoGenesis or its Affiliates, or
its or their respective employees, officers, directors or agents.

         SECTION 11.3.  OTHER CLAIMS.

         (a) NEOGENESIS. NeoGenesis will indemnify and be liable to the Celltech
Indemnified Party(s), for any losses suffered by Celltech Indemnified

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       34
<Page>

Party(s) arising from or related to: (i) any material breach of the NeoGenesis'
representations and warranties under this Agreement; (ii) any negligence or
intentional misconduct by NeoGenesis (or its employees, agents or
representatives) in performing its obligations under this Agreement, including
the performance of the Research Collaboration Plan; or (iii) the breach of its
obligations hereunder. The foregoing shall not apply in the event and to the
extent that a court of competent jurisdiction determines that such losses arose
as a result of any Celltech Indemnified Party's negligence, intentional
misconduct or breach of this Agreement.

         (b) CELLTECH. Celltech will indemnify and be liable to the NeoGenesis
Indemnified Party(s) for any losses suffered by a NeoGenesis Indemnified
Party(s) arising from: (i) any material breach of Celltech's representations and
warranties under this Agreement; (ii) any negligence or intentional misconduct
by Celltech (or its employees, agents or representatives) or by an Affiliate,
licensee, sublicensee, distributor or agent of Celltech in performing its
obligations under this Agreement, including the performance of the R&D Program;
or (iii) the labeling, packaging, package insert, other materials or promotional
claims with respect to any Licensed Product or the testing, Manufacturing,
Commercialization, use or other disposition of any Licensed Product by Celltech
or by an Affiliate, licensee, sublicensee, distributor or agent of Celltech. The
foregoing shall not apply in the event and to the extent that a court of
competent jurisdiction determines that such losses arose as a result of any
NeoGenesis Indemnified Party's negligence, intentional misconduct or breach of
this Agreement.

         SECTION 11.4. PROCEDURE. To receive the benefit of indemnification
under Sections 11. 1 or 11.2, the Indemnified Party must (a) promptly notify the
Party from whom indemnification is sought (the "Indemnifying Party") in writing
of a claim or suit; PROVIDED, that failure to give such notice shall not relieve
Indemnifying Party of its indemnification obligations except where, and solely
to the extent that, such failure actually and materially prejudices the rights
of Indemnifying Party); (b) provide reasonable cooperation (at the Indemnifying
Party's expense); and (c) with respect to claims under Section 11.1, tender to
the Indemnifying Party (and its insurer) full authority to defend or settle the
claim or suit; PROVIDED that no settlement requiring any admission by the
Indemnified Party or that imposes any obligation on the Indemnified Party shall
be made without the Indemnified Party's prior written consent. Neither Party has
any obligation to indemnify the other Party under Section 11.1 in connection
with any settlement made without the Indemnifying Party's written consent. The
Indemnified Party has the right to participate at its own expense in the claim
or suit and in selecting counsel therefor. The Indemnified Party shall cooperate
with Indemnifying Party

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       35
<Page>

(and its insurer), as reasonably requested, at Indemnifying Party's cost and
expense.

                                  ARTICLE XII.
                              TERM AND TERMINATION

         SECTION 12.1. TERM. This Agreement shall take effect on the Effective
Date and shall remain in effect until the later of (A) the expiration of the
Research Term or (B) if any compound is designated as a Designated Compound or
becomes a Licensed Product, then until (i) the later of the expiration of the
last to expire of the patents embodied in or related to such Licensed Products,
or (ii) the obligation to pay royalties hereunder expires due to the failure of
any patent to issue in respect of such Licensed Product or the expiration, lapse
of all patents covering such Licensed Product or the issuance of a final
decision, which is unappealed or unappealable, of a court of competent
jurisdiction or of an administrative agency having authority over patents, that
all patents covering such Licensed Product are invalid, unpatentable or
unenforceable, unless sooner terminated in accordance with Section 12.2,
collectively the ("Term").

         SECTION 12.2.  TERMINATION.

         (a) MATERIAL BREACH. Subject to Section 11.2 and 12.3(c), either Party
may terminate this Agreement and the rights granted hereunder with sixty (60)
days notice to the other Party if the other Party commits a material breach
hereof unless the breach is cured within the sixty (60) day notice period. In
addition, NeoGenesis may suspend work pursuant to the Research Collaboration
Plan with notice to Celltech if Celltech fails to pay NeoGenesis any amount due
NeoGenesis under this Agreement.

         (b) BANKRUPTCY OR RECEIVERSHIP OF A PARTY. Either Party may terminate
this Agreement and the rights granted hereunder with upon the filing or
institution of bankruptcy, reorganization, liquidation or receivership
proceedings, or upon an assignment of a substantial portion of the assets for
the benefit of creditors by the other Party; PROVIDED, HOWEVER, in the case of
any involuntary bankruptcy proceeding such right to terminate shall only become
effective if the other Party consents to the involuntary bankruptcy or such
proceeding is not dismissed within ninety (90) days after the filing thereof.

         (c) TERMINATION BY CELLTECH. Upon the conclusion of the Lock Up Period,
Celltech may terminate this Agreement upon ninety (90) days written notice to
NeoGenesis.

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       36
<Page>

         SECTION 12.3.  EFFECT OF TERMINATION.

         (a) TERMINATION ACTIVITIES. Upon termination (including expiration) of
this Agreement as permitted herein: (i) NeoGenesis will terminate all tasks in
process at the date of termination in an orderly manner, as soon as practical
and in accordance with a schedule agreed to by Celltech and NeoGenesis; (ii)
NeoGenesis shall deliver to Celltech all materials developed through the
termination of this Agreement; (iii) Celltech shall pay NeoGenesis any monies
due and owing NeoGenesis up to the termination date, for services actually
performed, PROVIDED, such fee shall not exceed the total FTE funding specified
in Section 5.1(b) of this Agreement (unless Celltech has requested additional
work for which a separate fee has been agreed to by the parties); (iv)
NeoGenesis shall destroy all NeoMorph Focused Libraries developed for Celltech;
and (v) within thirty (30) days following termination (including expiration) of
this Agreement, NeoGenesis shall deliver to Celltech a reasonably-detailed
written report describing the results of the research performed up to the date
of such termination. In addition, if Celltech terminates this Agreement in
accordance with Section 12.2(c), Celltech shall pay NeoGenesis as liquidated
damages an amount equal to the aggregate budgeted FTE fee for the 90-day period
following the date Celltech delivers notice of termination pursuant to Section
12.2(c) to the extent such funding has not already been received by NeoGenesis
as of the date Celltech delivers such termination notice to reimburse NeoGenesis
for non-cancelable commitments with respect to NeoGenesis staff allocated to the
performance of the Research Collaboration.

         (b) RETURN OF CONFIDENTIAL INFORMATION. Except as provided in Section
9.5, upon termination (including expiration) of this Agreement as permitted
herein, each Party shall return to the other Party or certify in writing to the
other Party that it has destroyed all documents and other tangible items it or
its employees or agents have received or created pertaining, referring or
relating to the Confidential Information of the other Party.

         (c) RIGHTS UPON TERMINATION. The licenses and assignments granted by
NeoGenesis under Section 2.2 and 8.1(a) shall survive any expiration or
termination of the Research Collaboration Plan or Research Term or this
Agreement with respect to any Designated Compound or Licensed Product and
Celltech shall continue to have the right to develop, have developed, make, have
made, use, distribute for sale, promote, market, offer for sale, have sold,
import, export and sell Licensed Products relating to such Designated Compounds;
subject to payment to NeoGenesis of milestone fees and royalties as required by
Section 6.1 and 6.2 and compliance with

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       37
<Page>

Sections 6.3 - 6.6. In the event the license granted to Celltech under Section
2.2 terminates for any reason, each of Celltech's sublicensees at such time
shall continue to have the rights and license set forth in their sublicense
agreements, PROVIDED such sublicensee agrees in writing that NeoGenesis is
entitled to enforce all relevant provisions directly against such sublicensee.

         (d) NO RELEASE OF MATURED OBLIGATION. Nothing herein shall be construed
to release either Party of any obligation which matured prior to the effective
date of any termination, or shall be deemed a waiver of any rights under Section
11.2. Except as otherwise provided herein, neither party shall be liable to the
other party for any compensation or damages by reason of termination of this
Agreement in accordance with this Section12.

         SECTION 12.4 SURVIVAL. In addition to those provisions which survive
upon a breach by a Party hereto, Articles I, VI, IX, X, XI, XIII, Section 8.1
and Section 8.5 shall survive any termination or expiration of this Agreement;
provided, that Article VI shall not survive expiration of this Agreement with
respect to any Licensed Product upon the expiration of the last to expire of the
patents embodied in or related to such Licensed Product.

                                  ARTICLE XIII.
                               GENERAL PROVISIONS

         SECTION 13.1. ISSUE RESOLUTION. The Parties shall use their best
efforts to resolve any controversy or dispute that arises under or relates to
this Agreement through good faith discussions.

         (a) NOTIFICATION OF DISPUTE. In the event of a controversy or dispute,
the Parties shall initiate dispute discussions using the following procedure:
Either Party shall notify the other Party of the nature of the controversy or
dispute (a "Dispute Notice"). Representatives of the Parties shall meet within
thirty (30) days after the date that the non-sending Party receives the Dispute
Notice to attempt to reach an agreement about the nature of the dispute and a
resolution of the dispute. If they are unable to resolve the dispute within
thirty (30) days, and they do not agree to extend the time period for resolving
the dispute, or if the terms and conditions of the resolution or settlement of
the dispute are breached, the dispute shall be resolved by arbitration pursuant
to the provisions of Section 13.1(b)-(e). Pending resolution of any dispute
covered by this Section 13.1, both Parties will continue their performance under
this Agreement including, without limitation, the payment of all amounts due to
the other Party that are not in dispute.

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       38
<Page>

         (b) LIMITATIONS. Except in the case of a dispute related to the
ownership, validity or enforceability of intellectual property rights of a
Party, any claim, dispute, or controversy arising out of or relating to this
Agreement that is not resolved in accordance with the provisions of Section
13.1(a) within the time period specified in Section 13.1(a) will be submitted by
the Parties to arbitration in accordance with the terms of Section 13.1(b)-(d).
Any dispute related to the ownership, validity or enforceability of intellectual
property rights of a Party or any action following termination for cause due to
a material breach hereof, may be brought in a court of competent jurisdiction in
the country where such rights arise.

         (c) ARBITRATION RULES. Any arbitration shall be conducted pursuant to
the International Arbitration Rules of the American Arbitration Association
("AAA"), under the rules then in effect for the AAA, as such rules may be
modified by this Agreement or by agreement of the Parties. Any such arbitration
shall be conducted in New York City by one arbitrator. Each Party irrevocably
and unconditionally (i) consents to the jurisdiction of any such proceeding; and
(ii) knowingly and voluntarily waives its rights to have disputes tried and
adjudicated by a judge and jury except as otherwise expressly provided herein.
The Parties will cooperate with each other in causing the arbitration to be held
in as efficient and expeditious a manner as practicable. The Parties will
attempt to agree upon a mutually acceptable arbitrator within thirty (30) days
of receipt of the notice of intent to arbitrate such arbitrator shall have
fifteen (15) years legal standing with experience in such matters. If the
Parties are unable to agree upon a single arbitrator within such thirty (30) day
period or any extension of time which is mutually agreed upon, three (3)
arbitrators shall be used, one selected by each Party within ten (10) days after
the conclusion of the thirty (30) day period and a third selected by the first
two within ten (10) days thereafter. Unless the Parties agree otherwise, they
shall be limited in their discovery to directly relevant documents. Responses or
objections to a document request shall be served twenty (20) days after receipt
of the request. The arbitrator(s) shall resolve any discovery disputes. Nothing
herein shall prevent the Parties from settling any dispute at any time by mutual
agreement of the Parties.

         (d) APPLICABLE LAW. The arbitrator(s) shall apply the substantive laws
of New York when construing this Agreement and attempting to resolve any dispute
relating to the transactions contemplated by this Agreement, without regard for
any choice or conflict of laws rule or principle that would result in the
application of the substantive law of any other jurisdiction. The arbitration
shall be of each Party's individual claims only, and no claim of any Third Party
shall be subject to arbitration in such proceeding. Except as otherwise required
by law, the Parties and the arbitrator(s) shall maintain as

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       39
<Page>

confidential all information or documents obtained during the arbitration
process, including the resolution of the dispute.

         (e) RESTRICTIONS ON DAMAGES. The arbitrator(s) shall not have the
authority to award exemplary or punitive damages, and the Parties expressly
waive any claimed right to such damages. The arbitrator(s) shall have the
authority to award actual money damages (with interest on unpaid amounts from
the date due) and may grant equitable relief as is just and provided by the AAA
Rules, in each case except as specifically provided to the contrary herein, the
costs and expenses of the arbitration, but not the costs and expenses of the
Parties, shall be shared equally by the Parties. Any award rendered by the
arbitrator(s) shall be final and binding upon the Parties. Judgment upon the
award may be entered in any court of competent jurisdiction. If a Party fails to
proceed with arbitration, unsuccessfully challenges the arbitration award, or
fails to comply with the arbitration award, the other Party is entitled to
costs, including reasonable attorneys' fees, for having to compel arbitration or
defend or enforce the award.

         SECTION 13.2. GOVERNING LAW. This Agreement shall be governed and
construed in accordance with the internal, substantive laws of the New York to
the exclusion of any choice or conflict of laws rule or provision that would
result in the application of the substantive law of any other jurisdiction.
Notwithstanding the foregoing, the laws of the applicable jurisdiction in the
Territory shall be used for purposes of governing and construing Section 10.1(e)
of this Agreement.

         SECTION 13.3. AMENDMENT AND WAIVER. No provision of or right under this
Agreement shall be deemed to have been waived by any act or acquiescence on the
part of either Party, its agents or employees, but only by an instrument in
writing signed by an authorized officer of each Party. No waiver by either Party
of any breach of this Agreement by the other Party shall be effective as to any
other breach, whether of the same or any other term or condition and whether
occurring before or after the date of such waiver.

         SECTION 13.4. INDEPENDENT CONTRACTORS. Each Party represents that it is
acting on its own behalf as an independent contractor and is not acting as an
agent for or on behalf of any Third Party. This Agreement and the relations
hereby established by and between Celltech and NeoGenesis do not constitute a
partnership, joint venture, franchise, agency or contract of employment. Neither
Party is granted, and neither Party shall exercise, the right or authority to
assume or create any obligation or responsibility on behalf of or in the name of
the other Party or its Affiliates. NeoGenesis shall

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       40
<Page>

be solely responsible for compensating all its personnel and for payment of all
related FICA, workers' compensation, unemployment and withholding taxes.
Celltech shall not provide NeoGenesis personnel with any benefits, including but
not limited to compensation for insurance premiums, paid sick leave or
retirement benefits.

         SECTION 13.5. ASSIGNMENT. Neither Party may assign this Agreement or
any of its rights and obligations under this Agreement without the prior written
consent of the other Party; PROVIDED, that either Party may assign this
Agreement to (a) any Person to which such Party transfers all or substantially
all of its assets or with which such Party is consolidated or merged; (b) any
Person that owns a majority of the voting stock of such Party; or (c) a single
Person of which such Party owns a majority of the voting stock; PROVIDED,
FURTHER, that in each instance the assignee expressly assumes all obligations
imposed on the assigning Party by this Agreement in writing and the other Party
is notified in advance of such assignment. Notwithstanding the foregoing,
Celltech shall have the right to assign its rights to Designated Compounds and
Licensed Products without the consent of NeoGenesis PROVIDED that any such
assignee expressly assumes all obligations imposed on Celltech by this Agreement
and agrees in writing that NeoGenesis shall have the right to enforce the terms
of this Agreement directly against such assignee.

         SECTION 13.6. SUCCESSORS AND ASSIGNS. This Agreement shall bind and
inure to the benefit of the Parties hereto and their respective successors and
permitted assigns.

         SECTION 13.7. NOTICES. Unless otherwise provided herein, any notice,
report, payment or document to be given by one Party to the other shall be in
writing and shall be deemed given when delivered personally or sent by an
internationally recognized overnight courier (such notice sent by courier to be
effective one business day after it is deposited with such courier), or sent by
telefax (such notice sent by telefax to be effective when sent, if confirmed by
overnight courier as aforesaid) to the address set forth on the signature page
to this Agreement or to such other address as any Party may designate as to
itself by written notice to the other Party.

         SECTION 13.8. SEVERABILITY. In the event any provision of this
Agreement shall for any reason be held to be invalid, illegal or unenforceable
in any respect, such invalidity, illegality or unenforceability shall not affect
any other term or provision hereof. The Parties agree that they will negotiate
in good faith or will permit a court or arbitrator to replace any provision
hereof so held invalid, illegal or unenforceable with a valid provision which is

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       41
<Page>

as similar as possible in substance to the invalid, illegal or unenforceable
provision.

         SECTION 13.9. CAPTIONS. Captions of the sections and subsections of
this Agreement are for reference purposes only and do not constitute terms or
conditions of this Agreement and shall not limit or affect the meaning or
construction of the terms and conditions hereof.

         SECTION 13.10. WORD MEANINGS. Words such as herein, hereinafter, hereof
and hereunder refer to this Agreement as a whole and not merely to a section or
paragraph in which such words appear, unless the context otherwise requires. The
singular shall include the plural, and each masculine, feminine and neuter
reference shall include and refer also to the others, unless the context
otherwise requires.

         SECTION 13.11. ENTIRE AGREEMENT. The terms and provisions contained in
this Agreement (including any Attachments or Exhibits) and the Stock Purchase
Agreement (including any Attachments and Exhibits) constitute the entire
understanding of the Parties with respect to the transactions and matters
contemplated by the Parties and supersede all previous communications,
representations, agreements and understandings relating to the subject matter
hereof. No representations, inducements, promises or agreements, whether oral or
otherwise, between the Parties not contained in this Agreement or the Stock
Purchase Agreement shall be of any force or effect. No agreement or
understanding extending this Agreement or varying its terms (including any
inconsistent terms in any purchase order, acknowledgment or similar form) shall
be binding upon either Party unless it is in a writing specifically referring to
this Agreement and signed by a duly authorized representative of the applicable
Party.

         SECTION 13.12. RULES OF CONSTRUCTION. The Parties agree that they have
participated equally in the formation of this Agreement and that the language
and terms of this Agreement shall not be construed against either Party by
reason of the extent to which such Party or its professional advisors
participated in the preparation of this Agreement.

         SECTION 13.13. COUNTERPARTS. This Agreement may be executed in multiple
counterparts, each of which shall be deemed an original, but all of which
together shall constitute one and the same instrument. In making proof of this
Agreement, it shall not be necessary to produce or account for more than one
such counterpart.

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       42
<Page>

         SECTION 13.14. FORCE MAJEURE. Except as otherwise provided in this
Agreement, in the event that a delay or failure of a Party to comply with any
obligation, other than a payment obligation, created by this Agreement is caused
by a Force Majeure condition, that obligation shall be suspended during the
continuance of the Force Majeure condition.

         SECTION 13.15. FURTHER ASSURANCES. Each Party covenants and agrees
that, subsequent to the execution and delivery of this Agreement and without any
additional consideration, it will execute and deliver any further legal
instruments and perform any acts which are or may become reasonably necessary to
effectuate the purposes of this Agreement.

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       43
<Page>

         IN WITNESS WHEREOF the Parties have caused this Agreement to be
executed on their behalf by their duly authorized representatives intending it
to take effect as an instrument under seal as of the Effective Date.

NEOGENESIS DRUG DISCOVERY, INC.              CELLTECH R & D LIMITED

By:   /s/  Allen H. Michels                  By:   /s/  Melanie C. Lee
------------------------------------------   -----------------------------------
Allen H. Michels, Chief Executive Officer    Melanie C. Lee, Research Director

NOTICE ADDRESS:                              NOTICE ADDRESS:
NeoGenesis Drug Discovery, Inc.              Celltech R & D Limited
840 Memorial Drive                           Attention: Legal Department
Cambridge,  MA  02139                        208 Bath Road
USA                                          Slough, Berkshire, SLI 3WE
Phone: 617.868.1500                          England
Fax: 617.868.1515                            Phone: +44 (1753) 534655
                                             Fax: +44 (1753)447859

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       44
<Page>

                                    EXHIBIT A

                           RESEARCH COLLABORATION PLAN

1.       SELECTION OF TARGETS.  Targets shall enter the Research Collaboration
in accordance with the following
procedures:

         (a) INITIAL TARGET ELECTION. Celltech and NeoGenesis agree that the
following are the initial Approved Targets each of which is a Proprietary
Target: [*]. The approval date for the initial [*] Approved Targets shall be the
Effective Date for purposes of determining the period of Approved Target
Exclusivity Period. The Steering Committee shall establish a schedule for
delivery of the protein for the [*] Approved Targets to NeoGenesis during the
Lock Up Period. Celltech may, in its sole discretion, replace any of the initial
[*] Approved Targets for any other Target that meets the Target Guidelines.

         (b) REMAINING TARGET ELECTION. After the initial Target election, as
set forth in paragraph 1(a) above, during the Research Term, Celltech shall
provide NeoGenesis with written notice of each additional Target. NeoGenesis
shall notify Celltech in writing within [*] of such notice whether the Target is
approved as eligible for entry into the Research Collaboration based on the
Target Guidelines. All Targets approved by NeoGenesis for entry into the
Research Collaboration shall become Approved Targets. If NeoGenesis fails to
respond to Celltech's written notice for Target approval within [*], that Target
shall be deemed an Approved Target. The Steering Committee shall establish a
schedule for delivery of Approved Targets to NeoGenesis based on the time
necessary to prepare and validate the Approved Target, not to exceed [*].

         (c) TARGET EXCLUSIVITY. NeoGenesis shall not screen an Approved Target
for a Third Party during the Approved Target Exclusivity Period. Additionally,
NeoGenesis shall not notify any Third Party that an Approved Target's Approved
Target Exclusivity Period has ended unless said Third Party makes a written
inquiry about that specific Approved Target after expiry of the Approved Target
Exclusivity Period.

2.       SCREENING.

         (a) PROVIDING TARGET. In accordance with timelines established for each
Approved Target by the Steering Committee, Celltech shall provide to NeoGenesis
between [*] of Approved Target, as determined by the Steering Committee. The
Approved Target shall be delivered via common carrier, CIP

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                        1
<Page>

to the port of entry agreed by both parties for deliveries from Celltech
facilities outside the United States and FOB Celltech's Seattle facility for
deliveries from such facility.

         (b) ESTABLISHING AN SOP. Upon receipt of the Approved Target protein,
NeoGenesis shall perform control experiments on each Approved Target to
determine specific characteristics for screening the Approved Target with the
ALIS method. These experiments shall be used to establish an SOP for a each
Approved Target. Additionally, upon recommendation by the Steering Committee and
to the extent that Celltech has known ligands to an Approved Target, NeoGenesis
shall perform follow up control experiments to validate the retention of binding
activity of the Approved Target.

         (c) SCREENING OF TARGET. NeoGenesis shall utilize the above developed
SOP for each Approved Target to perform its ALIS method to screen the NeoMorph
Screening Library for compounds having a minimum level of affinity to each
Approved Target. The minimum level of affinity shall be determined by the
Steering Committee on an Approved Target by Approved Target basis. Each compound
meeting the minimum level of affinity shall be referred to as a "Preliminary
Compound".

         (d) MASKING OF PRELIMINARY COMPOUNDS. Upon identification of any
Preliminary Compound(s), NeoGenesis shall Mask such Preliminary Compound(s) from
the NeoMorph Screening Library during the Preliminary Compound Exclusivity
Period.

3.       IDENTIFICATION OF PRIMARY ACTIVE COMPOUNDS.

         (a) PRELIMINARY COMPOUND DELIVERY. NeoGenesis shall provide Celltech
with [*] of each of the Preliminary Compounds. The Preliminary Compounds shall
be delivered via common carrier, CIP to the port of entry agreed by both Parties
for deliveries to Celltech facilities outside the United States and FOB
NeoGenesis' Cambridge facility for deliveries to Celltech facilities within the
United States.

         (b) ACTIVITY. Celltech shall assay each Preliminary Compound to
identify those having functional biological activity in a cell-based or
biochemical assay against an Approved Target. Celltech shall inform NeoGenesis
through the Steering Committee of any Preliminary Compound that demonstrates
functional biological activity in a cell-based or biochemical assay against an
Approved Target. Any Preliminary Compound that demonstrates functional
biological activity in a cell-based or biochemical

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                        2
<Page>

assay against an Approved Target shall be deemed a Primary Active Compound.

         (c) MASKING OF PRIMARY ACTIVE COMPOUNDS. Upon designation of any
Primary Active Compound, NeoGenesis shall Mask such Primary Active Compound(s)
from the NeoMorph Screening Library during the Primary Active Compound
Exclusivity Period.

         (d) OPTIMIZATION. The Steering Committee shall determine whether
Celltech or NeoGenesis shall undertake the process of optimization of each
Primary Active Compound. When the Steering Committee appoints Celltech to
perform the optimization, Celltech shall keep the Steering Committee reasonably
informed of the progress of the optimization progress. When the Steering
Committee appoints NeoGenesis to undertake the optimization activities,
NeoGenesis shall synthesize discrete compound(s) based upon each Primary Active
Compound to form NeoMorph Focused Libraries. NeoGenesis shall screen the
compounds in these NeoMorph Focused Libraries according to the ALIS method to
identify additional Preliminary Compounds. NeoGenesis shall continue the
optimization until additional Preliminary Compounds are identified with an
affinity as established by the Steering Committee. Thereafter, NeoGenesis shall
provide Celltech with [*] of each of these Preliminary Compounds. These
Preliminary Compounds shall be delivered via common carrier, CIP to the port of
entry agreed by both parties for deliveries to Celltech facilities outside the
United States and FOB NeoGenesis' Cambridge facility for deliveries to Celltech
facilities within the United States. As above, Celltech shall assay each
Preliminary Compound identified during the optimization to identify those having
functional activity against an Approved Target. Celltech shall inform NeoGenesis
through the Steering Committee of any Preliminary Compound that demonstrates
functional activity against an Approved Target. Any Preliminary Compound that
demonstrates functional activity against an Approved Target shall be deemed a
Primary Active Compound.

         (e) QSCD. The Steering Committee may recommend that any Approved Target
undergo QSCD. QSCD shall determine compounds that may have an affinity to an
Approved Target. These compounds shall be deemed QSCD Preliminary Compounds.
NeoGenesis shall synthesize the QSCD Preliminary Compounds. If needed, the QSCD
Preliminary Compounds shall be shipped at NeoGenesis' expense to Celltech. The
QSCD Preliminary Compounds will be tested for activity as set forth in paragraph
3(b) above. Those QSCD Preliminary Compounds that demonstrate activity shall be
deemed QSCD Primary Active Compounds. Any recommendation that an

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                        3

<Page>

Approved Target undergo QSCD must be made by the Steering Committee and recorded
in the minutes as set forth in Section 4.1(b) (i) prior to the date NeoGenesis
commences screening of such Approved Target, (ii) after NeoGenesis completes an
initial screening of such Approved Target against [*] Compounds in the NeoMorph
Screening Library and before NeoGenesis completes the initial screening of such
Approved Target against the NeoMorph Screening Library or (iii) upon the
conclusion of initial screening of such Approved Target against the entire
NeoMorph Screening Library. NeoGenesis will provide the Steering Committee with
notice of the number of Preliminary Compounds it identifies against [*]
compounds within the NeoMorph Screening Library when it completes the initial
screening for such Approved target against [*] compounds.

         (f) CHEMICAL STRUCTURE AND SYNTHETIC PROTOCOLS. For each Approved
Target the Steering Committee has directed NeoGenesis to optimize, NeoGenesis
shall provide Celltech with a report that outlines the chemical structure and
synthetic protocols for each Preliminary Compound and QSCD Preliminary Compound.
This information shall be provided as soon as reasonably possible after the
identification of the Preliminary Compound or QSCD Preliminary Compounds. For
each Approved Target the Steering Committee has directed Celltech to optimize,
NeoGenesis shall provide Celltech with a report that outlines the chemical
structure and synthetic protocols for each Primary Active Compound and QSCD
Primary Active Compound. This information shall be provided as soon as
reasonably possible after notification by Celltech of the Primary Active
Compound or QSCD Primary Active Compound.

         (g) NEOMORPH FOCUSED LIBRARIES. NeoGenesis agrees that NeoMorph Focused
Libraries shall never be utilized to screen any Third Party targets. Upon the
conclusion of the Research Term or as earlier elected by the Steering Committee
all NeoMorph Focused Libraries shall be destroyed. Promptly thereafter, such
destruction shall be certified to Celltech in writing. It is understood and
agreed that the use of the NeoGenesis NeoMorph Screening Library may result in
the independent generation of results or data similar to the results or data
generated in the course of the Research Collaboration and that the use of such
independently generated results or data shall not constitute a breach of
NeoGenesis obligations under this paragraph 3(g); PROVIDED FURTHER that the
obligations of NeoGenesis to not make any Designated Compound available to
NeoGenesis or any third party in NeoGenesis' compound libraries, including the
NeoMorph Screening Library shall operate independently of the foregoing
exception.

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                        4
<Page>

4.       DESIGNATING COMPOUNDS.

         (a) DESIGNATION. Celltech shall designate, at its sole discretion, and
by notice in writing to NeoGenesis, those Preliminary Compounds, Primary Active
Compounds, QSCD Preliminary Compounds and QSCD Primary Active Compounds, as
applicable, it wishes to become Designated Compounds with respect to each
Approved Target. Celltech shall make such designation within [*] following the
delivery by NeoGenesis of such Preliminary Compounds or QSCD Preliminary
Compounds. The number of compounds that may become Designated Compounds shall be
limited as follows: (1) Celltech may designate [*] compounds as Designated
Compounds when the optimization as set forth in 3(d) above is performed by
Celltech and such compounds are taken directly from the NeoMorph Screening
Library and (2) Celltech may designate [*] compounds as Designated Compounds
when the optimization as set forth in 3(d) above is performed by NeoGenesis and
such compounds are taken from NeoMorph Focused Libraries. Celltech shall have
the right to undesignate Designated Compounds, by written notice to NeoGenesis,
it considers unsuitable for further development. When a compound is
undesignated, Celltech shall have the right to replace that compound with a new
Designated Compound to the extent that such replacement compound is available to
become a Designated Compound. Celltech may only replace a total of [*]
Designated Compounds in the aggregate.

         (b) FURTHER OPTIMIZATION. Upon the recommendation of the Steering
Committee, NeoGenesis shall perform additional optimization to obtain compounds
related to the Designated Compounds that have improved affinity.

5.       REPORTS.

         (a) NeoGenesis shall keep and maintain adequate written records
containing laboratory data generated in the course of performing the Research
Collaboration Plan to enable it to furnish complete and accurate information to
Celltech. This information shall be available to Celltech via a secure internet
connection, the details of which shall be worked out by each Party's IT
department within thirty (30) days of the Effective Date. The internet
connection shall be supervised by the Steering Committee. These records shall be
the basis for any reports which NeoGenesis shall provide to Celltech. These
reports shall be reasonably detailed describing the results of the Research
Collaboration Plan.

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                        5
<Page>

         (b) Within thirty (30) days of the completion of the procedures
outlined in the Research Collaboration Plan on each Approved Target, NeoGenesis
shall provide to Celltech a Final Report for such Approved Target. The Final
Report shall set forth in reasonable detail the results of the procedures
outlined in the Research Collaboration Plan.

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                        6
<Page>

                                    EXHIBIT B

                             FTE INVOICE AND PAYMENT

Celltech shall pay NeoGenesis in advance for the FTE funding under Section 5.1
(c) in Quarterly payments as set forth on the FTE schedule under Section 5.1(b);
PROVIDED, that the initial installment will be paid within thirty (30) days of
the Effective Date. NeoGenesis will provide Celltech on a Quarterly basis within
thirty (30) days following each Quarter, commencing September 30, 2001, a
written report setting forth the FTE amounts expended by NeoGenesis and research
work undertaken in connection with the Research Collaboration Plan for the most
recently ended quarter, certified by the Chief Financial Officer (or equivalent
financial and accounting officer) of NeoGenesis to be correct to the best of
NeoGenesis' knowledge and information.

NeoGenesis shall monitor expenditures, in accordance with its corporate
policies, to ensure that the funds provided by Celltech are spent in accordance
with this Agreement. NeoGenesis shall keep and maintain adequate books and
records to furnish complete and accurate information to Celltech regarding
calculation of the FTE amounts expended by NeoGenesis on the Research
Collaboration according to the provisions of this Agreement. During the Research
Term and for two (2) years following the expiration of the Research Term,
NeoGenesis shall permit Celltech to examine such books and records during normal
business hours, upon thirty (30) days notice to NeoGenesis. Upon the expiration
of the two (2) year period, the calculation of the amounts expended on each year
of the Program shall be binding and conclusive upon the parties and NeoGenesis
shall be released from any further accountability with respect to the Research
Program.

If in any quarterly funding period, actual expenditures by NeoGenesis with
respect to FTEs exceed the amount budgeted for the period, the overrun will be
carried forward for the next period and paid for from the next payment(s);
PROVIDED, that Celltech payment obligations for any year of the Research
Collaboration shall not exceed the budgeted amount for such year UNLESS Celltech
has agreed to fund additional FTE work beyond that budgeted for such year by
means of a written amendment to such budget approved in writing by the parties.
If in any period actual expenditures are less than the amount budgeted for the
period, the underrun may be applied to the FTE expenses of the subsequent
periods by NeoGenesis but shall not reduce the amount due NeoGenesis from
Celltech for the subsequent period(s).

                                       7<Page>

                                                                   Exhibit 10.12

                             CONFIDENTIAL TREATMENT

                                    AGREEMENT

This Agreement (the "Agreement") is entered into as of the last date of
signature appearing below (the "EFFECTIVE DATE") between NeoGenesis Drug
Discovery, Inc., a Delaware corporation ("NEOGENESIS") and Schering-Plough Ltd.,
a Swiss corporation ("SPL"), and sets forth the terms and conditions that will
apply to the provision by NeoGenesis to SPL of certain screening and analysis
services.

                                   BACKGROUND

SPL is interested in identifying potential pharmaceutical products for treatment
of certain human diseases and wishes to identify compounds that exhibit a high
degree of chemical binding and functional activity to specific protein targets.
NeoGenesis has certain technology and know-how, including screening processes of
libraries of mass-encoded small molecule compounds, relating to the
identification, discovery, validation and optimization of novel compounds which
may be useful for development of novel therapeutics employing targets implicated
in a disease process. The parties wish to pursue a collaborative screening
process to identify compounds exhibiting a high degree of chemical binding
activity to targets designated by SPL from among the NeoGenesis libraries of
mass-encoded small molecule compounds and which have activity in target-specific
functional assays. The terms and conditions set forth below shall govern the
performance of such collaborative effort.

1.   DEFINITIONS.

     The following capitalized terms used in this Agreement, whether in the
singular or plural, shall have the meaning set forth below.

     1.1  "ACTIVE COMPOUND" means any Compound identified as having binding
activity when tested against a Target pursuant to the Screening Program and
which (a) has Kd values of [*] and (b) has demonstrated bioactivity in
functional assays against the applicable Target as determined by the Steering
Committee following SPL's performance of the procedure specified in Paragraph 3
of ATTACHMENT A.

     1.2  "AFFILIATE" means with respect to either party, any Person that,
directly or indirectly, is controlled by, controls or is under common control
with such party. For purposes of this definition, control means, with respect to
any Person, the direct or indirect ownership of fifty percent (50%) or more of
the outstanding voting securities of an entity, or the right to receive fifty
percent (50%) or more of the profits or earnings of an entity, or the possession
otherwise, directly or indirectly, of the power to direct the management,
business and affairs of an entity.

     1.3  "ALIS" means the Automated Ligand Identification System, an automated,
ultra-high throughput ligand selection system proprietary to NeoGenesis that is
used to identify multiple classes of chemical ligands against a target protein.

     1.4  "CHEMOTYPE" means a family or group of Compounds closely structurally
related to one or more Active Compounds.

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       1
<Page>

     1.5  "CIP" means "Carriage and Insurance Paid", as that expression is
defined in Incoterms 2000, ICC Publishing S.A.

     1.6  "COMMERCIALLY REASONABLE EFFORTS" shall mean, with respect to (a) any
objective by either party, reasonable, diligent, good faith efforts to
accomplish such objective as such Party would normally use to accomplish a
similar objective under similar circumstances; and (b) with respect to any
objective relating to the development or commercialization of any Licensed
Product efforts and resources normally used by such party with respect to a
product owned by such party or to which such party has similar rights which is
of similar market potential at a similar stage in the development or life of
such product, taking into account issues of safety, efficacy, product profile,
the competitiveness of the marketplace, the proprietary position of the product,
the regulatory structure involved, profitability of the product and other
relevant commercial factors.

     1.7  "COMPOUND" shall mean all proprietary compounds contained in the
NeoMorph Screening Library or any NeoMorph Focused Libraries which are screened
by NeoGenesis against one or more Targets in performance of the Screening
Program.

     1.8  "COMPOUND PATENT RIGHTS" shall mean any Schering Patent Rights which
claim Selected Compounds, Derivative Compounds, Designated Compounds or Licensed
Product, or the manufacture or use thereof.

     1.9  "CONFIDENTIAL INFORMATION" means any proprietary or confidential
information of either party (including but not limited to all Schering Know-How
and all NeoGenesis Know-How) disclosed to the other party pursuant to this
Agreement in written or other tangible medium and marked as confidential, or if
disclosed orally or displayed, confirmed in writing within thirty (30) days of
disclosure.

     1.10 "DERIVATIVE COMPOUND" means a compound which is derived from a
Selected Compound or a Lead Compound by or on behalf of SPL, or by NeoGenesis in
performance of medicinal chemistry optimization pursuant to Section 2.2(b), and
having activity against the same Target as such Selected Compound and/or Lead
Compound. A compound will be deemed to have been "derived" from a Selected
Compound or a Lead Compound if it (i) is the result of a chemical modification
made to a Selected Compound or Lead Compound, (ii) is otherwise derived from a
chemical synthesis program based upon a Selected Compound or Lead Compound, or
(iii) is based on proprietary structure-function data obtained from Selected
Compounds or Lead Compounds. Derivative Compounds will include, without
limitation, all Compounds contained in the NeoMorph Focused Library(ies).

     1.11 "DESIGNATED COMPOUND" means any Selected Compound or Derivative
Compound which becomes the subject of a development program conducted by SPL or
its Affiliates, as further defined in Section 2.8(b) of the Agreement.

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       2
<Page>

     1.12 "EMEA" means the European Medicines Evaluation Authority, or any
successor thereto.

     1.13 "FDA" means the United States Food and Drug Administration, or any
successor thereto.

     1.14 "FD&C ACT" means the United States Federal Food, Drug and Cosmetic Act
of 1938, as amended.

     1.15 "FIELD" means the treatment or prevention of any disease or condition
in humans or animals.

     1.16 "FIRST COMMERCIAL SALE" means, with respect to a Licensed Product, the
first sale (or other transfer for value in an arms-length transaction) for end
use of such Licensed Product in a country within the Territory after obtaining
all necessary Regulatory Approvals for the marketing and sale of the Licensed
Product in such country.

     1.17 "FTE" means the equivalent of a full time (12) months (including
normal vacations, sick days and holidays) work of an individual scientist,
carried out by one or more employees or agents of NeoGenesis, who devotes a
portion of his or her time to performing the Screening Program.

     1.18 "GOOD CLINICAL PRACTICE" means the then current standards for clinical
trials for pharmaceuticals, as set forth in the FD&C Act and applicable
regulations promulgated thereunder, as amended from time to time, and such
standards of good clinical practice as are required by the European Union and
other Regulatory Authorities in countries in which the Product is intended to be
sold, to the extent such standards are not in contravention with United States
Good Clinical Practices.

     1.19 "GOOD LABORATORY PRACTICE" means the then current standards for
laboratory activities for pharmaceuticals, as set forth in the FD&C Act and
applicable regulations promulgated thereunder, as amended from time to time, and
such standards of good laboratory practice as are required by the European Union
and other Regulatory Authorities in countries in which the Product is intended
to be sold, to the extent such standards are not in contravention with United
States Good Laboratory Practices.

     1.20 "GOOD MANUFACTURING PRACTICE" means the current standards for the
manufacture of pharmaceuticals, as set forth in the FD&C Act and applicable
regulations promulgated thereunder, as amended from time to time, and such
standards of good manufacturing practice as are required by the European Union
and other Regulatory Authorities in countries in which the Product is intended
to be sold, to the extent such standards are not in contravention with United
States Good Manufacturing Practices.

     1.21 "IMPROVED ACTIVE COMPOUND" means any Compound identified as a result
of initial optimization of one or more Active Compounds by NeoGenesis (as
described in paragraph

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       3
<Page>

4 of ATTACHMENT A) and having binding activity when tested against a Target
pursuant to the Screening Program with a Kd value of [*].

     1.22 "IND" means an investigational new drug application, as defined in the
FD&C Act and applicable regulations thereunder, or any equivalent document,
filed with the FDA and necessary for beginning clinical trials of any Licensed
Product in humans or any application or other documentation filed with any
Regulatory Authority of a country other than the United States prior to
beginning clinical trials of any Licensed Product in humans in that country.

     1.23 "INVENTIONS" means any and all discoveries, developments, inventions
and innovations (whether or not patentable) that are conceived and/or reduced to
practice (i) solely by one or more employees or consultants of NeoGenesis in
connection with the performance of the Screening Program; (ii) solely by one or
more employees or consultants of SPL in connection with the performance of the
Screening Program; or (iii) jointly by one or more employees or consultants of
NeoGenesis and one or more employees or consultants of SPL in connection with
the performance of the Screening Program.

     1.24 "LEAD COMPOUNDS" means those Selected Compounds which are designated
by SPL as Lead Compounds (pursuant to Section 2.2(b) of the Agreement) for the
performance of medicinal chemistry optimization by NeoGenesis.

     1.25 "LICENSED PRODUCT(S)" means any pharmaceutical product which contains
as an active ingredient a Selected Compound or Derivative Compound, and which is
covered by one or more claims of a NeoGenesis Patent Right and/or Compound
Patent Right.

     1.26 "MAJOR MARKET COUNTRY" means the United States, Japan, or any three or
more of the following European countries, the United Kingdom, France, Germany,
Italy or Spain, as the case may be.

     1.27 "NDA" means a new drug application or product license application,
each as defined in the FD&C Act and applicable regulations thereunder, seeking
approval to market and sell a Licensed Product in the United States.

     1.28 "NEOGENESIS KNOW-HOW" means all proprietary information, data and
know-how relating to the NeoMorph Screening Library, NeoMorph Focused Libraries,
NeoMorph Chemistry, ALIS, QSCD, the Compounds, Active Compounds, Improved Active
Compounds, Selected Compounds, Derivative Compounds, Designated Compounds or
Licensed Products together with, where applicable, any analogs, derivatives or
fragments thereof, which is (i) owned or controlled by NeoGenesis as of the
Effective Date, or (ii) developed by or on behalf of NeoGenesis during the term
of this Agreement.

     1.29 "NEOGENESIS PATENT RIGHTS" means any and all patents and patent
applications (which for the purposes of this Agreement shall be deemed to
include certificates of invention and applications for certificates of
invention) which during the term of this Agreement are owned by NeoGenesis
(and/or any of its Affiliates), or to which NeoGenesis (and/or any of its
Affiliates)

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       4
<Page>

through license or otherwise acquires rights, and which have claims covering:
(i) the NeoMorph Screening Library, the NeoMorph Focused Libraries, NeoMorph
Chemistry, ALIS or QSCD; or (ii) any Active Compounds, Improved Active
Compounds, Selected Compounds, Derivative Compounds, Designated Compounds or
Licensed Products, or the manufacture or use of any of the foregoing; or (iii)
NeoGenesis Inventions (as defined in Section 3.5(a)); or (iv) NeoGenesis' rights
in Joint Inventions (as defined in Section 3.5(b)), as well as all divisionals,
continuations, continuations-in-part, reissues, re-examinations, extensions,
renewals, registrations, supplementary protection certificates and/or foreign
counterparts of any of the foregoing which are owned or controlled by NeoGenesis
and its Affiliates during the term of this Agreement. The NeoGenesis Patent
Rights shall include those listed in ATTACHMENT B pursuant to Section 3.8.

     1.30 "NEOMORPH CHEMISTRY" means the process, proprietary to NeoGenesis, of
forming libraries and sub-libraries of discrete compounds by coupling a broad
set of diverse cores with diverse sets of building blocks employing proprietary
mass-coding algorithms.

     1.31 "NEOMORPH FOCUSED LIBRARIES" means any and all compounds or
collections of compounds synthesized by NeoGenesis which are derived from or
based upon Lead Compounds, and which are designed to optimize the structure of
such Lead Compounds with respect to activity against one or more specific
Targets.

     1.32 "NEOMORPH SCREENING LIBRARY" means the entire collection of libraries
consisting of mass-encoded small molecule organic compounds owned by NeoGenesis
and developed with NeoMorph Chemistry, comprising at least twelve million
(12,000,000) different compounds.

     1.33 "NET SALES" means the proceeds actually received by SPL or any of its
Affiliates or sub-licensees on all sales of a Product in the Territory to an
unaffiliated third party (whether an end-user, a distributor or otherwise), and
exclusive of intercompany transfers or sales, less the reasonable and customary
deductions from such gross amounts including: (i) normal and customary trade,
cash and quantity discounts, allowances and credits; (ii) credits or allowances
actually granted for damaged goods, returns or rejections of a Product and
retroactive price reductions; (iii) sales or similar taxes (including duties,
value added taxes or other governmental charges otherwise measured by the
billing amount, when included in billing); (iv) freight, postage, shipping,
customs duties and insurance charges; (v) charge back payments and rebates
granted to managed health care organizations or to federal, state and local
governments, their agencies, and purchasers and reimbursers or to trade
customers, including but not limited to, wholesalers and chain and pharmacy
buying groups; (vi) commissions paid to third parties other than sales personnel
and sale representatives or sales agents; and (vii) rebates (or equivalents
thereof) granted to or charged by national, state or local governmental
authorities in countries other than the United States. If a Product is sold in
the form of a combination product with one or more other active ingredients, Net
Sales for such combination product with one or more active ingredients will be
calculated by multiplying actual Net Sales of such combination product by the
fraction A/(A+B) where:

     "A" is the invoice price of the Product contained in the combination
     product if sold separately by SPL or any of its Affiliates or sub-licensee;
     and

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       5
<Page>

     "B" is the aggregate invoice price of any other active component(s) in the
     combination product if sold separately by SPL or any of its Affiliates or
     sub-licensee.

If one or more of the other active ingredients in the combination product are
not sold separately, then the above formula shall be modified such that:

     "A" shall be the fully allocated manufacturing cost to SPL or any of its
     Affiliates or sub-licensee of the Product, and

     "B" shall be the fully allocated manufacturing cost to SPL or any of its
     Affiliates or sub-licensee of any other active component(s) in the
     combination,

such fully allocated manufacturing costs being determined in accordance with
generally accepted accounting principles.

     1.34 "PERSON" means any individual, corporation, association, partnership
(general or limited), joint venture, trust, estate, limited liability company,
limited liability partnership, unincorporated organization, government (or any
agency or political subdivision thereof) or other legal entity or organization.

     1.35 "PRELIMINARY COMPOUND" means any Compound identified as having binding
activity when tested against a Target pursuant to the Screening Program and
which has Kd values of [*] or such other binding affinity threshold for a
specific Target as shall be agreed upon by the parties in writing.

     1.36 "QSCD" means Quantisized Surface Complimentary Diversity, a model
proprietary to NeoGenesis, in terms of which discrete chemical compliments to
the surfaces of a Target are defined.

     1.37 "REGULATORY APPROVAL" means, for any country in the Territory, those
authorizations by the appropriate Regulatory Authority(ies) required for the
manufacture, importation, distribution, marketing, promotion, pricing and sale
of the Licensed Product(s) in such country, including, without limitation, any
NDAs, Health Registration Dossiers, supplements, amendments, pre- and
post-approvals, marketing authorizations based upon such approvals (including
any prerequisite manufacturing approvals or authorizations related thereto) and
pricing, third party reimbursement or labeling approval(s), technical, medical
and scientific licenses, registrations or authorizations.

     1.38 "REGULATORY AUTHORITY" means any national, supra-national, regional,
state or local regulatory agency, department, bureau, commission, council or
other governmental entity in the Territory, including, without limitation, the
FDA and the EMEA.

     1.39 "SCHERING KNOW-HOW" means all information, data and know-how which is
owned or controlled by SPL or its Affiliates as of the Effective Date, or
developed by or on behalf of SPL or its Affiliates during the term of this
Agreement, related to the Screening Program, the Targets, Active Compounds,
Improved Active Compounds, Selected Compounds, Derivative Compounds, Designated
Compounds or Licensed Products. Schering Know-How includes, without limitation,
all processes, formulas, discoveries and inventions whether relating to
biological, chemical, pharmacological, toxicological, pharmaceutical, physical
and analytical

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       6
<Page>

safety, quality control and clinical data, including, without limitation,
clinical study data related to Designated Compounds and/or Licensed Products.
Schering Know-How also includes relevant medical information relating to the
Licensed Products (such as Regulatory Authority questions, responses thereto and
adverse drug event history) in the possession of SPL, its Affiliates or
sublicensees.

     1.40 "SCHERING PATENT RIGHTS" means any and all patents and patent
applications (which for the purposes of this Agreement shall be deemed to
include certificates of invention and applications for certificates of
invention) which during the term of this Agreement are owned by SPL (and/or any
of its Affiliates), or to which SPL (and/or any of its Affiliates) through
license or otherwise acquires rights, which have claims covering: (i) Selected
Compounds, Derivative Compounds, Designated Compounds or Licensed Products, or
the manufacture or use of any of the foregoing; (ii) the Targets; or (iii)
Schering Inventions (as defined in Section 3.5(a)) or Joint Inventions (as
defined in Section 3.5(b)), as well as all divisionals, continuations,
continuations-in-part, reissues, re-examinations, extensions, renewals,
registrations, supplementary protection certificates and/or foreign counterparts
of any of the foregoing which are owned or controlled by SPL and its Affiliates
during the term of this Agreement.

     1.41 "SELECTED COMPOUND" means any and all Active Compounds and/or Improved
Active Compounds which have demonstrated bioactivity in secondary functional
assays against the applicable Target as determined by SPL in accordance with
Section 2.7, and which are designated by SPL pursuant to Section 2.7(a) of the
Agreement.

     1.42 "SCREENING PROGRAM" means the screening program described in
ATTACHMENT A (including as it may be amended by the Steering Committee) to
identify Active Compounds and Improved Active Compounds against one or more
Targets.

     1.43 "STEERING COMMITTEE" means the joint steering committee established by
the parties pursuant to Section 2.6 of the Agreement.

     1.44 "SUCCESS CRITERIA" means the success criteria, to be defined by the
Steering Committee with respect to a given Target, for determining whether or
not Selected Compounds and/or Derivative Compounds have a certain desired degree
of chemical binding activity, activity in Target-based functional assays, and
other chemical, biological, pharmacological and toxicological properties,
suitable for drug development.

     1.45 "TARGET" means a specific biological target (including, without
limitation, nucleic acids and proteins, and/or active fragments thereof) that a
small molecule is screened against in order to determine whether the small
molecule demonstrates a specific biochemical or pharmaceutical effect, selected
by SPL and accepted by NeoGenesis in accordance with Section 2.1(b) for which
NeoGenesis will perform the Screening Program.

     1.46 "TERRITORY" means all of the countries and territories of the world
(including Puerto Rico), except for the United States and it territories,
possessions and commonwealths other than Puerto Rico.

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       7
<Page>

     1.47 "US AGREEMENT" means the contemporaneous Agreement entered into by
NeoGenesis and Schering's Affiliate, Schering Corporation relating to the United
States and its territories, possessions and commonwealths, excluding Puerto
Rico.

     1.48 "VALID CLAIM" means a composition-of-matter or method-of-use claim of
an issued and unexpired patent included within (i) the NeoGenesis Patent Rights
or (ii) Compound Patent Rights, and in each case which has not been revoked or
held unenforceable or invalid by a decision of a court or other governmental
agency of competent jurisdiction, unappealable or unappealed within the time
allowed for appeal, and which has not been disclaimed, denied or admitted to be
invalid or unenforceable through reissue or disclaimer or otherwise.

2.   SCREENING PROGRAM

     2.1  DELIVERY OF TARGETS.

          (a)  SPL shall deliver one or more of the Targets listed in ATTACHMENT
A to NeoGenesis for screening within [*] following the Effective Date. SPL shall
provide the Targets in the quantities and formats specified in ATTACHMENT A,
along with a written description of the concentration and volume of the Target.

          (b)  From time to time during the term of this Agreement, SPL may
select additional Targets for screening under the Screening Program. In such
event, SPL shall notify NeoGenesis in writing of the additional Target(s) to be
provided for screening. NeoGenesis shall notify SPL in writing within [*] of
such notice whether the Target is approved for inclusion in the Screening
Program. Subject to the terms of Section 2.1(c), the Target will be accepted for
inclusion in the Screening Program unless the proposed Target: (i) is subject to
an exclusivity period in an existing agreement between NeoGenesis and a third
party; or (ii) is the subject of an existing internal research program at
NeoGenesis. The parties shall promptly amend ATTACHMENT A to include each
additional Target added to the Screening Program pursuant to this Section
2.1(b). SPL shall thereafter provide the Targets to NeoGenesis in appropriate
quantities and formats for screening, along with a written description of the
concentration and volume of the Target. The Steering Committee shall establish a
schedule for delivery of the additional Targets to NeoGenesis based on the time
necessary to prepare and validate the approved Target; PROVIDED, that such
period shall not exceed [*] from NeoGenesis' notice to SPL that a Target is
approved.

          (c)  The parties acknowledge and agree that the Screening Program will
be limited to active screening and/or optimization programs at NeoGenesis
directed to [*] distinct Targets, based upon research support for [*] FTEs at
NeoGenesis. In the event that the screening and optimization programs directed
to a specific Target are completed or discontinued, SPL shall have the right to
select an additional Target to replace such discontinued Target. Further, in the
event that the number of FTEs working on the Screening Program is increased,
pursuant to Section 2.2(f), the limit on the number of active Targets shall be
increased proportionately.

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       8
<Page>

          (d)  All Targets to be supplied by SPL hereunder shall be delivered
CIP to NeoGenesis' Cambridge facility using a carrier selected by SPL. The
Targets are and shall remain the sole and exclusive property of SPL. NeoGenesis
will only use the Targets for screening in performance of the Screening Program
and will not use the Targets for any other purpose without SPL's prior written
consent.

          (e)  SPL will identify to NeoGenesis all Targets provided by SPL for
use in the Screening Program. The identity of the Targets and any other
information related thereto will be considered Schering Confidential
Information. During the applicable Exclusivity Period (as defined below) for a
Target, NeoGenesis shall not screen the NeoMorph Screening Library for itself or
for any third party against the same Target, without SPL's prior written
approval. The "Exclusivity Period" for a given Target shall begin on the date
the Target is accepted for inclusion in the Screening Program pursuant to
Section 2.1(b) and shall expire:

          (i)  if NeoGenesis does not perform any medicinal chemistry
               optimization activities pursuant to Section 2.2(b) to develop
               NeoMorph Focused Libraries with respect to the Target, [*] after
               NeoGenesis delivers to SPL the Final Target Report with respect
               to such Target; or

          (ii) if NeoGenesis does perform medicinal chemistry optimization
               activities pursuant to Section 2.2(b) to develop NeoMorph Focused
               Libraries with respect to such Target, [*] after the later of the
               date upon which SPL files an IND for a Licensed Product directed
               to the Target or discontinues the development of Licensed
               Products against such Target.

Upon the expiration of the Screening Program, and annually thereafter, SPL shall
notify NeoGenesis in writing of the list of Targets with respect to which SPL
has ongoing programs to discover and develop Licensed Products. SPL shall
promptly notify NeoGenesis in writing in the event that it discontinues the
development of Licensed Products against a Target. For purposes of this Section
2.1(e), SPL shall be deemed to have discontinued development of Licensed
Products against a Target if it ceases to maintain a minimum of [*] FTEs
assigned full time to work on the discovery and pre-clinical development of
Licensed Products against a Target. During the term of the Screening Program, if
NeoGenesis intends to screen the NeoMorph Screening Libraries (including all
newly created Compounds contained therein) for a third party against a Target
with respect to which SPL's Exclusivity Period has expired pursuant to
subsection (i), above, NeoGenesis shall first offer SPL the opportunity to
screen the NeoMorph Screening Libraries against the Target. SPL shall have [*]
in which to accept or reject such offer. If SPL accepts the offer, such
screening shall be conducted under the terms of this Agreement and SPL shall
have a renewed Exclusivity Period with respect to such Target. If NeoGenesis
does perform medicinal chemistry optimization activities pursuant to Section
2.2(b) to develop NeoMorph Focused Libraries with respect to a Target, then
notwithstanding the expiration of the applicable Exclusivity Period pursuant
subsection (ii), above, NeoGenesis shall be permanently prohibited from
screening the NeoMorph Screening Libraries against the Target for itself and in
such instance may only perform such screening for third parties. In the event
that NeoGenesis

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       9
<Page>

does screen the NeoMorph Screening Libraries against a Target for itself or a
third party as permitted under this Section 2.1(e), NeoGenesis shall not use (i)
any Schering Know-How (including without limitation any of SPL's proprietary
information related to the existence of or uses for the Target), or (ii) any
NeoGenesis Know-How related to the Target and developed in performance of the
Screening Program, in connection with such screening activities.

          (f)  For purposes of this Agreement, and in particular with respect to
the provisions of Sections 2.1(b) and 2.1(e), a Target identified by SPL for
screening under this Agreement will encompass the nucleic acid or amino acid
sequence of the actual Target to be provided by SPL, and in the case of a Target
which is a human biological molecule, shall be further defined by the nucleic
acid or protein encoded by the specified genomic location of origin (which will
be identified by SPL in the notification to NeoGenesis of a proposed Target
pursuant to Section 2.1(b)) and natural polymorphic variants thereof such as
SNP, insertion, deletion and splice variants or the synthetic equivalent
thereof. If a Target can not be distinguished from another biological target
based on the above, then the Target shall be considered the same as another
biological target if the other biological target comprises a contiguous region
of [*] identical to the Target or is derived from such Target by modification.
If a Target is a biological molecule of non-human origin, then the Target shall
be considered the same as another target if they are both derived from the
comparable chromosomal location of related strains of the applicable species.
For example, a target defined by [*] shall be considered the same as a target
specified by the [*] including targets derived by modification. Similarly, a
target specified by a chromosomal location in one particular strain of [*] shall
be considered identical to a target specified by the analogous location in a
second strain of bacteria. If the chromosomal locations of two targets can not
be defined, then a target shall be considered the same as a second target if it
comprises a contiguous region of [*] to said second target or is derived from
such a second Target by modification. It is expressly understood that a
non-human target falling outside the criteria defined above may not be screened
using the NeoMorph Screening Libraries with the intent of developing a product
affecting the activity of a human target that would meet the identity criteria.
For clarity, a primate ortholog of a human gene or protein may not be screened
using the Neomorph Screening Libraries if the intent is to develop a product for
human use against an otherwise excluded target. Nothing in this paragraph shall
limit the screening of non-human targets for non-human usage.

     2.2  SCREENING PROGRAM.

     (a)  During the term of the Screening Program, NeoGenesis will utilize its
proprietary technology and methods, including without limitation the ALIS
method, to screen the NeoMorph Screening Library for activity with respect to
each Target for purposes of identifying Active Compounds for further evaluation
and development. Screening will be performed pursuant to the protocol for the
Screening Program, as set forth in paragraphs 1-2 of ATTACHMENT A. With respect
to each accepted Target provided by SPL under Section 2.1, NeoGenesis shall
complete the screening of the NeoMorph Screening Library within [*] following
the date that the Target is delivered to NeoGenesis. The results of such
screening shall be provided to SPL through the Steering Committee in the form of
a Preliminary Target Report (as defined in ATTACHMENT A). NeoGenesis shall
provide SPL with samples of all Preliminary Compounds selected by the

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       10
<Page>

Steering Committee for further evaluation by SPL pursuant to paragraph 3 of
ATTACHMENT A. SPL will evaluate such Preliminary Compounds in Target-based
functional assays and/or secondary assays to identify Active Compounds, and will
report the results of such evaluations to the Steering Committee, and NeoGenesis
will promptly thereafter provide SPL with all available structural information
for each Active Compound so identified. NeoGenesis will, at the direction of the
Steering Committee, conduct initial optimization activities, as described in
paragraph 4, of ATTACHMENT A, to identify Improved Active Compounds. It is
acknowledged that all compounds generated from such initial optimization
activities and having activity against the relevant Target shall be deemed to be
Improved Active Compounds; provided that such optimization activities and all
Improved Active Compounds arising therefrom shall not be deemed to be
optimization of Lead Compounds for purposes of Section 2.1(e) or for determining
SPL's financial obligations under Sections 4.3 and 4.4.

          (b)  NeoGenesis will, at the direction of the Steering Committee,
conduct a full program of medicinal chemistry optimization activities, based
upon those Selected Compounds identified as Lead Compounds that are suitable for
optimization. Such optimization activities shall include the design and
preparation of NeoMorph Focused Libraries based upon such Lead Compounds, and
the screening of the NeoMorph Focused Libraries against the relevant Target(s).
The parties acknowledge and agree that, subject to the terms of Sections 3.5(a),
and effective on the date that SPL acquires an exclusive license to the relevant
Selected Compound(s) pursuant to Sections 2.7(c), 3.1 and 3.2, any and all
Compounds which are included in NeoMorph Focused Libraries prepared against the
relevant Target shall be the exclusive property of SPL. NeoGenesis shall not use
the NeoMorph Focused Libraries, any Compounds contained therein, or any
structural information or other know-how related thereto, for any purpose other
than the performance of the Screening Program. NeoGenesis shall not provide any
NeoMorph Focused Libraries, any Compounds contained therein, or any structural
information or other NeoGenesis Know-How related thereto, to any third party
without the prior written consent of SPL. Notwithstanding the foregoing
limitations, it is expressly understood and agreed that NeoGenesis may, through
use of the NeoMorph Screening Library on behalf of third parties independently
generate results or data similar to the results or data generated in the course
of the Screening Program and that the use of such independently generated
results or data shall not constitute a breach of NeoGenesis' obligations under
this Section 2.2(b); PROVIDED, that NeoGenesis has complied with its obligations
to mask Compounds in accordance with Section 2.3 of this Agreement.

          (c)  NeoGenesis shall not perform any tests on or using any of the
Targets that are outside the scope of the Screening Program, or attempt to
modify the Targets supplied by SPL, including, without limitation, the making of
any derivatives, analogs or components thereof. In the event that NeoGenesis
does not consume all of the Targets supplied by SPL in performance of the
Screening Program, NeoGenesis will upon completion of the Screening Program
promptly, return to SPL any quantities of such Target(s) and any derivatives,
analogs or components thereof.

          (d)  The term of the Screening Program shall begin on the Effective
Date and shall continue in effect for a period of two (2) years. SPL shall have
the right to extend the term

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       11
<Page>

of the Screening Program for up to three additional one (1) year terms, by
providing NeoGenesis with written notice to that effect at least sixty (60) days
prior to the expiration of the then current term of the Screening Program and
subject to the provisions of Section 4.1 concerning research funding for such
extension term. The Screening Program shall remain in effect for the period
specified in this Section 2.2(d), including as it may be extended, unless sooner
terminated in accordance with Section 8.2 or Section 9.5.

          (e)  During the term of the Screening Program, upon request,
NeoGenesis shall provide SPL with samples of Selected Compounds and Derivative
Compounds from NeoMorph Focused Libraries in a form and quantity suitable to
enable SPL to conduct additional testing to confirm the specific binding
activity of such Compounds and to evaluate and determine the functional activity
of the Selected Compounds and/or Derivative Compounds. SPL may also elect to
perform medicinal chemistry research using such Selected Compounds and/or
Derivative Compounds to discover and evaluate additional Derivative Compounds.
SPL shall keep NeoGenesis reasonably informed of the results of such activities
through the Steering Committee.

          (f)  During the term of the Screening Program NeoGenesis shall provide
appropriately trained dedicated scientific personnel to perform the Screening
Program in accordance with the terms of this Agreement. During the initial two
(2) year term of the Screening Program, NeoGenesis shall provide such support at
the level of [*] FTEs during each year of the Screening Program, it being
understood that NeoGenesis may allocate such FTE time within any calendar year
in a manner consistent with its obligations under the Screening Program based on
the workload for such Screening Program at any particular time during the
Screening Program. In addition, NeoGenesis will, upon written request by SPL,
provide additional FTE support for the Screening Program of up to an additional
[*] FTEs during the term of the Screening Program. In the event that the term of
the Screening Program is extended pursuant to Section 2.2(d), the Steering
Committee shall establish the number of FTEs to be provided by NeoGenesis for
performance of the Screening Program during the extended term.

          (g)  NeoGenesis shall monitor expenditures, in accordance with its
corporate policies, to ensure that the funds provided by SPL are spent in
accordance with this Agreement. NeoGenesis shall keep and maintain adequate
books and records to furnish information to SPL regarding calculation of the
amounts expended by NeoGenesis on the Screening Program according to the
provisions of this Agreement. During the Screening Program and for two (2) years
following the expiration of the Screening Program, NeoGenesis shall permit SPL
to examine such books and records during normal business hours, upon thirty (30)
days notice to NeoGenesis. Upon the expiration of the two (2) year period, the
calculation of the amounts expended on each year of the Screening Program shall
be binding and conclusive upon the parties and NeoGenesis shall be released from
any further accountability with respect to the Screening Program.

          (h)  NeoGenesis will perform its screening obligations in accordance
with all applicable laws, rules and regulations.

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       12
<Page>

     2.3  COMPOUND MASKING.

          (a)  Upon the identification of Preliminary Compounds and Active
Compounds through screening of the NeoMorph Screening Library against a
particular Target, NeoGenesis shall mask such Preliminary Compounds and Active
Compounds from the NeoMorph Screening Library by removing such Compounds from
the compound resource information associated with the NeoMorph Screening Library
and shall take all other steps reasonably necessary to ensure that information
with regard to such Compounds is not available or accessible to any third party,
including third parties for which NeoGenesis is screening the NeoMorph Screening
Library against other biological targets. NeoGenesis shall similarly mask any
Improved Active Compounds which are discovered pursuant to Section 2.2(a).

          (b)  NeoGenesis shall have the right to unmask any Preliminary
Compounds which are not confirmed as Active Compounds and are not in the same
Chemotype as such Active Compounds. In addition, upon expiration of SPL's right
to designate Selected Compounds with regard to a specific Target, pursuant to
Section 2.7(a), NeoGenesis shall have the right to unmask any Active Compounds
and/or Improved Active Compounds identified through screening against that
Target which are not (i) Selected Compounds or (ii) Preliminary Compounds,
Active Compounds and/or Improved Active Compounds of the same Chemotype as such
Selected Compounds.

     2.4  GRANT OF RESEARCH LICENSES.

          (a)  SPL hereby grants NeoGenesis a nonexclusive, nontransferable,
royalty-free license under the Schering Patent Rights and to use the Schering
Know-How solely for the purpose of conducting the Screening Program. NeoGenesis
will not use Schering Know-How or Schering Patent Rights for any other purpose,
and shall not offer or grant a sub-license to use Schering Know-How or Schering
Patent Rights to any third party, without the express prior written consent of
SPL.

          (b)  NeoGenesis hereby grants SPL a nonexclusive, nontransferable,
royalty-free license under the NeoGenesis Patent Rights and to use the
NeoGenesis Know-How solely for the purpose of conducting SPL's activities under
the Screening Program. SPL will not use NeoGenesis Know-How or NeoGenesis Patent
Rights for any other purpose, and shall not offer or grant a sub-license to use
NeoGenesis Know-How or NeoGenesis Patent Rights to any third party, without the
express prior written consent of NeoGenesis (not to be unreasonably withheld).

          (c)  With respect to Selected Compounds identified pursuant to Section
2.7(a), NeoGenesis hereby grants SPL, during the relevant Option Period (as
defined in Section 2.7(b)), an exclusive, nontransferable, royalty-free license
under the NeoGenesis Patent Rights and to use the NeoGenesis Know-How solely for
the purpose of performing research and development work necessary to enable SPL
to determine whether or not to exercise its option to obtain an exclusive
license with respect to such Selected Compounds.

     2.5  RECORD KEEPING AND REPORTS.

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       13
<Page>

          (a)  NeoGenesis will keep and maintain complete and accurate records
of all laboratory data and results generated in the course of the Screening
Program, including records of all Preliminary Compounds, Active Compounds, and
Improved Active Compounds identified, and any Inventions discovered and/or
developed by NeoGenesis, during the Screening Program. All such written records
of NeoGenesis shall be open to inspection by SPL during normal business hours
upon reasonable prior written notice; provided, however, that except with
respect to (i) Improved Active Compounds, (ii) Active Compounds, and (iii)
Preliminary Compounds of the same Chemotype as such Improved Active Compounds or
Active Compounds, NeoGenesis shall not provide SPL with access to any chemical
structures or structural data.

          (b)  NeoGenesis shall provide SPL with reasonably-detailed written
reports describing the results of the research performed pursuant to the
Screening Program including all Preliminary Compounds, Active Compounds and
Improved Active Compounds identified in the Screening Program but shall not
include any chemical structures or structural data with respect to any Compounds
which are not (i) Improved Active Compounds, (ii) Active Compounds, and (iii)
Preliminary Compounds of the same Chemotype as such Improved Active Compounds or
Active Compounds. Such reports shall be delivered to SPL at least quarterly
during the term of the Screening Program. In addition, with respect to each
Target, promptly following the completion of screening of the entire NeoMorph
Screening Library against such Target, NeoGenesis will deliver to SPL a
Preliminary Target Report (as defined in ATTACHMENT A) with respect to any and
all Preliminary Compounds identified during the Screening Program as having
activity with respect to such Target. Each Preliminary Target Report shall
include the binding affinities for all such Preliminary Compounds, as well as
any information generated by NeoGenesis with regard to Target specificities and
functional activities of such Preliminary Compounds. NeoGenesis shall also
provide SPL with a Final Target Report (as defined in ATTACHMENT A) in
accordance with the provisions of Paragraph 4 of ATTACHMENT A. NeoGenesis shall
also provide SPL with reports at least one (1) week prior to each Steering
Committee Meeting detailing the results of any Lead Compound optimization
activities performed by NeoGenesis pursuant to Section 2.2(b) and ATTACHMENT A,
which reports shall include the chemical structures and binding affinities of
all Derivative Compounds contained in NeoMorph Focused Libraries prepared by
NeoGenesis based upon such Lead Compound(s) and other information generated by
NeoGenesis with respect thereto.

     2.6  STEERING COMMITTEE.

          (a)  Promptly after the Effective Date, the parties shall establish a
joint committee (the "STEERING COMMITTEE") having oversight responsibility for
the day-to-day management and performance of the Screening Program. The Steering
Committee shall consist of six (6) members, three (3) members to be appointed by
each of NeoGenesis and SPL. Each party shall notify the other party of the names
and contact information for its members of the Steering Committee, and
thereafter may with notice to the other substitute any of its members serving on
the Steering Committee. Each member of the Steering Committee will have one vote
and all decisions of the Steering Committee will be by unanimous agreement. The
quorum for Steering Committee meetings shall be two, provided there is at least
one member from each of NeoGenesis and SPL present. The Steering Committee will
render decisions by unanimous vote.

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       14
<Page>

          (b)  The Steering Committee shall be responsible for the management
and conduct of the Screening Program and shall in particular: (i) consider,
review and amend the Screening Program from time to time in such manner as may
be appropriate; (ii) monitor progress of the Screening Program; (iii) report
regularly to the management of both parties upon the progress of the Screening
Program; and (iv) be the initial medium for transfer of information between the
parties. SPL shall keep the Steering Committee reasonably informed of the status
of SPL's activties with respect to the discovery and development of Licensed
Products against each Target.

          (c)  During the term of the Screening Program, the Steering Committee
shall hold meetings as mutually agreed by the parties (but in no event less
quarterly) to review the Screening Program. The first meeting of the Steering
Committee shall be held within forty-five (45) days of the Effective Date and
shall be held in Cambridge, MA. Thereafter, meetings may be held by telephone or
video conference if requested by either party in writing to the other, PROVIDED
THAT the parties shall meet in person at least four (4) times per year during
the term of the Screening Program. Minutes of all meetings setting forth
decisions of the Steering Committee relative to the Screening Program shall be
prepared by the host party and circulated to both parties within fifteen (15)
days after each meeting, but minutes shall not become official until approved
and countersigned by both parties (which approval the parties shall use
reasonable efforts to give within thirty (30) days of receipt of such minutes).

          (d)  In the event that the Steering Committee is unable to reach
agreement, the issue in dispute shall be referred to an "OVERSIGHT COMMITTEE"
consisting of the Executive Vice President, Discovery Research of the
Schering-Plough Research Institute (an Affiliate of SPL) and NeoGenesis' Chief
Executive Officer, or their respective designees, for resolution. If the
disagreement is not resolved by the Oversight Committee within thirty (30) days,
then SPL shall have the right to make the final decision on such matter;
PROVIDED, that in the event and to the extent that any dispute concerns whether
or not budgeted FTE funding for the Screening Program has been expended in
accordance with the provisions of this Agreement such matter shall be resolved
using the procedure specified in Section 9.1.

     2.7  SELECTED COMPOUNDS.

          (a)  From time to time during the term of this Agreement, SPL may
designate, by written notice to NeoGenesis, one or more Active Compounds and/or
Improved Active Compounds identified by screening of the NeoMorph Screening
Libraries pursuant to Section 2.2 as Selected Compounds; provided, that at any
given time SPL may not designate Active Compounds and Improved Active Compounds
representing more than [*] different Chemotypes against a given Target from the
NeoMorph Screening Library. The parties acknowledge and agree that the foregoing
limitation does not apply to the NeoMorph Focused Libraries. [*] Selected
Compounds that SPL may designate from the NeoMorph Focused Libraries. With
respect to each Target, SPL shall use diligent efforts to identify and designate
at least one Selected Compound within [*] following SPL's receipt of the Final
Target Report for all screening against such Target in accordance with Section
2.5(b) and ATTACHMENT A. In the event

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       15
<Page>

that the SPL does not designate any Selected Compounds with respect to such
Target, then upon expiration of the applicable [*] period, SPL's right to
designate Selected Compounds with respect to such Target shall expire. If the
NeoMorph Screening Library is subsequently re-screened against a given Target
pursuant to Section 2.1(e) and new Active Compounds and/or Improved Active
Compounds are identified as a result of such re-screening, then to the extent
SPL's right to designate Selected Compounds against such Target has previously
expired, SPL shall have a renewed right to designate Selected Compounds arising
from such re-screening on the same terms as set forth above.

          (b)  Effective upon the date of receipt by NeoGenesis of notice from
SPL, pursuant to Section 2.7(a) that one or more Active Compounds and/or
Improved Active Compounds have been designated as Selected Compounds, NeoGenesis
grants to SPL an exclusive option to obtain the exclusive license provided for
in Article 3 with respect to such Selected Compounds and related Derivative
Compounds (including without limitation any Compounds contained in a NeoMorph
Focused Library prepared based upon such Selected Compound). The masking of the
Selected Compound(s) (and any Preliminary Compounds, Active Compounds and
Improved Active Compounds of the same Chemotype(s) as such Selected Compound(s))
from the NeoMorph Screening Library in accordance with Section 2.3 shall be
maintained during the applicable Option Period (as defined below). In addition,
within [*] following receipt of notification from SPL identifying Selected
Compounds, NeoGenesis shall amend ATTACHMENT B to identify any applicable
NeoGenesis Patent Rights not previously identified to SPL. The "OPTION PERIOD"
with respect to each Selected Compound identified pursuant to Section 2.7(a),
shall extend until the later of: (i) the [*] anniversary of the expiration of
the Screening Program for the applicable Target, or (ii) in the event that SPL
is conducting an active internal medicinal chemistry research program to
identify Derivative Compounds based upon such Selected Compound (as documented
with written notice to NeoGenesis), a period of [*] following the termination of
such medicinal chemistry program. For purposes of this Section 2.7(b), SPL shall
be deemed to be conducting an active medicinal chemistry program if [*] working
full time on the design and discovery of Derivative Compounds with respect to a
given Selected Compound. SPL shall provide NeoGenesis with written
certification, at least [*] every [*], during the performance of such medicinal
chemistry program for purposes of monitoring the expiration of the Option
Period.

          (c)  SPL shall have the right to exercise the option granted to it
under Section 2.7(b) with respect to one or more Selected Compounds (and related
Derivative Compounds, including without limitation any Compounds contained in a
NeoMorph Focused Library prepared based upon such Selected Compound) at any time
prior to the expiration of the applicable Option Period, by providing written
notice to NeoGenesis to that effect. The exclusive licenses granted to SPL
pursuant to Article 3 with respect to such Selected Compounds (and related
Derivative Compounds, including without limitation any Compounds contained in a
NeoMorph Focused Library prepared based upon such Selected Compound) shall
become effective upon NeoGenesis' receipt of such notice, and SPL shall pay the
applicable license fee under Section 4.2 to NeoGenesis within five (5) business
days of such notice. As of such date of such notice, the masking of the
applicable Selected Compound(s) (and related Derivative Compounds, including
without limitation any Compounds contained in a NeoMorph Focused Library
prepared

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       16
<Page>

based upon such Selected Compound), as well as any Preliminary Compounds, Active
Compounds and Improved Active Compounds of the same Chemotype as such Selected
Compound, from the NeoMorph Screening Library in accordance with Section 2.3
shall become permanent, and during the term of this Agreement NeoGenesis shall
continue take such other steps as are reasonably necessary to ensure that
information with regard to the Selected Compounds and the relevant Active
Compounds, Improved Active Compounds and Preliminary Compounds of the same
Chemotype as such Selected Compounds are no longer available or accessible to
any third party.

          (d)  In the event that SPL fails to exercise its option rights with
respect to one or more Selected Compounds prior to the expiration of the
applicable Option Period, then upon expiration of the Option Period SPL's option
right shall expire with respect to the applicable Selected Compound(s), the
licenses provided for in Article 3 with respect to such Selected Compound(s)
shall be void and of no further force or effect, and NeoGenesis shall be free to
unmask such Selected Compound(s) in the NeoMorph Screening Library.

          (e)  In the event that during the applicable Option Period, one or
more Selected Compounds with respect to a given Target become Designated
Compounds and SPL has not, as of the effective date of such designation,
exercised the option and paid the license fee due under section 4.2 with respect
to Selected Compounds against such Target, then the license fee shall be paid
concurrently with the milestone payment due upon designation of such Designated
Compounds in accordance with Section 2.8.

          (f)  SPL shall not begin screening any Selected Compound or related
Derivative Compounds against any biological targets other than Targets until
such time as it has exercised its option in accordance with Section 2.7(c) and
paid the applicable licensee fee.

     2.8  PRODUCT DEVELOPMENT.

          (a)  During the term of this Agreement, SPL shall, at its expense,
conduct a research and development program to evaluate Selected Compounds and
Derivative Compounds as potential candidates for commercial development as
Licensed Products. Such efforts may include the performance of further medicinal
chemical research based upon such Selected Compounds and Derivative Compounds,
as well as biological, pharmacokinetic and toxicology studies and other
preclinical research activities. SPL shall have sole discretion over the scope
of such research and development program, and the selection of which Selected
Compounds and Derivative Compounds will be the focus of such activities.

          (b)  SPL shall notify NeoGenesis in writing in the event that SPL, in
its sole discretion (based on SPL's good faith evaluation of the satisfaction of
the applicable Success Criteria by such Selected Compound or Derivative
Compound), decides to proceed with a development program for any Selected
Compounds or Derivative Compounds as suitable candidates for drug development
(thereafter, each a "DESIGNATED COMPOUND"). A Selected Compound or Derivative
Compound will be deemed to be a Designated Compound upon the earlier of that
date on which (i) SPL (or its Affiliate) formally approves proceeding with full

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       17
<Page>

development of such Compound, or (ii) SPL (or its Affiliate) initiates IN VIVO
toxicology trials necessary, and meeting U.S. FDA (or corresponding European or
Japanese) standards, for obtaining approval for use of such Compound in human
clinical trials, unless SPL sooner designates such Selected Compound or
Derivative Compound as a Designated Compound with notice to NeoGenesis. Upon
SPL's designation of a Designated Compound, SPL shall thereafter, at its
expense, use Commercially Reasonable Efforts to develop and commercialize
Licensed Products incorporating the Designated Compound in the Territory. SPL
shall be solely responsible for determining in which countries in the Territory
to develop and commercialize each Licensed Product, provided that it shall use
Commercially Reasonable Efforts to obtain Regulatory Approval and to market and
sell each Licensed Product in the Major Market Countries.

          (c)  Subject to SPL's diligence obligations under this Agreement, the
Parties acknowledge and agree that all business decisions regarding research,
development and commercialization of Designated Compounds and Licensed Products
including, without limitation, decisions relating to the design, development,
manufacture, sale, price, distribution, marketing and promotion of Licensed
Products under this Agreement, and the decision of whether to develop a
particular Designated Compound, or to develop and commercialize a particular
Licensed Product, shall be within the sole discretion of SPL.

          (d)  SPL shall have no quotas or other minimum diligence obligations
with regard to the number of Designated Compounds and/or Licensed Products to be
developed and commercialized hereunder. The parties acknowledge and agree that
so long as SPL is using Commercially Reasonable Efforts to discover, develop and
commercialize [*] Licensed Product in the Territory, SPL shall be deemed to be
in compliance with its diligence obligations under this Agreement.

     2.9  COMMERCIALIZATION OF LICENSED PRODUCTS. With respect to each Licensed
Product developed and commercialized by SPL, or its designated Affiliates, under
this Agreement, SPL shall be solely responsible, at its sole expense, for all
aspects of the development and commercialization of the Licensed Product in the
Territory, including, without limitation:

     (i)  the manufacture of Designated Compounds and Licensed Products in
          accordance with the applicable Regulatory Approvals, laws, Good
          Laboratory Practices and Good Manufacturing Practices;

     (ii) preparation, filing, obtaining, maintaining and supporting, in its own
          name or that of its designated Affiliate, with the appropriate
          regulatory authorities of all regulatory approvals, authorizations,
          permits and licenses (including, without limitation, all Regulatory
          Approvals) that are necessary to conduct clinical studies of Licensed
          Products and/or to manufacture, import, distribute, market and sell
          Licensed Products;

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       18
<Page>

     (iii) the reporting all adverse events associated with any Licensed Product
          to the appropriate regulatory authorities in accordance with
          applicable laws, rules and regulations in the Territory; and

     (iv) the distribution, marketing, promotion and sale of Licensed Products.

Following the expiration of the Screening Program, SPL shall provide NeoGenesis
with semi-annual reports summarizing the status of SPL's development and
commercialization activities with respect to each Licensed Product being
developed under this Agreement. In addition, SPL shall notify NeoGenesis in
writing upon the filing of each application for Regulatory Approval of a
Licensed Product in the Territory.

     2.10 DILIGENCE EXCEPTIONS. All of SPL's diligence obligations hereunder
with respect to each Licensed Product being developed or commercialized
hereunder are expressly conditioned upon the continuing absence of any adverse
condition or event which warrants a delay in commercialization of the Licensed
Product due to an adverse condition or event relating to the safety or efficacy
of such Licensed Product or unfavorable pricing, pricing reimbursement, labeling
or lack of regulatory approval, and SPL shall have no obligation to develop or
market any such Licensed Product so long as in SPL's reasonable opinion any such
condition or event exists.

     2.11 THIRD PARTY LICENSES. SPL shall be solely responsible for (a)
obtaining any and all licenses from third parties necessary or desirable to
develop or commercialize any Licensed Product and (b) any and all consideration
payable with respect to such licenses. The decision as to whether or not to
obtain any such third party licenses relating to Licensed Products, and the
negotiation and acceptance of the terms and conditions for any such licenses,
shall be within the sole discretion and control of SPL, and nothing herein shall
be construed as obligating SPL to obtain any such third party licenses.

     2.12 COMPLIANCE WITH LAW. SPL shall be responsible for ensuring that all
activities related to the development and commercialization of Licensed Products
conducted by or on its behalf are performed in compliance with all applicable
laws, rules and regulations (including, but not limited to, those related to
occupational safety and health, public safety and health, protecting the
environment, the disposal of wastes, Good Clinical Practices, Good Laboratory
Practices and Good Manufacturing Practices, as applicable).

3.   LICENSES; INTELLECTUAL PROPERTY RIGHTS

     3.1  LICENSE TO LICENSED PRODUCTS. NeoGenesis hereby grants to SPL, and SPL
hereby accepts, an exclusive (even as to NeoGenesis), right and license in the
Territory and within the Field under the NeoGenesis Patent Rights and to use the
NeoGenesis Know-How to make, have made, use, distribute, promote, market, offer
for sale, sell, import and export Licensed Products. The licenses granted to SPL
under this Section 3.1 include the right to grant sublicenses to Affiliates or
third parties in accordance with the provisions of Section 3.3. SPL

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       19
<Page>

shall mark or have marked all containers or packages of Licensed Products that
are the subject of the license granted under this Section 3.1 in accordance with
the patent marking laws of the jurisdiction in which such Licensed Products are
manufactured, used or sold. For purposes of clarity and avoidance of doubt, it
is acknowledged that the exclusive licenses granted hereunder shall not be
construed as encompassing Compounds other than Selected Compounds (and Active
Compounds, Improved Active Compounds and Preliminary Compounds of the same
Chemotype as such Selected Compounds), Derivative Compounds and Designated
Compounds.

     3.2  LICENSE TO COMPOUNDS. NeoGenesis hereby grants to SPL, and SPL hereby
accepts, an exclusive (even as to NeoGenesis), right and license in the
Territory and within the Field under the NeoGenesis Patent Rights and to use the
NeoGenesis Know-How to research, develop, make, have made, import, export and
use the Selected Compounds (and Active Compounds, Improved Active Compounds and
Preliminary Compounds of the same Chemotype as such Selected Compounds),
Designated Compounds and Derivative Compounds, for research purposes and to
develop Licensed Products. The licenses granted to SPL under this Section 3.2
include the right to grant sublicenses to Affiliates or third parties in
accordance with the provisions of Section 3.3. SPL shall mark or have marked all
containers or packages of Selected Compounds Derivative Compounds and Designated
Compounds that are the subject of the license granted under this Section 3.1 in
accordance with the patent marking laws of the jurisdiction in which such
Selected Compounds, Derivative Compounds and Designated Compounds are
manufactured, used or sold.

     3.3  SUBLICENSING. SPL's shall have the right to grant sublicenses under
this Agreement to third parties and/or Affiliates; provided that all such
sublicenses shall be consistent with the terms and conditions of this Agreement,
and in particular shall include provisions to ensure that such sublicense is
subject to the obligations set forth in Section 3.1(last sentence), 4.4, 4.5,
4.6, 4.7 and 8.3(b) (last sentence) of this Agreement. SPL shall remain
responsible to NeoGenesis for all of its sublicensees financial and other
obligations under this Agreement. SPL's sublicensees shall have no further right
to grant sublicenses, and any sublicense granted by SPL under this Agreement
shall not be assigned, transferred or otherwise conveyed by the sublicensee to
any third party, as a matter of law or through any action by sublicensee,
without the prior written consent of NeoGenesis.

     3.4  RETAINED RIGHTS.

          (a)  Title to the NeoGenesis Know-How and NeoGenesis Patent Rights
shall at all times remain vested in NeoGenesis, and this Agreement does not
convey to SPL any ownership rights or other interest in any NeoGenesis Know-How
or NeoGenesis Patent Rights, by implication, estoppel or otherwise, except for
those rights and licenses expressly granted under this Agreement.

          (b)  Title to the Schering Know-How and Schering Patent Rights shall
at all times remain vested in SPL, and this Agreement does not convey to
NeoGenesis any ownership rights or other interest in any Schering Know-How or
Schering Patent Rights, by implication, estoppel or otherwise, except for the
rights and licenses expressly granted under this Agreement.

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       20
<Page>

          (c)  The parties acknowledge and agree that notwithstanding the
exclusive licenses granted to SPL hereunder, with respect to the NeoGenesis
Know-How and NeoGenesis Patent Rights, NeoGenesis shall retain the right to
continue to use its NeoMorph Screening Library to screen target proteins (other
than Targets) for third parties; PROVIDED that NeoGenesis complies with all of
its obligations with respect to the masking of Preliminary Compounds, Active
Compounds, Improved Active Compounds and Selected Compounds from the NeoMorph
Screening Library.

     3.5  INVENTIONS.

          (a)  Title to and ownership of all Inventions directly related to (i)
Selected Compounds, Derivative Compounds, Designated Compounds and Licensed
Products, or the manufacture or use thereof, or (ii) Targets provided to
NeoGenesis by SPL, in each case regardless of inventorship, as well as those
Inventions subject to Section 3.5(b)(ii), shall be the sole property of SPL
(hereinafter "SCHERING INVENTIONS") and are included in Schering Know-How and/or
Schering Patent Rights, as the case may be. NeoGenesis hereby assigns and agrees
to assign to SPL all of NeoGenesis' right, title and interest in such Schering
Inventions; such assignment to take effect with respect to particular Selected
Compounds (and related Derivative Compounds, Designated Compounds and Licensed
Products) upon the date NeoGenesis receives notice from SPL pursuant to Section
2.7(c) that SPL has decided to exercise its option to exclusively license the
Selected Compounds and related Derivative Compounds; and NeoGenesis shall use
Commercially Reasonable Efforts to perfect such assignment (at SPL's expense).
Title to and ownership of all Inventions directly related to the NeoMorph
Screening Library, ALIS screening technology or QSCD (regardless of
inventorship), as well as those Inventions subject to Section 3.5(b)(i)
(hereinafter "NEOGENESIS INVENTIONS"), shall be the sole property of NeoGenesis
and are included in NeoGenesis Know-How and/or NeoGenesis Patent Rights, as the
case may be. SPL hereby assigns and agrees to assign to NeoGenesis, all of SPL's
right title and interest (if any) in such NeoGenesis Inventions and SPL shall
use Commercially Reasonable Efforts to perfect such assignment (at the
NeoGenesis' expense).

          (b)  Title to and ownership of all other Inventions arising from the
Screening Program and which are not covered by Section 3.5(a) shall be
determined as follows:

          (i)  Inventions made solely by one or more employees or agents of
               NeoGenesis shall be the sole property of NeoGenesis are
               NeoGenesis Inventions and are included in NeoGenesis Know-How
               and/or NeoGenesis Patent Rights, as the case may be.

          (ii) Inventions made solely by one or more employees or agents of SPL
               shall be the sole property of SPL, are Schering Inventions, and
               are included in Schering Know-How and/or Schering Patent Rights,
               as the case may be.

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       21
<Page>

          (iii) Inventions made jointly by one or more employees or agents of
               NeoGenesis and one or more employees or agents of SPL shall be
               the joint property of NeoGenesis and SPL (hereinafter "JOINT
               INVENTIONS").

In determining each party's contribution to Inventions arising under this
Agreement, inventorship shall be determined in accordance with United States
patent law.

     3.6  PATENT PROTECTION FOR INVENTIONS. Each of NeoGenesis and SPL shall
promptly disclose to the other knowledge of any Inventions arising in connection
with the Screening Program. Responsibility for the preparation, filing,
prosecution and maintenance of any patent applications and patents claiming such
Inventions shall be determined based upon ownership of the Inventions and shall
be handled in accordance with the provisions of this Section 3.6. Within forty
five (45) days following disclosure of any Invention(s), the parties shall
classify such Invention as a Schering Invention, a NeoGenesis Invention or a
Joint Invention and shall update ATTACHMENT C to add such Invention and reflect
such classification.

          (a)  NeoGenesis shall have the right and responsibility to prepare,
file, prosecute, and maintain all patent applications and patent within the
NeoGenesis Patent Rights throughout the Territory at NeoGenesis sole expense,
including, without limitation, those with respect to NeoGenesis Inventions.
NeoGenesis shall have sole discretion as to all such activities with regard to
the NeoGenesis Patent Rights. NeoGenesis shall keep SPL currently advised as to
the status of all patents and patent applications with respect to the NeoGenesis
Patent Rights and shall supply SPL promptly with copies of all patents, patent
applications, substantive patent office actions, substantive responses received
or filed in connection with such applications. SPL may offer comments and
suggestions with respect to the matters that are the subject of this Section
3.6(a) and NeoGenesis agrees to consider such comments and suggestions; PROVIDED
that nothing herein shall obligate NeoGenesis to adopt or follow such comments
or suggestions. In the event that NeoGenesis elects not to file for patent
protection for any NeoGenesis Inventions or elects not to continue to prosecute
or maintain a patent or patent application under the NeoGenesis Patent Rights it
shall notify SPL of such decision at least forty-five (45) days prior to the due
date of any action or payment due with respect thereto. SPL shall have the
right, but not the obligation to assume the responsibility therefor at its own
cost and expense.

          (b)  SPL and NeoGenesis, acting through the Steering Committee, shall
select and retain patent counsel mutually acceptable to each of them for the
purpose of preparing, prosecuting, issuing and maintaining appropriate patent
applications concerning Joint Inventions. NeoGenesis, in consultation with SPL,
shall be primarily responsible for the preparation, filing (including foreign
filing decisions), prosecution and maintenance of such patent applications and
patents relating to Joint Inventions. NeoGenesis shall furnish or have furnished
to SPL copies of documents relevant to the same and provide SPL with the
opportunity to review and comment on patent decisions made by patent counsel.
Any disagreements between NeoGenesis and SPL with respect to preparation,
filing, prosecution, issuance and maintenance matters will be discussed and
resolved to their mutual satisfaction using the procedures specified in Section
9.1, if necessary; PROVIDED, that to the extent that any disagreement regards
only the costs associated with a particular proposed action, NeoGenesis may
assume responsibility for such costs and the

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       22
<Page>

requirement that the parties mutually agree upon resolution of the matter shall
not apply. Each party shall be responsible for fifty percent (50%) of all
expenses associated with the preparation, filing, prosecution, issuance and
maintenance of patents or other intellectual property protection for Joint
Inventions. In the event that either party elects not to pursue a particular
action with respect to which the parties disagree regarding costs, the other
party shall have the right to assume such costs and to have such action taken;
PROVIDED FURTHER that the non-paying party's licenses hereunder shall exclude
any intellectual property rights that are the subject of such action (e.g.,
patent coverage in a particular country) unless and until such party reimburses
the other party for one-half (50%) of the costs of such action.

          (d)  SPL shall have the sole right, but not the obligation, to file,
prosecute, and maintain, at SPL's sole expense, each of the Schering Patent
Rights throughout the Territory. Upon request, and at SPL's expense, NeoGenesis
will provide SPL with reasonable assistance to prepare, file, prosecute,
maintain and defend the Schering Patent Rights, and will take all steps
necessary to enable SPL to perfect its rights and title to the Schering Patent
Rights with respect to any Schering Inventions. Reasonable assistance shall
include, without limitation, providing SPL any data and information relating to
such Schering Inventions and access to the NeoGenesis employees who are
inventors of such Schering Inventions, as well as causing the execution of any
patent assignment or other documents.

     3.7  ENFORCEMENT. Each party shall promptly notify the other of its
knowledge of any actual or potential infringement of the NeoGenesis Patent
Rights, the Schering Patent Rights or any Joint Inventions.

          (a)  NeoGenesis shall be solely responsible for defense and
enforcement of NeoGenesis Know-How and NeoGenesis Patent Rights. SPL shall be
solely responsible for the defense and enforcement of Schering Know-How and
Schering Patent Rights. In the event that either party recovers any sums in such
litigation by way of damages or in settlement thereof, such party shall have the
right to retain all such sums; PROVIDED that any recovery of ordinary damages by
SPL to the extent based upon third party sales of products that infringe upon
Compound Patent Rights shall be deemed to be Net Sales and SPL shall pay
NeoGenesis an amount calculated in accordance with Section 4.4 to reimburse
NeoGenesis for royalties due on lost sales of Licensed Product represented by
such ordinary damages; PROVIDED FURTHER that this allocation shall not apply
with respect to special or punitive damages, and that SPL shall be entitled to
deduct all litigation costs incurred by it in connection therewith from such
settlement or award prior to calculating such royalties.

          (b)  SPL shall have the first option to pursue any enforcement or
defense of any patents claiming Joint Inventions within the Field and the
Territory ("JOINT PATENT RIGHTS"); PROVIDED, that SPL pays all costs and
expenses related thereto. SPL shall have three (3) months from the date it
receives notice of such infringement to obtain a discontinuance of such
infringement or bring suit against the third party infringer. SPL shall keep
NeoGenesis reasonably informed of the status of such activities. NeoGenesis
shall provide reasonable assistance to SPL in any suit for infringement of a
Joint Patent Right brought by SPL against a third party, and shall have the
right to consult with SPL and to participate in and be represented

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       23
<Page>

by independent counsel in such litigation at its own expense. For purposes of
this Section 3.7(b), reasonable assistance shall mean providing SPL reasonable
access to information, materials and NeoGenesis personnel which SPL reasonably
determines is necessary to enable SPL to conduct the suit. SPL shall
periodically reimburse NeoGenesis for its out-of-pocket costs (excluding the
costs of retaining independent counsel) incurred in cooperating with SPL. SPL
shall incur no liability to NeoGenesis as a consequence of such litigation or
any unfavorable decision resulting therefrom, including any decision holding any
of the Joint Patent Rights invalid or unenforceable. In the event that SPL
recovers any sums in such litigation by way of damages or in settlement thereof,
SPL shall have the right to retain all such sums; PROVIDED that any recovery of
ordinary damages to the extent based upon third party sales of products that
infringe upon the Joint Patent Rights shall be deemed to be Net Sales and SPL
shall pay NeoGenesis an amount calculated in accordance with Section 4.4 to
reimburse NeoGenesis for royalties due on lost sales of Licensed Product
represented by such ordinary damages; PROVIDED FURTHER that this allocation
shall not apply with respect to special or punitive damages and that SPL shall
be entitled to deduct all litigation costs incurred by it in connection
therewith from such settlement or award prior to calculating such royalties.

          (c)  If, after the expiration of the three (3) month period specified
in Section 3.6(b), SPL has not overcome the allegation of infringement, obtained
a discontinuance of such infringement, or brought suit against the third party
infringer, then, provided such infringement is substantial, NeoGenesis shall
have the right, but not the obligation, to bring suit against such infringer
under the Joint Patent Right, provided that NeoGenesis shall bear all the
expenses of such suit. SPL shall provide reasonable assistance to NeoGenesis in
any suit for infringement of a Joint Patent Right brought by NeoGenesis against
a third party, and shall have the right to consult with NeoGenesis and to
participate in and be represented by independent counsel in such litigation at
its own expense. For purposes of this Section 3.6(c), reasonable assistance
shall mean providing NeoGenesis reasonable access to information, materials and
SPL personnel which NeoGenesis reasonably determines is necessary to enable
NeoGenesis to conduct the suit. NeoGenesis shall periodically reimburse SPL for
its out-of-pocket costs (excluding the costs of retaining independent counsel)
incurred in cooperating with NeoGenesis. NeoGenesis shall incur no liability to
SPL as a consequence of such litigation or any unfavorable decision resulting
therefrom, including any decision holding any of the Joint Patent Rights invalid
or unenforceable. In the event that NeoGenesis recovers any sums in such
litigation by way of damages or in settlement thereof, NeoGenesis shall have the
right to retain all such sums.

          (d)  Each party shall immediately give written notice to the other of
any certification of which it becomes aware filed pursuant to the Waxman-Hatch
Act (21 U.S.C. Section 355(b)(2)(A), or Section 355(j)(2)(A)(vii)), or any
amendment or successor statute thereto, at least fourteen (14) days prior to
expiration of the forty five (45) day period set forth in 21 U.S.C. Section
355(c)(3)(c) (or any amendment or successor statute thereto).

     3.8  LIST OF NEOGENESIS PATENT RIGHTS. The NeoGenesis Patent Rights
exclusively licensed to SPL pursuant to Sections 3.1 and 3.2 shall be listed in
ATTACHMENT B, which shall be amended from time to time during the term of this
Agreement to reflect additions or changes to the NeoGenesis Patent Rights in
accordance with Section 2.7. For the avoidance of doubt, to the

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       24
<Page>

extent that ATTACHMENT B is not updated to include any NeoGenesis Patent Rights
that are directly related to any Selected Compounds (and Active Compounds and
Improved Active Compounds of the same Chemotype as such Selected Compounds),
Designated Compounds, Derivative Compounds and/or Licensed Products within the
scope of an exclusive license granted to SPL under Sections 3.1 and 3.2,
NeoGenesis agrees that it shall not have any action against SPL in relation
thereto and shall automatically amend ATTACHMENT B to include such NeoGenesis
Patent Rights.

     4.  CONSIDERATION

     4.0  ADDITIONAL PAYMENT OBLIGATIONS. The parties acknowledge that SPL's
payment obligations as set forth in Sections 4.1, 4.2, 4.3 and 4.4 of this
Agreement are in addition to the payment obligations of Schering Corporation set
forth in Sections 4.1, 4.2, 4.3 and 4.4 of the US Agreement.

     4.1  RESEARCH FUNDING. In consideration for the performance of the
Screening Program and activities related thereto by NeoGenesis, SPL shall pay to
NeoGenesis research funding during the term of the Screening Program at the rate
of [*] per FTE per year during the initial two year term of the Screening
Program. Such payments constitute [*] payment for FTEs at a rate of [*] per year
per FTE, with [*] of such funding to be paid by Schering Corporation under the
terms of the US Agreement. The amount of such funding shall be based upon the
actual number of FTEs assigned by NeoGenesis to work on the Screening Program
pursuant to Section 2.2(f), it being understood that except as otherwise agreed
by the parties in writing, research funding shall be paid based upon [*] FTEs.
Research funding shall be payable in equal quarterly installments during the
term of the Screening Program, with the first such payment due within [*] after
the Effective Date and each successive payment due quarterly in advance on the
first day of each calendar quarter starting on October 1, 2001. It is understood
and agreed by the parties that first two research funding payments due under
this Agreement [*] represents payment for work performed by NeoGenesis in
connection with the Screening Program during the entire 2001 calendar year,
including activities performed during the period extending from January 1, 2001
until the Effective Date. In the event that the term of the Screening Program is
extended, the FTE rate payable under this Section 4.1 in each such extension
year shall be increased by the CPI (as defined below). If SPL is unwilling to
provide funding for such documented cost increases and the parties are unable to
resolve such funding matter to their mutual satisfaction within forty five (45)
days then the Screening Program shall not be extended for such extension year.
If in any quarterly funding period, actual expenditures by NeoGenesis with
respect to FTE's exceed the amount budgeted for the period, the overrun will be
carried forward for the next period and paid for from the next payment(s);
PROVIDED, that SPL payment obligations for any year of the Screening Program
shall not exceed the budgeted amount for such year unless SPL has agreed to fund
additional FTE work beyond that budgeted for such year by means of a written
amendment to this Agreement approved in writing by the parties. For purposes of
this Section 4.1, "CPI" means the Consumer Price Index [*], as published by the
Bureau of Labor Statistics of the United States Department of Labor. In the
event that the Bureau of Labor Statistics ceases to publish the CPI or
substantially changes its content or format in a manner that

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       25
<Page>

precludes its further use hereunder, SPL and NeoGenesis shall substitute
therefor another comparable measure published by an agreed-upon source.

     4.2  LICENSE FEES.

          (a)  In partial consideration for the licenses and other rights
granted to SPL hereunder, SPL shall pay to NeoGenesis a license fee of [*] with
respect to each Target for which one or more Selected Compounds are designated
pursuant to Section 2.7. Each such license fee shall be payable within [*] after
the effective date of the licenses to such Selected Compounds, as provided under
Section 2.7(b). The license fee shall be payable [*], irrespective of the number
of Selected Compounds, Designated Compounds or Licensed Products which may be
identified and/or developed with respect thereto. Payment of any license fees
under this Section 4.2(a) shall be made concurrently with payment of the
corresponding license fees under Section 4.2(a) of the US Agreement.

     4.3  MILESTONES. In partial consideration for the licenses and other rights
granted to SPL hereunder, SPL shall pay to NeoGenesis the following payments
upon the occurrence of the indicated milestone event.

          (a)  with respect to any Designated Compound (and any Licensed
Products based upon such Designated Compound) which is being developed based
upon activity with respect to a specific Target, and was discovered as a result
of optimization of one or more Lead Compounds by NeoGenesis pursuant to Section
2.2(b):

               (i)  [*] upon designation of such Designated Compound pursuant to
                    Section 2.8;

               (ii) [*] upon initiating treatment of the first patient in a
                    Phase I clinical trial for the applicable Licensed Product
                    under an approved IND (or its equivalent);

               (iii) [*] upon initiating treatment of the first patient in a
                    Phase III clinical trial for the applicable Licensed
                    Product;

               (iv) [*] upon filing and acceptance of the first NDA (or its
                    European or Japanese equivalent) for the applicable Licensed
                    Product; and

               (v)  [*] upon receipt of the first Regulatory Approval for the
                    applicable Licensed Product in a Major Market Country.

          (b)  with respect to any Designated Compound (and any Licensed
Products based upon such Designated Compound) which is being developed based
upon activity with respect to a specific Target, but was not discovered as a
result of optimization of one or more Lead Compounds by NeoGenesis pursuant to
Section 2.2(b):

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       26
<Page>

               (i)  [*] upon designation of such Designated Compound pursuant to
                    Section 2.8;

               (ii) [*] upon initiating treatment of the first patient in a
                    Phase I clinical trial for the applicable Licensed Product
                    under an approved IND (or its equivalent);

               (iii) [*] upon initiating treatment of the first patient in a
                    Phase III clinical trial for the applicable Licensed
                    Product;

               (iv) [*] upon filing and acceptance of the first NDA (or its
                    European or Japanese equivalent) for the applicable Licensed
                    Product; and

               (v)  [*] upon receipt of the first Regulatory Approval for the
                    applicable Licensed Product in a Major Market Country.

          (c)  All payments made to NeoGenesis by SPL pursuant to Section 4.3(a)
or (b) shall be due within thirty (30) days after the achievement of the
corresponding milestone and shall be nonrefundable and not creditable against
other amounts due to NeoGenesis. The payments provided for under this Section
4.3 shall only be payable once upon the first achievement of the indicated
milestone with respect to Designated Compound and/or Licensed Product developed
against a particular Target and no additional payments shall be due on
subsequent or repeated achievement of the same milestone for another Designated
Compound and/or Licensed Product developed against the same Target. No
milestones shall be payable under this Section 4.3 with respect to (i) any
compounds or products other than Designated Compounds and Licensed Products, or
(ii) any Designated Compounds or Licensed Products being developed based upon
[*].

          (d)  In the event that SPL ceases all clinical development for a
Designated Compound/Licensed Product (a "Discontinued Product") for which one or
more milestones have been paid pursuant to this Section 4.3, no payment shall be
due under this Section 4.3 with respect to the achievement of the same
milestone(s) with respect to the another Designated Compound or Licensed Product
discovered or developed against the same Target as the Discontinued Product (a
"Back-up Product"). In the event that the Back-up Product achieves milestones
which were not previously achieved by the relevant Discontinued Product, such
milestone payments will be paid in accordance with this Section 4.3.

     4.4  ROYALTIES. In partial consideration for the licenses and other rights
granted to SPL hereunder, SPL shall pay royalties to NeoGenesis based upon Net
Sales of Licensed Products in the Territory.

          (a)  The royalties payable to NeoGenesis on Net Sales of Licensed
Products in the Territory by SPL, its Affiliates and sublicensees, shall be
determined as follows:

               (i)  [*] of Net Sales of Licensed Products in the Territory where
                    the Designated Compound in such Licensed Product was
                    discovered as a

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       27
<Page>

                    result of optimization of one or more Lead Compounds by
                    NeoGenesis pursuant to Section 2.2(b); or

               (ii) [*] of Net Sales of Licensed Products in the Territory where
                    the Designated Compound in such Licensed Product was not
                    discovered as a result of optimization of one or more Lead
                    Compounds by NeoGenesis pursuant to Section 2.2(b); or

               (iii) [*] of Net Sales of Licensed Products in the Territory
                    where the Designated Compound in such Licensed Product is a
                    Derivative Compound derived from an Selected Compound
                    identified through SPL's screening of a Selected Compound
                    against a target other than the specific Target(s) for which
                    the Selected Compound was screened by NeoGenesis.

          (b)  Starting with the First Commercial Sale of each Licensed Product
in the Territory, SPL shall provide NeoGenesis with quarterly reports of Net
Sales by country of each Licensed Product in the Territory. Each such quarterly
report shall be provided to NeoGenesis not later than sixty (60) days following
the close of the relevant calendar quarter, (i.e., following each March 31, June
30, September 30 and December 31). Concurrently with the making of such reports,
SPL shall pay to NeoGenesis royalties due for such period at the rates specified
in Section 4.4(a). The report due for the quarter ending December 31 of each
year shall also include the aggregate royalties due NeoGenesis for the entire
year.

          (c)  SPL's obligation to pay royalties with respect to each Licensed
Product shall expire on a country-by-country basis upon the later of (i) the
expiration (or revocation or complete rejection) of the last to expire (or to be
revoked or to be completely rejected) of any NeoGenesis Patent Right and/or
Compound Patent Right having a Valid Claim covering such Licensed Product in the
country, or (ii) ten (10) years from the First Commercial Sale of the Licensed
Product in such country. No royalties shall accrue on the disposition of any
Licensed Product in reasonable quantities by SPL, its Affiliates or its
sublicenses at no charge as samples (promotional or otherwise) or as donations
(for example, to non-profit institutions or government agencies for a
non-commercial purpose) or for clinical studies.

     4.5  REMITTANCE.

          (a)  All royalties, milestone and other payments required under this
Article 4 shall be made by bank wire transfer in United States dollars in
immediately available funds to an account designated by NeoGenesis. Royalties
shall be deemed payable by the entity making the Net Sales from the country in
which earned in local currency and subject to foreign exchange regulations then
prevailing. Royalty payments shall be made in United States dollars to the
extent that free conversion to United States dollars is permitted. The rate of
exchange to be used in any such conversion from the currency in the country
where such Net Sales occurs shall be in accordance with the policy set forth in
ATTACHMENT D attached hereto.

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       28
<Page>

          (b)  In the event that any payment due NeoGenesis under this Agreement
is not made when due, the amount due shall accrue interest beginning on the
fifth day following the final date on which such payment was due, calculated at
the annual rate equal to two percent (2%) above the prime interest rate reported
in the WALL STREET JOURNAL for the due date, calculated from the due date until
paid in full. Such payment when made shall be accompanied by all interest so
accrued.

          (c)  If at any time legal restrictions or prohibitions imposed by
national or international authority prevent the conversion of the local currency
and such currency cannot be removed from such country such that prompt
remittance by SPL of any royalties owed by SPL to NeoGenesis in respect of sales
in such country is prevented, the parties shall consult with a view to finding a
prompt and acceptable solution, and SPL or its designated Affiliates will make
payment through any means as NeoGenesis may lawfully direct at no additional
out-of-pocket expense to SPL.. Notwithstanding the foregoing, if royalties in
any country cannot be remitted to NeoGenesis for any reason within three (3)
months after the end of the calendar quarter during which they are earned, then
SPL shall be obligated to pay NeoGenesis in the local currency of such country
and shall deposit the relevant royalties in a bank account in such country
designated by NeoGenesis and in the name of NeoGenesis.

     4.6  RECORDS. SPL, its Affiliates and sublicensees shall keep and maintain
complete, true and accurate books of account and records (prepared in accordance
with United States Generally Accepted Accounting Principles, consistently
applied) sufficient to determine the amounts of Net Sales and any royalty
payments due with respect thereto. All such books and records shall be
maintained in accordance with SPL's records retention policies consistently
applied but for a period of at least thirty six (36) months from the date of
each payment of royalties.

     4.7  INSPECTION. Upon prior written notice SPL and its Affiliates shall,
within a period not to exceed forty-five (45) days, permit an independent
certified public accounting firm of nationally recognized standing selected by
NeoGenesis and reasonably acceptable to SPL, at NeoGenesis' expense, to have
access during regular business hours to examine pertinent books and records of
SPL and its Affiliates necessary to verify the accuracy of the royalty reports
and payments by SPL hereunder. The examination shall be limited to pertinent
books and records for any calendar year ending not more than twenty-four (24)
months prior to the date of such request. Such inspection right shall not be
exercised more than once in any calendar year. The accounting firm employees
shall sign confidentiality agreements reasonably acceptable to SPL as a
condition precedent to their inspection. SPL may designate competitively
sensitive information which such auditor may not disclose to NeoGenesis;
PROVIDED, HOWEVER, that such designation shall not encompass the auditor's
conclusions. The accounting firm shall disclose to NeoGenesis only whether the
royalty reports are correct or incorrect and the specific details concerning any
discrepancies. No other information shall be provided to NeoGenesis. In the
event that the accounting firm correctly concludes that a variation or error has
occurred resulting in an underpayment of royalties by SPL of five percent (5%)
or more of the amount actually due for the period covered by the inspection, SPL
shall pay to NeoGenesis in addition to such underpayment, the costs relating to
the inspection, within thirty (30) days of receipt of an invoice

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       29
<Page>

for such amounts. Any overpayment of royalties by SPL discovered through such
audit shall be fully creditable against royalties subsequently due hereunder.
SPL shall include in each sublicense granted by it pursuant to this Agreement a
provision requiring the sublicensee to make reports to SPL, to keep and maintain
records of sales made pursuant to such sublicense and to grant access to such
records by NeoGenesis' independent accountant to the same extent required of SPL
under this Agreement. Upon expiration of the twenty-four (24) month period
immediately following the receipt by NeoGenesis of SPL's fourth quarter royalty
report for a given calendar year, the calculation of royalties payable with
respect to such year shall be binding and conclusive upon NeoGenesis, and SPL,
its Affiliates and its sublicensees shall be released from any liability or
accountability with respect to royalties for such year, except for instances of
fraud or other intentional misconduct.

     4.8  TAXES. If at any time, any jurisdiction within the Territory requires
the withholding of income taxes or other taxes imposed upon payments set forth
in this Article 4, SPL shall make such withholding payments as required and
subtract such withholding payments from the payments to be made to NeoGenesis as
set forth in this Article 4, or if applicable, NeoGenesis will promptly
reimburse SPL or its designee(s) of the amount of such withholding payments that
are not subtracted from the payments made to NeoGenesis as set forth in this
Article 4. SPL shall provide NeoGenesis with documentation of such withholding
and payment in a manner that is satisfactory for purposes of reporting to the
U.S. Internal Revenue Service. Any withholdings paid when due hereunder shall be
for the account of NeoGenesis. Withholding payments made by SPL pursuant to this
Section 4.8 shall be made based upon financial information provided to SPL by
NeoGenesis, and to the extent that such information is incorrect, NeoGenesis
shall be liable for any deficiency, and any fine, assessment or penalty imposed
by any taxing authority in the Territory for any deficiency in the amount of any
such withholding or the failure to make such withholding payment. If SPL is
required to pay any such deficiency, or any fine, assessment or penalty for any
such deficiency, NeoGenesis shall promptly reimburse SPL for such payments.

5.   CONFIDENTIALITY

     5.1  PUBLICITY. Each of the parties hereto agrees not to disclose to any
third party the existence or the terms of this Agreement without the prior
written consent of the other party hereto. Notwithstanding the foregoing, the
parties may agree upon an initial press release to announce the execution of
this Agreement, together with a corresponding Q&A outline for use in responding
to inquiries about the Agreement. In the event of such agreed upon press
release, each party may thereafter disclose to third parties the specific
information contained in such press release and Q&A without the need for further
approval by the other party. Nothing in this Section 5.1 shall prohibit a party
from making such disclosures to the extent required under applicable federal or
state securities laws or any rule or regulation of any nationally recognized
securities exchange. In such event, however, the disclosing party shall use good
faith efforts to notify and consult with the other party prior to such
disclosure and, where applicable, shall diligently seek confidential treatment
to the extent such treatment is available under applicable securities laws.

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       30
<Page>

     5.2  CONFIDENTIALITY.

          (a)  Confidential Information received by one party (the "RECEIVING
PARTY") from the other party (the "DISCLOSING PARTY") in connection with this
Agreement will be used by the Receiving Party solely for the performance of the
Screening Program or as otherwise expressly permitted by this Agreement. All
Confidential Information will be received and held in confidence by the
Receiving Party, and shall not be disclosed to any third party without the prior
written consent of the Disclosing Party. Each party acknowledges that, except as
expressly set forth herein, it will not obtain any rights of any sort in or to
the Confidential Information of the Disclosing Party as a result of such
disclosure.

          (b)  The Receiving Party will restrict disclosure of the Disclosing
Party's Confidential Information to those of the Receiving Party's and its
Affiliates' employees, officers, directors, consultants and agents to whom it is
necessary to disclose such Confidential Information in connection with the
performance of its obligations under this Agreement. The Receiving Party shall
use all reasonable efforts, which shall be at least fully commensurate with
those employed by the Receiving Party for the protection of its own Confidential
Information, to protect the Confidential Information of the Disclosing Party.

          (c)  The confidentiality and use restrictions set forth in this
Article 5 shall not apply to Confidential Information to the extent such
information:

               (i)  was already known to the Receiving Party, other than under
                    an obligation of confidentiality, at the time of disclosure;

               (ii) was generally available to the public or otherwise part of
                    the public domain at the time of its disclosure to the
                    Receiving Party;

               (iii) became generally available to the public or otherwise part
                    of the public domain after its disclosure and other than
                    through any act or omission of the Receiving Party in breach
                    of this Agreement;

               (iv) was independently developed by the Receiving Party without
                    the aid, application or use of the Disclosing Party's
                    Confidential Information, as demonstrated by documented
                    evidence prepared contemporaneously with such independent
                    development; or

               (v)  was subsequently lawfully disclosed to the Receiving Party,
                    other than under a duty of confidentiality, by a third party
                    that had the right to make such disclosure.

          (d)  Each party hereto may use or disclose Confidential Information
disclosed to it by the other party to the extent (i) such use or disclosure is
reasonably necessary and

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       31
<Page>

permitted in the exercise of the rights granted hereunder in filing or
prosecuting patent applications and prosecuting or defending litigation, (ii)
such disclosure is reasonably required to be made to any institutional review
board of any entity conducting clinical trials with Designated Compound(s)
and/or Licensed Product(s), or to any governmental or other regulatory agency,
in order to gain approval to conduct clinical trials or to market Designated
Compound(s) and/or Licensed Products, (iii) such disclosure is required by law,
regulation, rule, act or order of any governmental authority, court, or agency,
or is made in connection with submitting required information to tax or other
governmental authorities, or (iv) such disclosure or use is reasonably required
in conducting clinical trials, or making a permitted sublicense or otherwise
exercising license rights expressly granted to it by the other party pursuant to
the terms of this Agreement; in each case, provided that if the Receiving Party
is required to make any such disclosure of the Disclosing Party's Confidential
Information, other than pursuant to a confidentiality agreement, it will give
reasonable advance notice to the Disclosing Party of such disclosure and, except
to the extent inappropriate in the case of patent applications, will use its
reasonable diligent efforts to secure confidential treatment of such
Confidential Information in consultation with the Disclosing Party prior to its
disclosure (whether through protective orders or otherwise) and disclose only
the minimum necessary to comply with such requirements.

          (e)  Following the termination of this Agreement, or at any time upon
written request by the Disclosing Party, the Receiving Party shall promptly
return to the Disclosing Party all of the Disclosing Party's Confidential
Information, including all copies thereof, in its possession; provided that the
Receiving Party's legal counsel may retain one (1) copy of the Disclosing
Party's Confidential Information in a secure location solely for the purpose of
determining its obligations under this Agreement.

     5.3  PUBLICATION. Each of SPL and NeoGenesis acknowledges the other party's
interest in publishing its results to obtain recognition within the scientific
community and to advance the state of scientific knowledge. Each party also
recognizes the mutual interest in obtaining valid patent protection and in
protecting business interests and trade secret information. Consequently, either
party, its Affiliates, employees or consultants wishing to make a publication
relating to the results of the Screening Program shall deliver to the other
party a copy of the proposed written publication or an outline of an oral
disclosure at least sixty (60) days prior to submission for publication or
presentation. For purposes of this Agreement, the term "publication" shall
include, without limitation, abstracts and manuscripts for publication, slides
and texts of oral or other public presentations, and texts of any transmission
through any electronic media, any computer access system such as the internet,
world wide web, or similar medium. The reviewing party shall have the right to
(i) propose modifications to the publication for patent reasons, trade secret
reasons or business reasons or (ii) delay the publication or presentation in
order to protect patentable information. If the reviewing party requests a
delay, the publishing party shall delay submission or presentation for a period
not to exceed eighteen (18) months from the filing date of the first patent
application covering the information contained in the proposed publication, or
shall modify such Publication to eliminate such patentable information. If the
reviewing party requests modifications to the publication, the publishing party
shall edit such publication to prevent disclosure or trade secret or proprietary
business information prior to submission of the publication or presentation.

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       32
<Page>

6.   REPRESENTATIONS AND WARRANTIES.

     6.1  REPRESENTATIONS AND WARRANTIES OF EACH PARTY. Each of NeoGenesis and
SPL hereby represents, warrants and covenants to the other party hereto as
follows:

          (a)  it is a corporation or entity duly organized and validly existing
under the laws of the state or other jurisdiction of its incorporation or
formation;

          (b)  the execution, delivery and performance of this Agreement by such
party has been duly authorized by all requisite corporate action;

          (c)  it has the power and authority to execute and deliver this
Agreement and to perform its obligations hereunder;

          (d)  the execution, delivery and performance by such party of this
Agreement and its compliance with the terms and provisions hereof does not and
will not conflict with or result in a breach of any of the terms and provisions
of or constitute a default under (i) a loan agreement, guaranty, financing
agreement, agreement affecting a product or other agreement or instrument
binding or affecting it or its property; (ii) the provisions of its charter or
operative documents or bylaws; or (iii) any order, writ, injunction or decree of
any court or governmental authority entered against it or by which any of its
property is bound;

          (e)  except for the governmental and regulatory approvals required to
market the Licensed Product(s), the execution, delivery and performance of this
Agreement by such party does not require the consent, approval or authorization
of, or notice, declaration, filing or registration with, any governmental or
regulatory authority and the execution, delivery or performance of this
Agreement will not violate any law, rule or regulation applicable to such party;

          (f)  this Agreement has been duly authorized, executed and delivered
and constitutes such party's legal, valid and binding obligation enforceable
against it in accordance with its terms subject, as to enforcement, to
bankruptcy, insolvency, reorganization and other laws of general applicability
relating to or affecting creditors' rights and to the availability of particular
remedies under general equity principles; and

          (g)  it shall comply with all applicable material laws and regulations
relating to its activities under this Agreement.

     6.2  NEOGENESIS' REPRESENTATIONS. NeoGenesis hereby represents, warrants
and covenants to SPL as follows:

          (a)  to the best of NeoGenesis' knowledge, as of the Effective Date,
NeoGenesis is the sole and exclusive owner of the NeoMorph Screening Library,
the NeoGenesis

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       33
<Page>

Patent Rights and the NeoGenesis Know-How free and clear of all liens, charges
and encumbrances and no other person, corporate or other private entity, or
governmental entity or subdivision thereof, has or shall have any claim of
ownership with respect thereto;

          (b)  as of the Effective Date it has the full right, power and
authority to grant all of the right, title and interest in the licenses and
other rights granted to SPL under this Agreement;

          (c)  to the best of NeoGenesis' knowledge, as of the Effective Date
the NeoMorph Screening Library, NeoGenesis Patent Rights and NeoGenesis
Know-How, and the use thereof in performance of the Screening Program as
contemplated hereunder, do not infringe on any intellectual property rights
owned or possessed by any third party;

          (d)  during the term of this Agreement, NeoGenesis shall not grant or
attempt to grant any licenses, options or other rights to any third party that
are contrary to or otherwise inconsistent with the licenses and other rights
granted to SPL hereunder;

          (e)  as of the Effective Date there are no claims, judgments or
settlements against or owed by NeoGenesis or pending or, to the best of
NeoGenesis' knowledge, threatened claims or litigation against NeoGenesis
relating to the NeoMorph Screening Library, NeoGenesis Patent Rights and
NeoGenesis Know-How;

          (f)  as of the Effective Date, it is in compliance in all material
respects with any agreements with third parties, and during the term of this
Agreement (i) it will use diligent efforts not to diminish the rights under the
NeoGenesis Patent Rights and NeoGenesis Know-How granted to SPL hereunder,
including without limitation, by not committing or permitting any actions or
omissions which would cause the breach of any agreements between itself and
third parties which provide for intellectual property rights applicable to the
performance of the Screening Program, and (ii) it will provide SPL promptly with
notice of any such alleged breach; and

          (g)  during the term of this Agreement it will not use in any
capacity, in connection with any activities to be performed under this
Agreement, any individual who has been debarred pursuant to the United States
Food, Drug and Cosmetic Act.

     6.3  SPL'S REPRESENTATIONS. SPL hereby represents, warrants and covenants
to NeoGenesis as follows:

          (a)  during the term of this Agreement it will not use in any
capacity, in connection with any services to be performed under this Agreement,
any individual who has been debarred pursuant to the United States Food, Drug
and Cosmetic Act;

          (b)  to the best of SPL's knowledge, as of the Effective Date it is
the sole and exclusive owner or licensee of the Schering Patent Rights and the
Schering Know-How, all of which is free and clear of any liens, charges and
encumbrances, and no other person, corporate or

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       34
<Page>

other private entity, or governmental entity or subdivision thereof, has or
shall have any claim of ownership with respect thereto;

          (c)  to the best of SPL's knowledge, as of the Effective Date it is
the owner of the Targets and any other tangible materials to be provided to
NeoGenesis hereunder for use in the Screening Program;

          (d)  to the best of SPL's knowledge, as of the Effective Date, the use
of the Targets in performance of the Screening Program as contemplated
hereunder, does not infringe a valid and enforceable claim of any issued U.S.
patent owned or possessed by any third party; and

          (e)  as of the Effective Date, there are no claims, judgments or
settlements against or owed by SPL or pending or, to the best of SPL's
knowledge, threatened claims or litigation against SPL relating to the Schering
Patent Rights and Schering Know-How.

     6.4  DISCLAIMER.

          (a)  EXCEPT FOR THE WARRANTIES EXPRESSLY MADE IN SECTIONS 6.1-6.3,
NEITHER PARTY MAKES ANY OTHER REPRESENTATION OR WARRANTY, EITHER EXPRESS OR
IMPLIED (WHETHER WRITTEN OR ORAL), INCLUDING, WITHOUT LIMITATION ANY WARRANTY
AGAINST INFRINGEMENT OF ANY THIRD PARTY PATENT OR OTHER INTELLECTUAL PROPERTY
RIGHTS, ANY WARRANTY OF MERCHANTABILITY OR ANY WARRANTY OF FITNESS FOR A
PARTICULAR PURPOSE WITH RESPECT TO THE NEOMORPH SCREENING LIBRARY, THE NEOMORPH
FOCUSED LIBRARIES, QSCD, THE COMPOUNDS, THE ACTIVE COMPOUNDS, THE IMPROVED
ACTIVE COMPOUNDS, THE SELECTED COMPOUNDS, THE DESIGNATED COMPOUNDS, THE TARGETS,
THE LICENSED PRODUCTS, THE NEOGENESIS KNOW-HOW, THE SCHERING KNOW-HOW, THE
SCOPE, VALIDITY OR ENFORCEABILITY OF THE NEOGENESIS PATENT RIGHTS OR THE
SCHERING PATENT RIGHTS, OR SUCH PARTY'S OBLIGATIONS UNDER THIS AGREEMENT.

          (b)  THE REPRESENTATIONS AND WARRANTIES OF EACH OF NEOGENESIS AND SPL
EXTEND ONLY TO THE OTHER PARTY. NEITHER PARTY WILL BE LIABLE FOR ANY CLAIM OR
DEMAND AGAINST SUCH OTHER PARTY BY A THIRD PARTY, EXCEPT TO THE EXTENT PROVIDED
IN SECTIONS 7.2-7.3.

7.   INDEMNIFICATION.

     7.1  INDEMNIFICATION BY SPL. SPL shall indemnify, defend and hold harmless
NeoGenesis and its Affiliates, and each of its and their respective employees,
officers, directors and agents from and against any and all liability, loss,
claims, damage, cost, and expense (including reasonable attorneys' fees) arising
out of or in connection with third party claims relating to (i) the discovery,
development, manufacture, use, testing, marketing, sale or other

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       35
<Page>

disposition of Designated Compounds and/or Licensed Products by or on behalf of
SPL or its Affiliates or sublicensees, (ii) performance of the Screening Program
by SPL, (iii) the use of any and all Targets with respect to which screening or
other research activities are conducted in the Screening Program, or (iv) any
breach by SPL of its representations and warranties under this Agreement,
except, in each case, to the extent such liability, loss, claims, damage, cost
or expense is caused by the negligence or willful misconduct of NeoGenesis, its
Affiliates, or any of their respective employees, officers, directors or agents.

     7.2  INDEMNIFICATION BY NEOGENESIS. NeoGenesis shall indemnify, defend and
hold harmless SPL and its Affiliates, and each of its and their respective
employees, officers, directors and agents from and against any and all
liability, loss, claims, damage, cost, and expense (including reasonable
attorneys' fees) arising out of or in connection with third party claims
relating to (i) the performance of the Screening Program by NeoGenesis, except
to the extent directly related to the use of Targets provided by SPL, (ii) any
breach of NeoGenesis' contractual obligations to third parties, or (iii) any
breach by NeoGenesis of its representations and warranties made under this
Agreement, except, in each case, to the extent such liability, loss, claims,
damage, cost, and expense is caused by the negligence or willful misconduct of
SPL, its Affiliates, or any of their respective employees, officers, directors
or agents.

     7.3  PROCEDURE. As a condition to the indemnification provided for under
Sections 7.1 and 7.2, the indemnified party shall promptly notify the party from
whom indemnification is sought (the "INDEMNIFYING PARTY") in writing of any
claim or suit; PROVIDED, that failure to give such notice shall not relieve
Indemnifying Party of its indemnification obligations under this Article 7,
except to the extent such failure actually and materially prejudices the rights
of Indemnifying Party to defend against such claim or suit. The Indemnifying
Party shall have the right to assume the defense of any suit or claim related to
the liability if it has assumed responsibility for the suit or claim in writing;
however, if in the reasonable judgment of the indemnified party, such suit or
claim involves an issue or matter which could have a materially adverse effect
on the business operations or assets of the indemnified party, the indemnified
party may retain control of the defense or settlement thereof by providing
written notice of such effect to the Indemnifying Party, but in no event shall
such action or notice be construed as a waiver of any indemnification rights
that the indemnified party may have at law or in equity. If the Indemnifying
Party defends the suit or claim, the indemnified party may participate in (but
not control) the defense thereof at its sole cost and expense. If Indemnifying
Party elects to compromise or defend a claim that is the subject of this Article
7, it shall notify the indemnified party of its decision within thirty (30) days
after delivery of the notice described above (or sooner if the nature of the
third party claim requires). If Indemnifying Party elects not to defend the
indemnified party or fails to notify the indemnified party of its election as
provided in this Section 7.3, the indemnified party may pay, compromise or
settle such claim (subject to the provisions of Section 7.5) and the indemnified
party shall be free to pursue such remedies as may be available under applicable
law to recover from Indemnifying Party.

     7.4  LIMITATIONS ON LIABILITY. With respect to any claim by one party
against the other arising out of the performance or failure of performance of
the other party under this Agreement, the parties expressly agree that the
liability of such party to the other party for such

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       36
<Page>

breach shall be limited under this Agreement or otherwise at law or equity to
direct damages only and in no event shall a party be liable for punitive,
exemplary or consequential damages; PROVIDED that this limitation shall not
apply to the extent arising under third party claims which are subject to
indemnification under Section 7.1 or Section 7.2.

     7.5  SETTLEMENTS. Neither party may settle a claim or action related to a
liability, loss, claims, damage, cost or expense arising in connection with this
Agreement without the consent of the other party, which consent shall not be
unreasonably withheld, if such settlement would impose any monetary obligation
on the other party or require the other party to submit to an injunction or
otherwise limit the other party's rights under this Agreement. Any payment made
by a party to settle any such claim or action shall be at its own cost and
expense; PROVIDED, that in the event and to the extent that an indemnified party
enters into a settlement of a matter with respect to which it believes it is
entitled to indemnification under this Article 7 after the other party has
refused to assume the defense of such matter, the provisions of this Section 7.5
shall not constitute a waiver of such party's right to seek remedies from the
other party concerning such matter.

     7.6  INSURANCE. Each party acknowledges and agrees that during the term of
this Agreement it shall maintain adequate insurance and/or a self-insurance
program for liability insurance, including products liability and contractual
liability insurance, to cover such party's obligations under this Agreement.
Each party shall provide the other party with evidence of such insurance and/or
self-insurance program, upon request.

8.   TERM AND TERMINATION

     8.1  TERM. This Agreement shall take effect as the Effective Date and
shall, unless sooner terminated in accordance with Section 8.2 or Section
9.5(a), expire on a Licensed Product-by -Licensed Product and country-by-country
basis upon the later of: (i) the expiration of the last-to-expire of the
NeoGenesis Patent Rights having a Valid Claim covering the Licensed Product in
such country, or (ii) ten (10) years following the First Commercial Sale of the
Licensed Product in such country. Upon expiration of this Agreement with respect
to a Licensed Product in a given country, the licenses granted to SPL hereunder
with respect to such Licensed Product in such country shall become fully paid,
royalty-free, irrevocable licenses.

     8.2  TERMINATION.

          (a)  SPL shall have the right to terminate this Agreement, with or
without cause at any time following the first anniversary of the Effective Date
upon one hundred and eighty (180) days written notice.

          (b)  During the term of the Screening Program, either party may
terminate the Screening Program and this Agreement (i) upon thirty (30) days
written notice to the other party if the other party fails to pay any amounts
properly due and owing under this Agreement, unless such amount is paid prior to
the expiration of such thirty (30) day period, or (ii) upon ninety (90)

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       37
<Page>

days written notice to the other party if the other party commits a material
breach of this Agreement (other than non-payment), unless such breach is cured
within the ninety (90) day notice period, or if such breach is not capable of
being cured within ninety (90) days unless such party during such ninety (90)
day period initiates actions reasonably expected to cure the breach and
thereafter diligently proceeds to cure the breach.

          (c)  Following completion of the Screening Program, either party may
terminate this Agreement (i) upon thirty (30) days written notice to the other
party if the other party fails to pay any amounts properly due and owing under
this Agreement, unless such amount is paid prior to the expiration of such
thirty (30) day period, or (ii) upon ninety (90) days written notice to the
other party if the other party commits a material breach of this Agreement
(other than non-payment), unless such breach is cured within the ninety (90) day
notice period, or if such breach is not capable of being cured within ninety
(90) days unless such party during such ninety (90) day period initiates actions
reasonably expected to cure the breach and thereafter diligently proceeds to
cure the breach. Notwithstanding the foregoing, in the event that the
non-payment or breach is related to a Licensed Product, any such termination
shall be effective only with respect to such Licensed Product and this Agreement
shall remain in full force and effect with respect to any other Licensed
Products being developed and commercialized by SPL under this Agreement.

          (d)  This Agreement may be terminated by either party upon the filing
or institution of bankruptcy, reorganization, liquidation or receivership
proceedings, or upon an assignment of a substantial portion of the assets for
the benefit of creditors by the other party, or in the event a receiver or
custodian is appointed for such party's business, or if a substantial portion of
such party's business is subject to attachment or similar process; provided,
however, that in the case of any involuntary bankruptcy proceeding such right to
terminate shall only become effective if the proceeding is not dismissed within
sixty (60) days after the filing thereof.

     8.3  EFFECT OF TERMINATION.

          (a)  Upon termination of this Agreement pursuant to Section 8.2: (i)
NeoGenesis will terminate all tasks then in process in an orderly manner, as
soon as practical and in accordance with a schedule agreed to by SPL and
NeoGenesis; (ii) NeoGenesis shall deliver to SPL all materials developed through
the termination of this Agreement; (iii) SPL shall pay NeoGenesis any monies due
and owing NeoGenesis up to the time of termination for services actually
performed (including all work-in process), and (iv) within thirty (30) days
following termination (including expiration) of this Agreement, NeoGenesis shall
deliver to SPL a reasonably-detailed written report describing the results of
the research performed up to the date of such termination. In addition, upon
termination (including expiration) of this Agreement each party shall return to
the other party or certify in writing to the other party that it has destroyed
all Confidential Information of the other party in its possession.

          (b)  The licenses granted by NeoGenesis under Article 3 shall survive
any expiration or termination of the Screening Program or the termination of
this Agreement with respect to any Designated Compound or Licensed Product for
which the applicable service fees

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       38
<Page>

and milestone fees and royalties have been paid (when due in accordance with the
terms of this Agreement) and SPL shall continue to have the right to develop,
have developed, make, have made, use, distribute, offer for sale, import, export
and sell Licensed Products relating to such Designated Compounds; PROVIDED that
SPL continues to pay NeoGenesis milestone fees and royalties as required by
Sections 4.3 and 4.4 and complies with Sections 4.5-4.8. In the event the
licenses granted to SPL under Article 3 terminates for any reason, each of SPL's
sublicensees at such time shall continue to have the rights and license set
forth in their sublicense agreements, PROVIDED such sublicensee agrees in
writing that NeoGenesis is entitled to enforce all relevant provisions directly
against such sublicensee.

          (c)  Nothing herein shall be construed to release either party of any
obligation which matured prior to the effective date of any termination. SPL's
liability for any charges, payments or expenses due to NeoGenesis that accrued
prior to the termination date shall not be extinguished by termination, and such
amounts (if not otherwise due on an earlier date) shall be immediately due and
payable on the termination date.

          (d)  Termination of this Agreement by either party pursuant to Section
8.2 or 9.5(a) hereof shall constitute termination of the U.S. Agreement under
the corresponding provisions thereof.

     8.4  SURVIVAL. Articles 1, 5, 6, 7 and 9 and Sections 2.2(b), 2.2(c),
2.2(g), 2.5, 3.4, 3.5, 3.6, 3.7, 4.6, 4.7, 4.8 and 8.3(a-c), and the second and
third sentences of Section 2.1(c), shall survive any termination or expiration
of this Agreement.

9.   GENERAL PROVISIONS.

     9.1  DISPUTE RESOLUTION. Any controversy or dispute that arises under or
relates to this Agreement (with the exception to disputes relating to the
performance of the Screening Program which are governed by the terms of Section
2.6(d)) shall be referred to the Oversight Committee (as defined in Section
2.6(d)) for resolution. If the Oversight Committee is unable to resolve the
dispute within thirty (30) days, the dispute shall be resolved by binding
arbitration pursuant to the provisions of Schedule 9.1 (attached hereto).
Nothing herein shall prevent the parties from settling any dispute by mutual
agreement at any time.

     9.2  GOVERNING LAW. This Agreement shall be governed and construed in
accordance with the laws of the State of New York without regard for any
conflict of laws rule or provision thereof that would result in the application
of the substantive laws of any other jurisdiction. Notwithstanding the
foregoing, the parties (and the arbitrators) shall use United States (Federal)
patent and copyright laws for purposes of governing and construing Sections 3.5,
3.6 or 3.7 of this Agreement. The United Nations Convention on Contracts for the
International Sale of Goods shall not apply to the transactions contemplated by
this Agreement.

     9.3  AMENDMENT AND WAIVER. This Agreement may only be modified or amended
by a written instrument signed by authorized representatives of each party. No
provision of or right

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       39
<Page>

under this Agreement shall be deemed to have been waived by any act or
acquiescence on the part of either party, its agents or employees, but only by
an instrument in writing signed by an authorized officer of each party. No
waiver by either party of any breach of this Agreement by the other party shall
be effective as to any other breach, whether of the same or any other term or
condition and whether occurring before or after the date of such waiver.

     9.4  INDEPENDENT CONTRACTORS. Each party represents that it is acting on
its own behalf as an independent contractor and is not acting as an agent for or
on behalf of any third party. This Agreement and the relations hereby
established by and between SPL and NeoGenesis do not constitute a partnership,
joint venture, franchise, agency or contract of employment. Neither party is
granted, and neither party shall exercise, the right or authority to assume or
create any obligation or responsibility on behalf of or in the name of the other
party or its Affiliates. NeoGenesis shall be solely responsible for compensating
all its personnel and for payment of all related FICA, workers' compensation,
unemployment and withholding taxes.

     9.5  ASSIGNMENT. (a) This Agreement, and any of a party's rights and
obligations under this Agreement, may not be assigned, delegated, sold,
transferred, sublicensed (except as otherwise provided herein) or otherwise
disposed of, by operation of law or otherwise, to any third party without the
prior written consent of the other party; PROVIDED, that either party may assign
this Agreement to an Affiliate or in connection with the transfer or sale of all
or substantially all of its assets related to the division or the subject
business, or in the event of its merger or consolidation or change in control or
similar transaction PROVIDED, FURTHER, that in each instance the assignee
expressly assumes all obligations imposed on the assigning party by this
Agreement in writing. This Agreement shall be binding upon, and inure to the
benefit of, each party, its Affiliates, and its permitted successors and
assigns. Each party shall be responsible for the compliance by its Affiliates
with the terms and conditions of this Agreement.

          (b)  In the event that any (i) third party or "group" (within the
meaning of Section 13(d) or 14(d) of the Exchange Act of 1934, as amended) other
than the current officers and directors of NeoGenesis or SPL, as the case may
be, has acquired, directly or indirectly, the beneficial ownership, by way of
merger, consolidation or otherwise of 50% of the voting power of NeoGenesis or
SPL, as the case may be, on a fully-diluted basis or (ii) the sale, lease or
transfer of all or substantially all of the assets of NeoGenesis or SPL to any
third party or group not controlled directly or indirectly by such party (each,
a "CHANGE IN CONTROL") during the term of the Screening Program causes either
party's rights and obligations hereunder to pass to any third party, the other
party shall have the right to terminate the Screening Program and this Agreement
upon written notice within thirty (30) days of receipt of actual knowledge of
such Change of Control, without providing the party that is the subject of such
Change in Control any opportunity to cure. Thereafter, such party shall also
have the right to terminate this Agreement if the assignee of the party that is
the subject of such Change in Control does not provide the writing required
under Section 9.5(a). In addition, if the beneficial ownership (in the manner
described in Section 9.5(b)(i)-(ii)) of more than fifty percent (50%) of the
voting or income interest in NeoGenesis or SPL, as applicable, on a fully
diluted basis, is acquired by a third party or group that is reasonably regarded
as a competitor of the other party, such determination being made with reference
to the products and services that such third party then markets or for which

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       40
<Page>

it has made regulatory submissions with the FDA or an equivalent Regulatory
Authority in another Major Country or for which it has publicly announced its
intention to do either of the foregoing, the other party shall have the right,
but not the obligation, to terminate the Screening Program with six (6) months
notice to the party being acquired.

     9.6  NOTICES. Any notice required or permitted to be given or sent under
this Agreement shall be hand delivered or sent by express delivery service or
certified or registered mail, postage prepaid, or by facsimile transmission
(with written confirmation copy by registered first-class mail) to the parties
at the addresses and facsimile numbers indicated below.

     If to NeoGenesis, to:

                         NeoGenesis Drug Discovery, Inc.
                         840 Memorial Drive
                         Cambridge, Massachusetts 02139
                         Attention: Satish Jindal, President and CSO
                         Fax: (617) 868-1515

     If to SPL, to:

                         Schering-Plough Ltd.
                         Toepferstrasse 5
                         CH 6004 Lucerne
                         Switzerland
                         Attention: President
                         Facsimile No.: (011) (41) (41) 418 16 32

     with copies to:

                         Schering Corporation
                         2000 Galloping Hill Road
                         Kenilworth, New Jersey 07033
                         Attention: Vice President, Business Development
                         Facsimile No.: (908) 298-7366

     and

                         Schering Corporation
                         2000 Galloping Hill Road
                         Kenilworth, New Jersey 07033
                         Attention: Law Department - Staff Vice-President,
                                    Licensing
                         Facsimile No.: (908) 298-2739

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       41
<Page>

Any such notice shall be deemed to have been received on the earlier of the date
actually received or the date five (5) days after the same was posted or sent.
Either party may change its address or its facsimile number by giving the other
party written notice, delivered in accordance with this Section 9.6.

     9.7  PROVISIONS FOR INSOLVENCY.

          (a)  All rights and licenses granted under or pursuant to this
Agreement by NeoGenesis to SPL are, for all purposes of Section 365(n) of Title
11 of the United States Code ("TITLE 11"), licenses of rights to "intellectual
property" as defined in Title 11. NeoGenesis agrees during the term of this
Agreement to create and maintain current copies or, if not amenable to copying,
detailed descriptions or other appropriate embodiments, to the extent feasible,
of all such intellectual property. If a case is commenced by or against
NeoGenesis under Title 11, then, unless and until this Agreement is rejected as
provided in Title 11, NeoGenesis (in any capacity, including
debtor-in-possession) and its successors and assigns (including, without
limitation, a Title 11 Trustee (as defined therein)) shall, as SPL may elect in
a written request, immediately upon such request:

          (i)  perform all of the obligations provided in this Agreement to be
               performed by NeoGenesis including, where applicable and without
               limitation, providing to SPL portions of such intellectual
               property (including embodiments thereof) held by NeoGenesis and
               such successors and assigns or otherwise available to them; or

          (ii) provide to SPL all such intellectual property (including all
               embodiments thereof) held by NeoGenesis and such successors and
               assigns or otherwise available to them.

          (b)  If a Title 11 case is commenced by or against NeoGenesis, and
this Agreement is rejected as provided in Title 11, and SPL elects to retain its
rights hereunder as provided in Title 11, then NeoGenesis (in any capacity,
including debtor-in-possession) and its successors and assigns (including,
without limitation, a Title 11 Trustee) shall provide to SPL all such
intellectual property (including all embodiments thereof) held by NeoGenesis and
such successors and assigns, or otherwise available to them, immediately upon
SPL's written request. Whenever NeoGenesis or any of its successors or assigns
provides to SPL any of the intellectual property licensed hereunder (or any
embodiment thereof) pursuant to this Section 9.7, SPL shall have the right to
perform the obligations of NeoGenesis hereunder with respect to such
intellectual property, but neither such provision nor such performance by SPL
shall release NeoGenesis from any such obligation or liability for failing to
perform it.

          (c)  All rights, powers and remedies of SPL provided herein are in
addition to and not in substitution for any and all other rights, powers and
remedies now or hereafter existing at law or in equity (including, without
limitation, Title 11). In the event of the commencement of a Title 11 case by or
against NeoGenesis, SPL, in addition to the rights, power and remedies expressly
provided herein, shall be entitled to exercise all other such rights and powers
and resort

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       42
<Page>

to all other such remedies as may now or hereafter exist at law or in equity
(including, without limitation, Title 11) in such event. The parties agree that
they intend the foregoing SPL rights to extend to the maximum extent permitted
by law, including, without limitation, for purposes of Title 11:

          (i)  the right of access to any intellectual property (including all
               embodiments thereof) of NeoGenesis, or any third party with whom
               NeoGenesis contracts to perform an obligation of NeoGenesis under
               this Agreement, and, in the case of the third party, which is
               necessary for the development, registration, manufacture and
               marketing of Designated Compounds and/or Licensed Products; and

          (ii) the right to contract directly with any third party described in
               (i) to complete the contracted work.

     9.8  SEVERABILITY. In the event any provision of this Agreement shall for
any reason be held to be invalid, illegal or unenforceable in any respect, such
invalidity, illegality or unenforceability shall not affect any other term or
provision hereof. The parties agree that they will negotiate in good faith to
replace any provision hereof so held invalid, illegal or unenforceable with a
valid provision which is as similar as possible in substance to the invalid,
illegal or unenforceable provision.

     9.9  CAPTIONS. Captions of the sections and subsections of this Agreement
are for reference purposes only and do not constitute terms or conditions of
this Agreement and shall not limit or affect the meaning or construction of the
terms and conditions hereof.

     9.10 ENTIRE AGREEMENT. This Agreement (including the Attachments or
Schedules hereto) constitutes the entire understanding of the parties with
respect to the transactions and matters contemplated hereby and supersedes all
previous communications, representations, agreements and understandings, whether
written or verbal, relating to the subject matter hereof. No representations,
inducements, promises or agreements, whether oral or otherwise, between the
parties not contained in this Agreement shall be of any force or effect.

     9.11 RULES OF CONSTRUCTION. The parties agree that they have participated
equally in the formation of this Agreement and that the language and terms of
this Agreement shall not be construed against either party by reason of the
extent to which such party or its professional advisors participated in the
preparation of this Agreement.

     9.12 COUNTERPARTS. This Agreement may be executed in multiple counterparts,
each of which shall be deemed an original, but all of which together shall
constitute one and the same instrument.

     9.13 FORCE MAJEURE. Failure of any party to perform its obligations under
this Agreement (except the obligation to make payments when properly due) shall
not subject such party to any liability or place them in breach of any term or
condition of this Agreement to the

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       43
<Page>

other party if such failure is due to any cause beyond the reasonable control of
such non-performing party ("FORCE MAJEURE"), unless conclusive evidence to the
contrary is provided. Causes of non-performance constituting force majeure shall
include, without limitation, acts of God, fire, explosion, flood, drought, war,
riot, sabotage, embargo, strikes or other labor trouble, failure in whole or in
part of suppliers to deliver on schedule materials, equipment or machinery,
interruption of or delay in transportation, a national health emergency or
compliance with any order or regulation of any government entity acting with
color of right. The party affected shall promptly notify the other party of the
condition constituting force majeure as defined herein and shall exert
reasonable efforts to eliminate, cure and overcome any such causes and to resume
performance of its obligations with all possible speed; provided that nothing
herein shall obligate a party to settle on terms unsatisfactory to such party
any strike, lockout or other labor difficulty, any investigation or other
proceeding by any public authority or any litigation by any third party. If a
condition constituting force majeure as defined herein exists for more than
ninety (90) consecutive days, the parties shall meet to negotiate a mutually
satisfactory resolution to the problem, if practicable. If the parties cannot in
good faith reach a satisfactory resolution to the problem within sixty (60) days
of meeting, the matter shall be referred to binding arbitration pursuant to
Section 9.1.

     9.14 RELATIONSHIP TO US AGREEMENT, CONTROLLING PROVISIONS. The parties
acknowledge that this Agreement and the US Agreement are intended to operate
together as a single worldwide agreement governing the rights and obligations of
NeoGenesis, SPL and Schering Corporation. For purposes of clarity and avoidance
of doubt, the parties agree that rights and obligations of the parties under
Sections 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7 and 2.8 of this Agreement shall be
controlled by the corresponding provisions of the U.S. Agreement. The parties
further agree that SPL's rights and obligations under Sections 3.5, 3.6 and 3.7
of this Agreement shall be exercised and performed by the employees and/or
agents of Schering Corporation having responsibility for Schering Corporation's
rights and obligations under Sections 3.5, 3.6 and 3.7 of the US Agreement, and
that all such activities will be performed in a coordinated manner.

     9.15 FURTHER ASSURANCES. Each party agrees that, subsequent to the
execution and delivery of this Agreement and without any additional
consideration, it will execute and deliver any further legal instruments and
perform any acts which are or may become reasonably necessary to effectuate the
purposes of this Agreement.

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       44
<Page>

IN WITNESS WHEREOF the parties have caused this Agreement to be executed on
their behalf by their duly authorized representatives.

<Table>
<S>                                          <C>
NEOGENESIS DRUG DISCOVERY, INC.              SCHERING-PLOUGH LTD.

By: /s/ Satish Jindal                        By: /s/ David Poorvin
    ------------------------------               ------------------------------
Satish Jindal                                David Poorvin, Ph.D.
President and CSO                            Prokurist

Date: August 2, 2001                         Date: August 2, 2001
      ----------------------------                 ----------------------------
</Table>

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       45
<Page>

                                  ATTACHMENT A

                                SCREENING PROGRAM

The Screening Program to be performed by NeoGenesis with respect to the Targets
will screen up to [*] Compounds contained in the NeoGenesis NeoMorph Screening
Library against each Target using the protocol described below.

1.   SPL will provide NeoGenesis with approximately [*] of each of the purified
functionally-active Target proteins. Control experiments will be performed with
each of the Targets to determine screening characteristics in NeoGenesis' ALIS
protocols. Follow-up control experiments will be performed using SPL ligands (if
available) to validate the retention of binding activity of the Targets. Written
Standard Operating Procedures ("SOPS") will be established by the Steering
Committee for ALIS screening based on the preceding experiments.

2.   Using the SOPs, NeoGenesis will perform ALIS screening of the NeoMorph
Screening Library against each Target. The ALIS screening will be carried out to
identify Target-specific Compounds that bind to the SPL Target with binding
affinities less than [*] micromolar (Kd < [*]), or such other binding affinity
threshold for a specific Target as shall be agreed upon by the parties in
writing (each, a Preliminary Compound as defined in Section 1.36).

3.   NeoGenesis will deliver to SPL [*] of each of the discrete Preliminary
Compounds. SPL will evaluate the activity of these discrete compound(s) in a
Target-based functional assay and/or secondary assay and will notify NeoGenesis
of any such Preliminary Compound(s) which has demonstrated activity in the
Target-based functional assays (each, an Active Compound as defined in Section
1.1 within [*] after completion of such assays and not later than [*] after the
discrete compounds are delivered by NeoGenesis. NeoGenesis will prepare a report
for all Preliminary Compound(s) that details the binding affinities of such
Preliminary Compound(s) (each, a "PRELIMINARY TARGET REPORT"). NeoGenesis will
deliver such Preliminary Target Report when it delivers the discrete compounds.

4.   Following identification of Active Compounds by SPL, NeoGenesis will
disclose to SPL the structures of all Active Compounds and Preliminary Compounds
of the same Chemotype. At the direction of the Steering Committee, NeoGenesis
will perform initial optimization of such Active Compounds to obtain compounds
with binding affinities of [*] micromolar or less (Kd < [*]) (each, an Improved
Active Compound as defined in Section 1.21 and NeoGenesis will provide SPL with
[*] of discrete Improved Active Compounds. SPL will evaluate the activity of
these discrete compound(s) in a Target-based functional assay and/or secondary
assay and will notify NeoGenesis of any such Improved Active Compound(s) which
has demonstrated activity in the Target-based functional assays within [*] after
completion of such assays and not later than [*] after the discrete Improved
Active Compounds are delivered by NeoGenesis. NeoGenesis will prepare a report
for all Improved Active Compound(s) that details the chemical structures,
binding affinities and competition analysis data for such Improved Active
Compound(s) (each, a "FINAL TARGET REPORT"). NeoGenesis will deliver such Final
Target Report when it delivers the discrete Improved Active Compounds. In the
event and to the extent that the Steering

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       46
<Page>

Committee determines that the aggregate amount of initial optimization
activities performed by NeoGenesis pursuant to this Paragraph 4 will adversely
effect the ability of NeoGenesis to perform initial screening activities for the
Targets that are the subject of the Screening program during a particular
funding period, the Screening Committee may determine that SPL rather than
NeoGenesis should perform certain optimization activities.

5.   SPL will select those Improved Active Compounds with respect to each Target
that have demonstrated activity in the Target-based functional assay and/or
secondary assay and that it considers worthy of further study or optimization as
Selected Compounds in accordance with Section 2.7 of the Agreement. In addition,
those Selected Compounds which are to be optimized by NeoGenesis as Lead
Compounds pursuant to Section 2.2(b) of the Agreement will also be identified by
SPL at the time it designates Selected Compounds for the applicable Target.

6.   At the request of SPL in accordance with Section 2.2(b), NeoGenesis will
perform medicinal chemistry optimization on each Lead Compound.

                            LIST OF ACCEPTED TARGETS

          1.   [*]

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       47
<Page>

                                  ATTACHMENT B
                            NEOGENESIS PATENT RIGHTS

                  [TO BE SUPPLIED BY NEOGENESIS AS APPLICABLE]

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       48
<Page>

                                  ATTACHMENT C
                                   INVENTIONS

                          [TO BE SUPPLIED AS DEVELOPED]

                                  ATTACHMENT D

                        BOOKKEEPING EXCHANGE RATE POLICY

                                     PURPOSE

To provide general guidelines for the establishment and communication of current
bookkeeping exchange rates by Corporate Treasury to divisions and subsidiaries.

                                   APPLICATION

Applies to Schering-Plough Corporation, its divisions and all subsidiaries.

                                     POLICY

ESTABLISHMENT OF RATES

The current bookkeeping exchange rates will be determined monthly by S-P
Corporate Treasury. The rates will be based on:

     -    The market rates for selling foreign currencies in New York on the
          morning of the 25th of each month; the 31st in December; or

     -    In thinly traded currencies the local rate established in that country
          for buying U.S. dollars.

If the 25th occurs on a holiday, Saturday or Sunday, the rates used are those of
the last business day prior to the 25th. If for any reason a rate established is
significantly different from the rate prevailing locally, the Chief Financial
Officer of the subsidiary should promptly telex Corporate Treasury.

NOTIFICATION

Rates will be communicated to subsidiaries on the last day of each accounting
period by Corporate Treasury (1st workday of ensuing year at year-end). The
communication will advise each subsidiary of all Corporate wide current rates,
regardless of whether or not they have changed from the prior accounting period.

As there is no January closing, January rates will not be issued and December
rates will remain in effect until the February month-end closing.

RECORDKEEPING OF RATES

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       49
<Page>

At the beginning of each year, a worksheet will be sent to all subsidiaries by
Corporate Treasury. Each subsidiary will maintain a monthly record of all
exchange rates throughout the Corporate system which may affect its accounting
transactions and reporting.

The worksheet lists all countries in which subsidiaries are located and for each
country gives:

     1.   The cable code (based on country abbreviation) so as to identify the
          country for which there is a change in exchange rate.

     2.   The average exchange rate used in the Operating Plan for the current
          year and

     3.   The exchange rate established as of the end of the previous year.
          Twelve columns are provided for the subsidiary to record changes in
          exchange rates from communication received each month.

QUOTING OR RATES

To conform with practices generally prevailing in each country, and to avoid any
confusion, ALL exchange rates will be quoted in terms of the number of foreign
currency units per U.S. dollar. This means that for those foreign currency units
that are valued at more than one U.S. dollar, the exchange rates are quoted as a
decimal of the foreign currency unit.

For example, the pound sterling plan rate is quoted as (pound).571 per U.S.
dollar rather than U.S.$1.75 per pound sterling.

Exchange rates are generally quoted as follows:

     -    In THREE decimals for currencies with less than one unit per U.S.
          dollar (e.g., UK .571)

     -    In TWO decimals for those with one or more but less than ten units
          (e.g., France 5.70)

     -    In ONE decimal for those with ten or more but less than 100 units
          (e.g., Austria 12.0) and

     -    With NO decimals for those with 100 or more units (e.g. Italy 1270)

Rates will be quoted in more than three digits only when necessary to conform to
rates required for official purposes locally or when the exchange rate exceeds
1,000 (e.g., Italy 1270). If the rate exceeds 1,000, it should be rounded to
three significant digits (e.g., rate of 4633 would be shown as 4630).

                                 RESPONSIBILITY

The Corporate Treasury Department will:

     A.   Distribute the Current Bookkeeping Exchange rate Worksheet at the
          beginning of each year to all divisions and subsidiaries.

     B    Establish and communicate the Current Bookkeeping Exchange rate as
          stated in the above policy.

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       50
<Page>

The chief financial officer of each subsidiary will maintain monthly records of
communicated exchange rates.

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       51
<Page>

                                  ATTACHMENT E

                               DISPUTE RESOLUTION

(a)  SCOPE. Subject to and in accordance with the terms of this Agreement and
this Schedule 9.1, all differences, disputes, claims or controversies arising
out of or in any way connected or related to this Agreement, whether arising
before or after the expiration of the term of this Agreement, and including,
without limitation, its negotiation, execution, delivery, enforceability,
performance, breach, discharge, interpretation and construction, existence,
validity and any damages resulting therefrom or the rights, privileges, duties
and obligations of the parties under or in relation to this Agreement (including
any dispute as to whether an issue is arbitrable) shall be referred to binding
arbitration in accordance with the rules set forth herein and of the American
Arbitration Association, as in effect at the time of the arbitration. The time
frames set forth herein shall control the timing of the arbitration procedure.

(b)  PARTIES TO ARBITRATION. For the purposes of each arbitration under this
Agreement, SPL shall constitute one party to the arbitration and NeoGenesis
shall constitute the other party to the arbitration.

(c)  NOTICE OF ARBITRATION. A party requesting arbitration hereunder (the
"REQUESTING PARTY") shall give a notice of arbitration to the other party (the
"NON-REQUESTING PARTY") containing a concise description of the matter submitted
for arbitration (a "NOTICE OF ARBITRATION"). Notice of Arbitration shall be
delivered to the other party in accordance with Section 9.6 of the Agreement.

(d)  RESPONSE. The Non-Requesting Party must respond in writing within thirty
(30) days of receiving a Notice of Arbitration with an explanation responding to
each issue raised, including references to the relevant provisions of the
Agreement. The Non-Requesting Party may add additional issues to be submitted to
arbitration by including a description of such issue in the response.

(e)  MEETING. Within fifteen (15) days of receipt of the response from the
Non-Requesting Party pursuant to Paragraph (d), the parties shall meet and
discuss in good faith options for resolving the dispute. The Requesting Party
must initiate the scheduling of this resolution meeting. Each party shall make
available appropriate personnel to meet and confer with the other party during
such fifteen (15) day period.

(f)  SELECTION OF ARBITRATOR. Any and all disputes that cannot be resolved
pursuant to Paragraphs (c), (d) and (e) shall be submitted to an arbitrator (the
"ARBITRATOR") to be selected by mutual agreement of the parties. The Arbitrator
shall be a retired judge of a state or federal court, to be chosen from a list
of such retired judges to be prepared jointly by the parties within fifteen (15)
days following the response, with each party entitled to submit the names of
three such retired judges for inclusion in the list, provided that to the extent
the dispute involves issues of patent law the parties shall limit such list to
judges retired from federal courts having jurisdiction

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       52
<Page>

over patent law issues; PROVIDED FURTHER, that in the event a dispute relates to
matters that are the subject Section 3.4, 3.5 or 3.6 such judge shall be a
retired federal judge with expertise in patent law. Upon completion of the list,
the parties shall decide within ten (10) days thereafter which of the retired
judges will be selected as the Arbitrator. No Arbitrator appointed or selected
hereunder shall be an employee, director or shareholder of, or otherwise have
any current or previous relationship with, any party or its respective
Affiliates. If the parties fail to agree on the selection of the Arbitrator
within the allotted time frame, the Arbitrator shall be designated by the then
President of the American Arbitration Association.

(g)  POWERS OF ARBITRATOR. The Arbitrator may determine all questions of law and
jurisdiction (including questions as to whether a dispute is arbitrable) and all
matters of procedure relating to the arbitration, except that the Arbitrator
shall be bound by the time frames set forth herein in connection with such
arbitration. The Arbitrator shall have the right to grant legal and equitable
relief (including injunctive relief) and to award costs (including reasonable
legal fees and costs of arbitration) and interest. The Arbitrator is not
permitted to award punitive, exemplary or any similar damages.

(h)  ARBITRATION PROCEDURE. The arbitration shall take place in the City and
State of New York at such place and time, consistent with the time frames set
forth herein, as the Arbitrator may fix for the purpose of hearing the evidence
and representations that the parties may present. The arbitration proceedings
shall be conducted in the English language. The law applicable to the
arbitration shall be the law of the State of New York.

(i)  DISCOVERY AND HEARING. During the meeting referred to in Paragraph (e), the
parties shall negotiate in good faith the scope and schedule of discovery,
relating to depositions, document production and other discovery devices, taking
into account the nature of the dispute submitted for resolution. If the parties
are unable to reach agreement as to the scope and schedule of discovery, the
Arbitrator may order such discovery as it deems necessary. The parties and the
Arbitrator must adhere to the following schedule: (1) all discovery shall be
completed within forty-five (45) days from the date of the selection of the
Arbitrator, and (2) the arbitration hearing shall commence within fifteen (15)
days after completion of such discovery. At the arbitration hearing, the parties
may present testimony (either live witness or deposition), subject to
cross-examination, and documentary evidence. To the extent practicable taking
into account the nature of the dispute submitted for resolution and the
availability of the Arbitrator, the hearing shall be conducted over a period not
to exceed ten (10) consecutive calendar days, with each party entitled to one
half of the allotted time.

(j)  WITNESS LISTS. At least twenty (20) calendar days prior to the date set for
the hearing, each party shall submit to each other party and the Arbitrator a
list of all documents on which such party intends to rely in any oral or written
presentation to the Arbitrator and a list of all witnesses, if any, such party
intends to call at such hearing and a brief summary of each witness' testimony.
Each party shall be given the opportunity to depose any such designated
witnesses not already deposed during the discovery phase. At least five (5)
calendar days prior to the hearing, each party must submit to the Arbitrator and
serve on each other party a proposed findings of fact and conclusions of law on
each issue to be resolved. Following the close of hearings, the parties

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       2
<Page>

may each submit such post-hearing briefs to the Arbitrator addressing the
evidence and issues to be resolved as may be required or permitted by the
Arbitrator. No later than fifteen (15) calendar days after hearing the
representations and evidence of the parties, the Arbitrator shall make its
determination in writing and deliver one copy to each of the parties.

(k)  CONFIDENTIALITY. The arbitration proceedings shall be confidential and,
except as required by law, no party shall make, or instruct the Arbitrator to
make, any public announcement with respect to the proceedings or decision of the
Arbitrator without the prior written consent of the other party. The existence
of any dispute submitted to arbitration and the award of the Arbitrator shall be
kept in confidence by the parties and the Arbitrator, except as required in
connection with the enforcement of such award or as otherwise required by law.

(l)  AWARDS AND APPEAL. Subject to the provisions of this Schedule 9.1, the
decision of the Arbitrator shall be final and binding upon the parties in
respect of all matters relating to the arbitration, the conduct of the parties
during the proceedings, and the final determination of the issues in the
arbitration. There shall be no appeal from the final determination of the
Arbitrator to any court, except in the case of fraud or bad faith on the part of
the Arbitrator or any party to the arbitration proceeding in connection with the
conduct of such proceedings. Judgment upon any award rendered by the Arbitrator
may be entered in any court having jurisdiction thereof.

(m)  COSTS OF ARBITRATION. The costs of any arbitration hereunder shall be borne
by the parties in the manner specified by the Arbitrator in its determination.

(n)  PERFORMANCE OF THE AGREEMENT. During the pendency of the arbitration
proceedings, the parties shall continue to fully perform their respective
obligations under the Agreement; PROVIDED that if the matter which is the
subject of such arbitration proceeding is a matter relating to SPL's development
of Designated Compounds and/or Licensed Products, then the matter shall be
performed by SPL, in its sole discretion; and if the matter which is the subject
of such arbitration proceeding is a matter relating to payment for the Screening
Program services, then the Screening Program shall be performed by NeoGenesis in
its sole discretion. For purposes of this Paragraph (n) the term "pendency of
the arbitration proceeding" shall mean the period starting on the date on which
arbitration proceedings are commenced by a party in accordance with Paragraph
(c) of this Schedule 9.1 and ending on the date on which the Arbitrator delivers
its final determination in writing to the parties.

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00033-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00033-of-00352.parquet"}]]